Bacterial strains for treatment of disease
By using the composition of the Intestinicoccus colisanans bacterial strain, the existing IBD treatment methods have solved the problems of large side effects, low compliance and inability to maintain remission for a long time, significantly alleviating inflammation, improving intestinal barrier function, and improving patients' quality of life.
Patent Information
- Application Number
- CN202280087981.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2021-11-11
- Filing Date
- 2022-11-11
- Publication Date
- 2024-12-03
AI Technical Summary
Existing treatments for inflammatory bowel disease (IBD) have great side effects, low compliance, high cost and inability to maintain long-term remission, and lack effective solutions to improve patients' quality of life and reduce surgical needs.
Develop compositions containing Intestinicococcus colisanans bacterial strains for enhancing or improving intestinal barrier function, for the treatment and prevention of inflammatory and autoimmune conditions, including in particular the use of live bacterial strains with specific 16S rRNA sequences and derivatives thereof , in combination with pharmaceutically acceptable excipients, diluents or carriers, to make a dry composition for oral administration.
Significantly reduce inflammation, improve intestinal barrier function, reduce systemic inflammation, enhance mucosal healing, reduce intestinal ulcers and wounds, improve patients' quality of life, and provide safer and more effective long-term relief solutions.
Smart Images

Figure CN119072244A_ABST
Abstract
Description
Technical Field
[0001] The present invention generally relates to the field of therapeutic compositions comprising bacterial strains and methods for treating or preventing diseases. More specifically, the present invention relates to compositions comprising bacterial strains isolated from the human digestive tract and their use in treating or preventing inflammatory and autoimmune disorders. Background Art
[0002] The human gut microbiota contains more than 500-1000 different phylotypes belonging to several bacterial phyla, including Firmicutes, Bacteroidetes, Proteobacteria, Fusobacteria, and Verrucomicrobia. Two major phyla, Bacteroidetes and Firmicutes, typically account for more than 90% of the gut microbiota (Arumugam et al., 2011). The successful symbiotic relationship initiated by bacterial colonization of the human gut has resulted in a variety of metabolic, structural, protective, and other beneficial functions. Gut bacteria are key regulators of gastrointestinal (GI) digestion; commensal bacteria play an important role in the extraction, synthesis, and absorption of many nutrients and metabolites, including bile acids, lipids, amino acids, vitamins, and short-chain fatty acids (SCFAs). Recently, the immunological importance of the gut microbiota and its products in regulating the development, homeostasis, and function of innate and adaptive immune cells has been recognized (Brestoff and Atris, 2013).
[0003] It is now increasingly recognized that the gut microbiome can modulate the host's intestinal mucosal immunity and inflammatory susceptibility ( Geva-Zatorsky et al., 2017 ; Kabat et al., 2014 ), thus opening up new avenues for novel therapeutic interventions.
[0004] It has been shown that the composition of the microbiota varies significantly in many inflammatory and autoimmune conditions, including inflammatory bowel disease (IBD). After recognizing that certain bacterial strains may have a potential positive effect on the intestinal tract of animals, various strains have been proposed to treat various diseases. Certain strains, including lactobacillus and bifidobacterium strains, have been proposed for the treatment of various extraintestinal inflammatory and autoimmune conditions (see Goldin & Gorbach, 2008; Azad et al., 2013). However, the exact effects of specific bacterial strains on the local and systemic GI system have not yet been resolved. Therefore, the relationship between different diseases and different bacterial strains in the human gastrointestinal tract has not yet been clearly elucidated.
[0005] IBD (including two major disease subtypes, Crohn's disease (CD) and ulcerative colitis (UC)) is characterized by episodic and disabling inflammation of the gastrointestinal tract. An estimated 6.8 million people worldwide suffered from IBD in 2017, with the highest prevalence in the United States and Europe (GBD 2017; Inflammatory Bowel Disease Collaborators, 2019). Up to 20% of patients are diagnosed before the age of 16, and childhood-onset IBD (PIBD) is associated with more complex and aggressive disease, with adverse effects on growth and psychosocial development.
[0006] There is currently no cure for IBD, and long-term clinical management requires effective therapies with a good safety profile. However, existing therapies have a range of drawbacks, and remission periods are often short. In addition, IBD therapies are ineffective when early onset combined with more aggressive disease leads to progressive intestinal damage and requires surgery. Therefore, there is an urgent need to develop more effective and safer therapies to improve patients' quality of life, maintain remission in the long term, reduce surgery, and reduce personal and public health costs.
[0007] Existing IBD treatments are suboptimal, with significant side effects, low compliance (average non-compliance rate is 50% (see Chan et al., 2017)), and high costs. Furthermore, there is no effective solution to maintain long-term disease-free remission. Mesalmine is one of the most widely used first-line therapies for treating mild to moderate ulcerative colitis flares and maintaining remission, with response rates of 40%-70% and remission rates of 15%-20% (Karagozian and Burakoff, 2007).
[0008] There is a need in the art for new methods of treating inflammatory and autoimmune disorders. There is also a need to characterize the potential roles of intestinal bacteria in order to develop new therapies that utilize intestinal bacteria. SUMMARY OF THE INVENTION
[0010] The present invention is based in part on the inventors' discovery that the Intestinicoccus colisanans bacterial strain can enhance or improve intestinal barrier function. Based on this consideration, it is proposed that the I. colisanans strain is particularly suitable for therapeutic use in the treatment and prevention of inflammatory and autoimmune disorders, as described below.
[0011] The present inventors have developed new compositions comprising live bacterial strains of the species Intestinicoccus colisanans which are useful for the treatment and prevention of inflammatory and autoimmune disorders.
[0012] Thus, in one aspect, the invention provides a cell of the Intestinicoccus colisanans strain deposited under accession number V21 / 015887 or V21 / 015888, or a derivative thereof.
[0013] In some embodiments, the cells are at least partially isolated.
[0014] In another aspect, the present invention provides a biologically pure culture of the Intestinicoccus colisanans strain deposited under accession number V21 / 015887 or V21 / 015888, or a derivative thereof.
[0015] In another aspect, the invention provides a composition comprising a cell or culture as described above and elsewhere herein.
[0016] In another aspect, the present invention provides a composition comprising a bacterial strain having a 16S rRNA sequence that is at least about 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identical to SEQ ID NO: 1; or a bacterial strain having a 16S rRNA sequence represented by SEQ ID NO: 1. In some embodiments, the bacterial strain comprises two or more copies of the 16S rRNA sequence (e.g., two copies, three copies, four copies, five copies, six copies, seven copies, eight copies) in its genome.
[0017] In some embodiments, the composition further comprises a pharmaceutically acceptable excipient, diluent, or carrier.
[0018] In another aspect, the present invention provides a pharmaceutical composition comprising a bacterial strain having a 16S rRNA sequence that is at least about 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identical to the 16S rRNA sequence of a bacterial strain of the species Intestinicoccus colisanans, and a pharmaceutically acceptable carrier, diluent or excipient.
[0019] Typically, the bacterial strain is at least partially isolated.
[0020] In some embodiments, the bacterial strain is alive. In some alternative embodiments, the bacterial strain is dead.
[0021] In some embodiments, the composition further comprises a prebiotic.
[0022] In some embodiments, the composition is formulated in a dry form. Typically, the composition is dried using a technique selected from freeze drying, spray drying, fluidized bed drying, vacuum drying, or a combination thereof.
[0023] In some embodiments, the composition is formulated for oral administration.
[0024] In some embodiments, the bacterial strain produces an agent that attenuates or reduces signal transducer and activator of transcription 3 (STAT3) signaling in a cell.
[0025] In some such embodiments, the active agent is a small molecule, a peptide or a nucleotide. Typically, the active agent is released by the bacterial strain.
[0026] In some embodiments, the active agent specifically binds to any one of STAT3, JAK2, TYK2, or IL-23.
[0027] In some embodiments, the I. colisanans metabolizes one or more substances selected from the group consisting of starch, glucose, fructose, gluconic acid, lactose, trehalose, and lactaldehyde as a carbon source.
[0028] In another aspect, the present invention provides a method for restoring or improving the intestinal barrier function of a subject, the method comprising administering a bacterial strain of the species I. colisanans to the subject, thereby restoring or improving the intestinal barrier function.
[0029] In some preferred embodiments, restoration or improvement of intestinal barrier function is characterized by at least one of the following: (i) increasing the quality and / or quantity of mucin; (ii) improving the integrity of tight junction proteins; (iii) reducing the translocation of intestinal luminal contents into the systemic circulation; or (iv) reducing intestinal ulcers and / or intestinal wounds.
[0030] In some embodiments, the intestinal luminal contents include lipopolysaccharide (LPS).
[0031] In some embodiments, the restoration or improvement of intestinal barrier function leads to a reduction in systemic inflammation in the subject. In some embodiments of this type, systemic inflammation is characterized in that the levels of inflammatory cytokines (e.g., IL-1β, IL-8, IL-6, and TNF) in the subject are elevated compared to the levels of inflammatory cytokines in healthy subjects.
[0032] In some embodiments, the I. colisanans bacterial strain stimulates PBMCs to produce cytokines IL-10 and IL-12 at a ratio equal to or greater than 5. For example, the I. colisanans bacterial strain can stimulate PBMCs to produce cytokines IL-10 and IL-12 at a ratio equal to or greater than 10, 15, 20, 25, or 30.
[0033] In yet another aspect, the present invention provides a method of maintaining an intestinal barrier function in a subject, the method comprising administering a bacterial strain of the species I. colisanans to the subject, thereby maintaining the intestinal barrier function in the subject.
[0034] In yet another aspect, the present invention provides a method of reducing inflammation in a subject, the method comprising administering to the subject a bacterial strain of the species I. colisanans, thereby reducing inflammation in the subject.
[0035] In some embodiments, the inflammation is local inflammation of the intestinal environment or systemic inflammation.
[0036] In another aspect, the present invention provides a method of inducing or enhancing mucosal healing in a subject, the method comprising administering to the subject an amount of a bacterial strain of the species I. colisanans sufficient to induce epithelial cell migration, proliferation and / or differentiation, thereby inducing mucosal healing in the subject.
[0037] In some embodiments, one or more stool or serum markers can be used to measure mucosal healing in a subject. As an illustrative example, the one or more stool markers can be selected from calprotectin, lactoferrin, metalloproteinase (MMP)-9, and lipocalin-2.
[0038] In some embodiments, the bacterial strain reduces inflammation by attenuating the NFκB pathway. In some embodiments of this type, the bacterial strain inhibits the production of one or more transcription factors, cytokines or chemokines selected from NFκB, TNF, IFN-γ, IL-1β, IL-8 and MCP-1.
[0039] In another aspect, the invention provides a method of blocking or otherwise inhibiting STAT3 signaling in a target cell, the method comprising contacting the cell with at least a soluble component of a bacterial cell preparation of the species I. colisanans to block or otherwise inhibit STAT3 signaling in the cell. Typically, the method of this aspect is performed in vitro.
[0040] In some embodiments, the target cell is selected from a reporter cell (eg, HEK cell), an immune cell (eg, Th17 immune cell), an epithelial cell or an endothelial cell. In some embodiments, the target cell is a mammalian cell, and preferably a human cell.
[0041] In some embodiments, the bacterial cell preparation is a bacterial cell culture. Therefore, the soluble component may include, consist of, or consist essentially of a soluble fraction (e.g., cell culture supernatant) of a bacterial cell culture. The soluble component may also include some insoluble components of the bacterial cell culture. For example, the soluble component may include essentially all of the bacterial culture. Preferably, the soluble component is essentially free of bacterial cells.
[0042] In some alternative embodiments, the bacterial cell preparation is a bacterial cell lysate. In this type of exemplary embodiment, the soluble component can be related to the soluble fraction of the cell lysate. The soluble fraction can be suitably obtained by any method, including obtaining by centrifugation.
[0043] In another aspect, the invention provides a method of blocking or otherwise inhibiting STAT3 signaling in a cell, the method comprising administering to a subject a bacterial strain of the species I. colisanans, thereby blocking or otherwise inhibiting STAT3 signaling in the cell. Typically, the method of this aspect is performed in vivo.
[0044] In some embodiments, the cell is an immune cell (eg, a Th17 immune cell) or an epithelial cell.
[0045] In some embodiments, the cell is an epithelial cell and the bacterial strain or a metabolite produced by the bacterial strain increases IL-22 production in the subject.
[0046] In some embodiments, the bacterial strain produces a molecule that is a direct inhibitor or an indirect inhibitor of STAT3. For example, the bacterial strain can produce a metabolite that directly inhibits at least one of an IL-23 polypeptide, a JAK2 polypeptide, a TYK2 polypeptide, or a STAT3 polypeptide.
[0047] In some embodiments, the bacterial strain used in the methods described above and elsewhere herein produces the metabolite acetate.
[0048] In some embodiments, the bacterial strain has a 16S rRNA sequence that is at least about 97.5%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% identical to the 16S rRNA sequence of the I. colisanans bacterial strain.
[0049] In some alternative embodiments, the bacterial strain has a 16S rRNA sequence that is at least about 97.5%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% identical to SEQ ID NO: 1, or wherein the bacterial strain has a 16S rRNA gene sequence represented by SEQ ID NO: 1. In some embodiments, the bacterial strain comprises two or more copies (e.g., two copies, three copies, four copies, five copies, six copies, seven copies, eight copies) independently selected from the 16S rRNA sequence listed in SEQ ID NO: 1. In some alternative embodiments, the bacterial strain has a 16S rRNA sequence that is at least about 97.5%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% identical to SEQ ID NO: 2, or wherein the bacterial strain has a 16S rRNA gene sequence represented by SEQ ID NO: 2. In some embodiments, the bacterial strain comprises two or more copies (e.g., two copies, three copies, four copies, five copies, six copies, seven copies, eight copies) independently selected from the 16S rRNA sequence shown in SEQ ID NO: 2.
[0050] In some embodiments, the bacterial strain is an I. colisanans strain with deposit number V21 / 015887 or V21 / 015888, or a derivative thereof.
[0051] Preferably, the bacterial strain is at least partially isolated.
[0052] In some embodiments, the bacterial strain is formulated into a pharmaceutical composition, which further comprises a pharmaceutically acceptable carrier, diluent or excipient. In some embodiments, the pharmaceutical composition is a dry composition. In some embodiments, the dry composition is selected from granules, particles and powders. As an illustrative example, the pharmaceutical composition can be freeze-dried, spray-dried, fluidized bed dried, vacuum dried or a combination thereof.
[0053] In some embodiments, the pharmaceutical composition is formulated for oral administration.
[0054] In yet other aspects, the present invention provides a method of treating an inflammatory or autoimmune disorder in a subject, the method comprising administering to the subject an effective amount of an I. colisanans bacterial strain, thereby treating or preventing the inflammatory or autoimmune disorder.
[0055] In some embodiments, the inflammatory or autoimmune disorder is selected from inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis); asthma (e.g., allergic asthma or neutrophilic asthma); fatty liver disease (e.g., non-alcoholic fatty liver disease (NAFLD)); ankylosing spondylitis; systemic lupus erythematosus (SLE); scleroderma; Sjögren's syndrome; and vasculitis. Preferably, the inflammatory or autoimmune disorder is inflammatory bowel disease (IBD).
[0056] In some embodiments, the bacterial strain blocks or otherwise inhibits STAT3 signaling in at least one cell of the subject. Typically, the cell is an epithelial cell, an endothelial cell, or an immune cell (e.g., a Th17 immune cell).
[0057] In some embodiments, the bacterial strain has a 16S rRNA sequence that is at least about 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% identical to the 16S rRNA sequence of the I. colisanans bacterial strain.
[0058] Alternatively, in some embodiments, the bacterial strain has a 16S rRNA sequence that is at least about 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identical to SEQ ID NO: 1, or wherein the bacterial strain has a 16S rRNA gene sequence represented by SEQ ID NO: 1. Alternatively, the bacterial strain may have a 16S rRNA sequence that is at least about 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identical to SEQ ID NO: 2, or wherein the bacterial strain has a 16S rRNA gene sequence represented by SEQ ID NO: 2.
[0059] In some alternative embodiments, the bacterial strain can have a 16S rRNA sequence that is at least about 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identical to any one of SEQ ID NOs: 7-10, or wherein the bacterial strain has a 16S rRNA gene sequence represented by any one of SEQ ID NOs: 7-10.
[0060] Preferably, the bacterial strain is at least partially isolated.
[0061] In some embodiments, the bacterial strain is formulated into a pharmaceutical composition together with a pharmaceutically acceptable carrier, diluent and / or excipient. In some embodiments, the composition is a dry composition selected from particles, granules and powders. For example, the composition can be freeze-dried. Alternatively, the composition can be spray-dried, fluidized bed dried or vacuum dried.
[0062] In some embodiments, the composition is formulated for oral administration.
[0063] In one aspect, the present invention provides a composition comprising a bacterial strain of the genus Intestinicoccus for use in therapy.
[0064] In another aspect, the invention provides a composition comprising an I. colisanans bacterial strain for use in treatment. In some identical embodiments and some other embodiments, the bacterial strain has a 16S rRNA sequence that is at least about 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% identical to a 16S rRNA sequence of an I. colisanans bacterial strain.
[0065] Alternatively, the bacterial strain may have a 16S rRNA sequence that is at least about 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identical to SEQ ID NO:1, or wherein the bacterial strain has a 16S rRNA gene sequence represented by SEQ ID NO:1.
[0066] Alternatively, the bacterial strain may have a 16S rRNA sequence that is at least about 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identical to SEQ ID NO:2, or wherein the bacterial strain has a 16S rRNA gene sequence represented by SEQ ID NO:2.
[0067] Alternatively, the bacterial strain may have a 16S rRNA sequence that is at least about 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identical to any one of SEQ ID NOs: 7-10, or wherein the bacterial strain has a 16S rRNA gene sequence represented by any one of SEQ ID NOs: 7-10.
[0068] In yet another aspect, the present invention provides a composition comprising a bacterial strain of the genus Intestinicoccus for use in treating or preventing inflammatory or autoimmune disorders.
[0069] In yet another aspect, the present invention provides a composition comprising the I. colisanans bacterial strain for use in treating or preventing inflammatory or autoimmune disorders.
[0070] In some embodiments, the bacterial strain is an I. colisanans strain or a derivative thereof.
[0071] In some embodiments, the inflammatory or autoimmune disorder is selected from inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis); asthma (e.g., allergic asthma or neutrophilic asthma); arthritis (e.g., rheumatoid arthritis, osteoarthritis, psoriatic arthritis, or juvenile idiopathic arthritis); fatty liver disease (e.g., non-alcoholic fatty liver disease (NAFLD)); ankylosing spondylitis; psoriasis; systemic lupus erythematosus (SLE); scleroderma; Sjögren's syndrome ( syndrome); and type 1 diabetes. In some preferred embodiments, the inflammatory or autoimmune disorder is inflammatory bowel disease (IBD).
[0072] In one aspect, the present invention provides a composition for treating an inflammatory or autoimmune disorder, the composition comprising a bacterial strain of I. colisanans; and an adjunctive therapeutic agent.
[0073] In some embodiments, the adjunctive therapeutic agent is an anti-inflammatory agent. As an illustrative example, the anti-inflammatory agent is selected from 5-aminosalicylate, corticosteroids, azathioprine or a combination thereof. In some other embodiments, the adjunctive therapeutic agent is an antibody (e.g., a monoclonal antibody). As an illustrative example, the antibody can be selected from infliximab, adalimumab, golimumab, certolizumab, natalizumab and vedolizumab.
[0074] In another aspect, the present invention provides a composition for treating an inflammatory or autoimmune disorder, the composition comprising a bacterial strain of I. colisanans; and a nutritional supplement. In embodiments of this type, the nutritional supplement improves engraftment of the bacterial strain.
[0075] In some related aspects, the technology described herein provides bacterial species and compositions comprising them in the form of probiotics. Preferably, such probiotics are effective in improving intestinal microbial ecology, alleviating symptoms of microbial dysbiosis, promoting health, and / or treating or preventing inflammation and / or autoimmune disorders. BRIEF DESCRIPTION OF THE DRAWINGS
[0077] The following drawings constitute part of this specification and are used to further illustrate certain aspects of the present disclosure. The present disclosure may be better understood by referring to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.
[0078] Figure 1 A graphical representation of the association between I. colisanans and representative inflammatory and / or autoimmune conditions is provided. (A) Using high-resolution gut metagenomic data (MDD) from 6,020 subjects, we found that I. colisanans had a significantly lower prevalence (P < 0.05, Fisher's exact test) in a range of inflammatory and autoimmune conditions (striped bars) compared to healthy individuals (black bars). (B) The strongest reduction was observed in IBD (including the two major subtypes, Crohn's disease (CD) and ulcerative colitis (UC)). These observations were validated in an independent IBD cohort previously published by Harvard (Franzosa et al., 2019).
[0079] Figure 2Photographs and graphical representations of the morphology and phylogeny of I. colisanans are provided. (A) Morphology shown by Gram-stained I. colisanans isolates. (B) Phylogenetic tree constructed using alignment of 120 bacteria-specific single-copy marker genes from a high-quality reference genome (GTDB r89). Nonparametric bootstrap values were calculated from 1000 iterations. Intestinicoccus was previously referred to as UBA1417.
[0080] Figure 3 A graphical representation is provided that I.colisanans does not affect healthy intestinal function in naive C57Bl / 6 mice. (A) Overview of the model used to evaluate the effects of I.colisanans on naive C57Bl / 6 mice. (B) Treatment with I.colisanans had little effect on body weight in naive animals. (C)-(D): Treatment with I.colisanans had no effect on colon length or colon weight / length ratio in naive animals compared to vehicle-treated controls. (E)-(F): Treatment with I.colisanans had no effect on epithelial damage, inflammation, and hypervascularization in naive animals compared to vehicle-treated controls. (G) Treatment with I.colisanans had no effect on intestinal histology in naive animals compared to vehicle-treated controls. All data are reported as mean and standard deviation. ns, not significant.
[0081] Figure 4A graphical representation of the restoration of intestinal barrier function by I.colisanans is provided. (A) Overview of the DSS mouse model used to evaluate the efficacy of I.colisanans treatment. (B) The effects of daily treatment with vehicle, prednisone, and I.colisanans in healthy and DSS-treated mice. All treatment groups were compared with the DSS+vehicle group. Significance was determined using two-way ANOVA and Tukey's multiple comparison test. (C) Endoscopic assessment of colitis was performed on days 1, 2, and 6. For each day, all groups were compared with the DSS+vehicle group, using the Kruskal-Wallis test and Dunn's multiple comparison correction (day 1) or one-way ANOVA and Dunnett's multiple comparison correction (days 2 and 6), as appropriate. All data are expressed as mean and standard deviation. (D) Representative intestinal histology images of C57Bl / 6 mice treated with vehicle, prednisone, or I.colisanans. (E) DSS treatment resulted in an increase in histopathological scores, which was ameliorated by treatment with prednisone, F. prausnitzii A2-165, and I. colisanans. All data are presented as mean and standard deviation. All groups were compared to the DSS+vehicle group, and significance was determined using one-way ANOVA with Dunnett's multiple comparison test. (F) DSS treatment resulted in an increase in epithelial damage, which was ameliorated by treatment with prednisone and I. colisanans. All data are presented as mean and standard deviation. All groups were compared to the DSS+vehicle group, using the Kruskal-Wallis test with Dunn's multiple comparison correction. (G) Total histopathological scores of mice, (H) epithelial subscores of the total histopathological scores of all mice, and (I) inflammatory subscores of the total histopathological scores of all mice. All groups were compared to the DSS control group using ordinary one-way ANOVA with Dunnett's multiple comparison test. All data were subjected to the D'Agostino-Pearson Omnibus test to check for normal distribution and all data passed this test. All data were subjected to the Brown-Forsyth test to check for significant differences in group standard deviations and all data passed this test. All groups are visually displayed as points representing individual mice, and the bar graphs and error bars represent the mean and standard deviation of each group. The following annotations are used to indicate statistical significance after correction for multiple comparisons: *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001. (J) Disease Activity Index scores of healthy or DSS-treated mice after treatment with the indicated doses and formulations of I.colisanans MH27-2 or control drugs minocycline and prednisone.All groups treated with I.colisanans MH27-2 or control drugs were compared to DSS-vehicle controls using Brown-Forsythe and Welch ANOVA and Dunnett's T3 multiple comparison test. (K) Mouse body weight expressed as a percentage of initial body weight in healthy or DSS-treated mice after treatment with I.colisanans MH27-2 or control drugs minocycline and prednisone at the indicated doses and formulations. All groups treated with I.colisanans MH27-2 or control drugs were compared to DSS-vehicle controls using ordinary one-way analysis of variance and Dunnett's multiple comparison test. (L) Fecal occult blood scores in healthy or DSS-treated mice after treatment with I.colisanans MH27-2 or control drugs minocycline and prednisone at the indicated doses and formulations. All groups treated with I.colisanans MH27-2 or control drugs were compared to DSS-vehicle controls using Brown-Forsythe and Welch ANOVA and Dunnett's multiple comparison test. (MP) Total and sub-item histopathological scores of healthy or DSS-treated mice after treatment with I.colisanans MH27-2 or control drugs minocycline and prednisone at the indicated doses and formulations. All groups treated with I.colisanans MH27-2 or control drugs were compared to DSS-vehicle controls using ordinary one-way analysis of variance and Dunnett's multiple comparison test. All groups are visually displayed as points representing each individual mouse, and the bar graphs and error bars represent the mean and standard deviation of each group. For all statistical analyses, the D'Agostino-Pearson omnibus test was used to determine whether the data were normally distributed, and all data passed this test. The Brown-Forsyth test was used to determine whether the standard deviations between groups were significantly different, and if the test was significant, the Brown-Forsyth and Welch ANOVA tests were used instead of ordinary one-way ANOVA. In this case, Dunnett's T3 multiple comparison test was used instead of Dunnett's test. The following statistical significance annotations were used after correction for multiple comparisons: *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.
[0082] Figure 5(A) Overview of the SKG model used to evaluate the efficacy of I. colisanans treatment. (B) Curdlan treatment resulted in an increase in histopathological scores, which was ameliorated by treatment with anti-IL-23 antibody and I. colisanans. All data are presented as mean and standard deviation. All groups were compared to the Curdlan + vehicle group using ANOVA and Dunnett's multiple comparison test. (C) Curdlan treatment resulted in an increase in IL-6 and IL-12p70, which was ameliorated by treatment with I. colisanans. All data are presented as mean and standard deviation. For IL-6, all groups were compared to the Curdlan + vehicle group using ordinary one-way ANOVA and Dunnett's multiple comparison test. For IL-12p70, all groups were compared to the DSS + vehicle group using the Kruskal-Wallis test and Dunn's multiple comparison correction. For IL-6, all groups were compared to the Curdlan + vehicle group using ordinary one-way ANOVA and Dunnett's multiple comparison test. For all data, ns: not significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001 ****, p < 0.0001. (E) Overview of the TNBS model used to evaluate the efficacy of I. colisanans MH27-2 treatment. (F) TNBS treatment resulted in an increase in macroscopic lesion histopathology scores, which was ameliorated by treatment with I. colisanans MH27-2 and cyclosporin A. The results were analyzed using a standard one-way ANOVA test and TNBS + vehicle group was compared with I.colisanans MH27-2 and cyclosporin A treated groups after correction for multiple comparisons. (G) Treatment with I.colisanans MH27-2 significantly improved the ulcer / inflammation score. TNBS + vehicle group was compared with I.colisanans MH27-2 and cyclosporin A treated groups. (H) TNBS treatment resulted in an increase in total histopathological score, which was improved by treatment with I.colisanans MH27-2 and cyclosporin A. TNBS + vehicle group was compared with I.colisanans MH27-2 and cyclosporin A treated groups using Brown-Forsythe and Welch ANOVA test with Dunnett's T3 correction for multiple comparisons. (IL) Treatment with I.colisanans MH27-2 significantly improved the scores for the degree of inflammation, erosions or ulcers, epithelial regeneration, and percentage involvement. The TNBS + vehicle group was compared with the I.colisanans MH27-2 and cyclosporin A treated groups using the Kruskal-Wallis test and Dunn's multiple comparison test. (M) Treatment with I.colisanans MH27-2 significantly reduced IL-6 concentrations. The TNBS + vehicle group was compared with the I.colisanans MH27-2 and cyclosporin A treated groups. Data were log-transformed and compared with the Kruskal-Wallis test and Dunn's multiple comparison test or with ordinary one-way ANOVA test and Analyses were corrected for multiple comparisons (ns: not significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001).
[0083] Figure 6 A graphical representation of the inhibition of IL-6-mediated STAT3 activation in vitro by I. colisanans MH27-1 and MH27-2 is provided. Inhibition of STAT3 signaling when HEKBlue IL-6 reporter cells were treated with 10% v / v of cell-free supernatant stock or <3 KDa fractionated culture supernatant of (A) I. colisanans MH27-1 and (B) MH27-2 (unpaired t-test, n=18); (C) MH27-3 (unpaired t-test, n=18); (D) MH27-4v (unpaired t-test, n=18); (E) MH27-5 v (unpaired t-test, n=18) and (F) R. bromii MCB950 (unpaired t-test, n=12). STAT3 activation caused by IL-6 trans-signaling was inhibited by cell-free supernatant stock of I. colisanans MH27-2.
[0084] Figure 7 A graphical representation showing that I.colisanans promotes migration of human intestinal epithelial cells is provided. (A) The effect of a sterile culture supernatant extract of I.colisanans on the migration of HCT116 colon cancer cells was investigated using a Transwell migration assay. Under serum starvation conditions (0.5% FBS), the addition of I.colisanans 0.5x extract to the bottom of the chamber significantly increased the basolateral movement of HCT116 cells compared to the culture medium extract control. (Untreated and culture medium control n = 6 technical replicates; I.colisanans n = 4 technical replicates, 3 biological replicates per technical replicate; unpaired t-test, two-tailed P>0.0001). (B) As a second readout of cell migration, an Incucyte scratch wound assay was performed. After scratching the HCT116 cell monolayer, the relative wound confluence was measured every two hours. At 24 hours after wounding, serum-starved HCT116 cells incubated in 0.3x extract of I. colisanans strain MH27-2 showed significantly higher wound confluence compared to cells treated with medium extract (one-way ANOVA with Dunnett's multiple comparison test, *, p<0.05).
[0085] Figure 8 A graphical representation of MH27 inhibition of IL 23-mediated STAT3 activation is provided. HEK-Blue cells were treated with 25% cell-free supernatant or <3 kDa size fractionated I. colisanans supernatant (but not R. bromii supernatant and similarly prepared YG / P medium). TM STAT3 signaling was inhibited when IL-23 was used as the reporter cell line. Samples were compared using an unpaired t-test (***, p<0.001; ns not significant). The data shown are the results of three independent experiments. Technical and biological replicates of the original and <3 kDa fractions were combined.
[0086] Fig. 9 After treatment with IFNγ (48 hours treatment (grey area)), the culture supernatant of I. colisanans MH27-2 improved the decrease of TEER at 168, 192, 216, 240, 288, 312 and 336 hours relative to the YG / V medium control (two-way ANOVA test p<0.05). (▲) Untreated, (◆) IFNγ + I. colisanans MH27-2 extract, (·) IFNγ + culture medium extract, (■) IFNγ.
[0087] Fig.10Treatment with I. colisanans MH27-2 culture supernatant extracts ameliorated IL-6 (96 h treatment (grey area))-mediated TEER reduction in a dose-dependent manner relative to medium control. Statistical significance was determined by unpaired t-test. (▲) Untreated, (◆) IL-6 + I. colisanans MH27-2 extracts, (·) IL-6 + medium extracts, (■) IL-6.
[0088] Fig.11 A graphical representation is provided showing that re-treatment with I. colisanans MH27 extract ameliorates IFNγ-induced reduction in ZO1 expression in T84 cells. (A) T84 cells were pretreated with YG / V medium control or extracts of I. colisanans MH27-1, MH27-2, or MH27-3 (1X) for 18 h or left untreated. Cells were then stimulated with recombinant IFNγ for 48 h, and ZO1 was stained and imaged by confocal microscopy. The scale bar represents 10 μm. (B) Quantification of the relative brightness of ZO1 (normalized to unstimulated cells) shows that pre-treatment with I. colisanans MH27 extract significantly attenuated IFNγ-induced reduction in ZO1 expression in T84 cells. Data are mean ± SD of one experiment and four replicates. One-way ANOVA with Dunnett's multiple comparison correction, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
[0089] Fig.12 A graphical representation is provided showing that pretreatment with I. colisanans MH27 fraction ameliorates IFNγ-induced reduction in ZO1 expression in T84 cells. Effects of fractionated (A) YG / V and (B) I. colisanans MH27-2 extracts on ZO1 expression. Scale bar represents 40 μm. (C) Quantification of ZO1 relative brightness (normalized to unstimulated cells) shows that pretreatment with 15% and 30% fractions of I. colisanans MH27-2 extract significantly attenuated IFNγ-induced reduction in ZO1 expression in T84 cells. Data are mean ± SD of one experiment and four replicates. ***p < 0.001, ****p < 0.0001 using one-way ANOVA with Dunnett's multiple comparison correction.
[0090] Fig.13Provided are graphical representations showing that metabolites produced by I. colisanans MH27 can ameliorate IFNγ-induced reduction in ZO1 expression in T84 cells. (A) T84 cells were pretreated with ornithine, indole-3-acrylic acid (IAyA), or indole-3-propionic acid (IPA) for 18 h or left untreated. Cells were then stimulated with recombinant IFNγ for 48 h, and ZO1 was stained and imaged by confocal microscopy. Scale bar represents 10 μm. (B) Quantification of the relative brightness of ZO1 (normalized to unstimulated cells) showed that pretreatment with all studied metabolites significantly attenuated IFNγ-induced reduction in ZO1 expression in T84 cells. Data are mean ± SD of one experiment and four replicates. **p < 0.01, ***p < 0.001, ****p < 0.0001 using one-way ANOVA with Dunnett's multiple comparison correction. (C) Cyclic (-Phe-Pro) (CPP) inhibits IL-23-mediated STAT3 activation compared to vehicle control. Data are mean ± SD of three experiments. Data were analyzed using unpaired t-test. ****p < 0.0001.
[0091] Fig.14 IL-10 / IL-12 ratio of PBMCs stimulated with I. colisanans. Data are means and SD of single experiments.
[0092] Fig.15 .NF-κB activation was inhibited when LS174T-NF-κB cell line was treated with 25% cell-free or <3 kDa size fractionated I. colisanans supernatant compared to similarly prepared medium (AC). R. bromii MCB950 cell-free supernatant did not inhibit NF-κB activation (D). Samples were compared using an unpaired t-test (*, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001, ns not significant). Data shown are pooled results from 3 independent experiments.
[0093] Fig.16 Gating strategy of the CytoFLEX SRT benchtop cell sorter used to separate I. colisanans MH27-4 (A), MH27-5 (B), MH27-6 (C) and R. bromii MCB950 (D).
[0094] Sequence Description
[0095]
[0096] DETAILED DESCRIPTION OF THE INVENTION
[0098] 1. Definition
[0099] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, preferred methods and materials are described. For purposes of the present invention, the following terms are defined below.
[0100] As used herein, the articles "a" and "an" refer to one or to more than one (ie, to at least one) of the grammatical object of the article. For example, "an" element refers to one element or more than one element.
[0101] The term "about" as used herein refers to the usual error range of the corresponding value that is readily known to those skilled in the art. Herein, when referring to a value or parameter of "approximately", embodiments for the value or parameter itself are included (and described).
[0102] The term "administering" as used herein refers to placing an active agent (e.g., bacteria) disclosed herein into a subject's body by a method or approach, thereby at least partially delivering the active agent to a desired site. Compositions comprising compounds disclosed herein can be administered by any appropriate route, thereby producing effective biological activity or therapeutic effects in the subject's body. In some embodiments, administration includes physical activity of a person (e.g., injection, ingestion action, application action, and / or manipulation of a delivery device or machine). Such activities can be performed by (e.g., a medical professional and / or a subject being treated).
[0103] Specifically, "administering" and "administering" as used herein encompass embodiments in which one human individual instructs another human individual to consume live bacteria, dead bacteria, spent culture medium from bacteria, cell pellets of bacteria, purified metabolites produced by bacteria, purified proteins produced by bacteria, prebiotics, small molecules, or combinations thereof in a certain manner and / or for a certain purpose, which behavior may be independent of or a function of any instructions received by the second individual. Non-limiting examples of embodiments in which one human individual instructs another human individual to consume live bacteria, dead bacteria, spent culture medium from bacteria, cell pellets of bacteria, purified metabolites produced by bacteria, purified proteins produced by bacteria, prebiotics, small molecules, or combinations thereof in a certain manner and / or for a certain purpose include when a physician prescribes a behavioral and / or therapeutic regimen to a patient, when a parent instructs a minor user (e.g., a child) to ingest such a product, when a coach advises a user (e.g., an athlete) to follow a specific behavioral and / or therapeutic regimen, or when a manufacturer, distributor, or marketer recommends conditions of use to an end user, such as by advertising or labeling on packaging or other materials provided in connection with the sale or marketing of the product. In some embodiments, the disclosed compositions can be administered orally, intravenously, intramuscularly, intrathecally, subcutaneously, sublingually, buccally, rectally, vaginally, ocularly, visually, nasally, by inhalation, by atomization, by skin, transdermally, or by a combination thereof, and formulated for delivery with a pharmaceutically acceptable excipient, carrier, or diluent. It is noteworthy that, although the disclosed compositions encompass a variety of formulations and delivery methods for treatment to improve dysbiosis and its sequelae, it should be noted that live biological therapeutic products such as probiotics are not typically administered intravenously, intramuscularly, or intraperitoneally. These delivery methods may be reserved for small molecule products of bacterial metabolism.
[0104] The term "simultaneous administration" or "parallel administration" or "co-administration" and the like refers to the administration of a single composition containing two or more active ingredients, or the administration of each active ingredient as a separate composition and / or the delivery of each active ingredient by separate routes simultaneously or simultaneously or sequentially in a sufficiently short time to make the effective result equivalent to the result obtained when all such active ingredients are administered as a single composition. "Simultaneous" means that multiple active agents are administered at substantially the same time, and are preferably administered together in the same formulation. "Contemporaneous" means that multiple active agents are administered at close times, for example, one active agent is administered within about one minute to about one day before or after another active agent. Any contemporaneous time is useful. However, it is usually the case that when not administered simultaneously, these active agents will be administered within about one minute to about eight hours, and are preferably administered within less than about one hour to about four hours. When administered contemporaneously, the active agents are preferably administered at the same site of the subject. The term "same site" includes the exact location, but may be within about 0.5 to about 15 centimeters, preferably within about 0.5 to about 5 centimeters. As used herein, the term "separately" refers to the administration of multiple active agents at intervals, such as intervals of about one day to several weeks or months. These active agents can be administered in any order. As used herein, the term "sequentially" refers to the administration of multiple active agents in sequence, such as at intervals of a few minutes, hours, days or weeks. If appropriate, these active agents can be administered in regular repeating cycles.
[0105] The term "active agent" includes compounds that induce the desired pharmacological and / or physiological effects. The term also includes pharmaceutically acceptable and pharmacologically active ingredients of those compounds specifically mentioned herein, including but not limited to salts, esters, amides, prodrugs, active metabolites, analogs, etc. When using the above terms, it should be understood that this includes the active agent itself as well as pharmaceutically acceptable, pharmacologically active salts, esters, amides, prodrugs, metabolites, analogs, etc. The term "active agent" should not be interpreted narrowly, but should be extended to small molecules, proteinaceous molecules (such as peptides, polypeptides and proteins) and compositions and genetic molecules (such as RNA, DNA and mimetics and chemical analogs thereof) containing them, as well as cell active agents. The term "active agent" includes cells capable of producing and secreting the polypeptides described herein and polynucleotides comprising the nucleotide sequence encoding the polypeptides. Therefore, the term "active agent" extends to nucleic acid constructs, including vectors for expression and secretion in a range of cells, such as viral or non-viral vectors, expression vectors and plasmids.
[0106] The "amount" or "level" of a biomarker is the level detectable in a sample. These can be measured by methods known to those skilled in the art and disclosed herein. The expression level or amount of the assessed biomarker can be used to determine responsiveness to treatment.
[0107] As used herein, "and / or" refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as the lack of a combination when interpreted in an alternative (or) manner.
[0108] The term "anaerobic" means that oxygen is not required for growth. Anaerobic bacterial strains include obligate anaerobes (i.e., strains that are harmed by the presence of oxygen); aerotolerant anaerobes (i.e., strains that cannot utilize oxygen for growth but can tolerate the presence of oxygen); and facultative anaerobes (i.e., strains that can grow without oxygen but can utilize oxygen if it is present).
[0109] "Anaerobic conditions" are defined as conditions in which the oxygen concentration in the fermentation medium is too low for the microorganism to use it as a terminal electron acceptor. "Anaerobic conditions" can be further defined as conditions in which no oxygen is added to the medium or a small amount of oxygen is added to the medium at a rate of <3mmol / L / h, preferably <2.5mmol / L / h, more preferably <2mmol / L / h, and most preferably <1.5mmol / L / h. "Anaerobic conditions" refer in particular to complete absence of oxygen (=0mmol / L / h oxygen) or a small amount of oxygen is added to the medium at a rate of, for example, <0.5 to <1mmol / L / h. "Anaerobic metabolism" refers to a biochemical process in which oxygen is not the final acceptor for the electrons contained in NADH. Anaerobic metabolism can be divided into anaerobic respiration (in which compounds other than oxygen serve as terminal electron acceptors) and substrate level phosphorylation (in which electrons from NADH are utilized to generate reduction products through a fermentative pathway).
[0110] The term "carbon source" generally refers to a substrate or compound suitable for maintaining microbial growth. Carbon sources can be in various forms, including but not limited to polymers, carbohydrates, alcohols, acids, aldehydes, ketones, amino acids, peptides, etc. For example, these can include monosaccharides (e.g., glucose, fructose, xylose), oligosaccharides (i.e., sucrose, lactose), polysaccharides (i.e., starch, cellulose, hemicellulose), lignocellulosic materials, fatty acids (i.e., succinic acid, lactic acid, acetic acid), glycerol, etc., or mixtures thereof. The carbon source can be a product of photosynthesis, such as glucose or cellulose.
[0111] The monosaccharide used as carbon source can be the product of polysaccharide hydrolysis, such as acid hydrolysis or enzymatic hydrolysis of cellulose, starch and pectin. The term "energy source" can be used interchangeably with carbon source in this article, because in chemo-organic nutrition metabolism, carbon source is used as both electron donor in the decomposition process and carbon source in the cell growth process.
[0112] In this specification, unless the context requires otherwise, the words "comprise", "include" and "contain" should be understood as intended to include the steps or elements or steps or groups of elements, but not to exclude any other steps or elements or groups of steps or elements. Therefore, the use of the term "comprising" and the like indicates that the listed elements are required or mandatory, but other elements are optional and may or may not be present. "Consisting of" means including and limited to the elements following the phrase "consisting of". Therefore, the phrase "consisting of" indicates that the listed elements are required or mandatory and no other elements may be present. "Substantially consisting of" means including any elements listed after the phrase and is limited to other elements that do not interfere with or contribute to the activities or effects specified by the listed elements in the present disclosure. Therefore, the phrase "substantially consisting of" indicates that the listed elements are required or mandatory, but other elements are optional and may or may not be present depending on whether they affect the activity or effect of the listed elements.
[0113] As used herein, "culture", "cultured", etc. refer to a set of procedures used in vitro in which a cell population (or a single cell) is incubated under conditions that have been shown to support the growth or maintenance of the cells in vitro. It is known in the art that a variety of specifications, culture media, temperature ranges, gas concentrations, etc. need to be defined in a culture system. These parameters will vary depending on the specifications selected and the specific needs of the person practicing the methods disclosed herein. However, it will be appreciated that the determination of the culture parameters is routine in nature.
[0114] The terms "reduce", "lower", "decrease", "inhibit", "suppress", "attenuate" and the like are all used herein to indicate a statistically significant amount of reduction. In some embodiments, these terms typically mean a reduction of at least 10% compared to a reference level (e.g., in the absence of a given treatment or active agent), and may include, for example, a reduction of at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99% or more. "Reduce", "inhibit" and "suppress" as used herein do not necessarily mean a complete inhibition or reduction compared to a reference level. "Complete inhibition" and the like refer to 100% inhibition compared to a reference level. The reduction may preferably be reduced to a level within an acceptable normal range (e.g., for an individual without a given disease).
[0115] The terms "increase," "enhance," "enhance," or "activate" are all used herein to refer to an increase by a statistically significant amount. In some embodiments, the terms "increase", "enhance", "enhance" or "activate" can mean an increase of at least 10% compared to a reference level (e.g., in the absence of a given treatment or active agent), and can include, for example, an increase of at least about 10% compared to a reference level, such as an increase of at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or up to and including a 100% increase, or any increase between 10-100%, or an increase of at least about 2-fold, or at least about 3-fold, or at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 10-fold, or any increase between 2-fold and 10-fold or greater compared to a reference level. In the case of a marker or symptom, "increase" refers to a statistically significant increase in such level.
[0116] As used herein, the term "isolated" encompasses bacteria or other entities or substances that have been (1) separated from at least some of the components with which they were originally associated when they were produced (whether in nature, such as human feces, or in an experimental setting, such as a petri dish consisting of an artificial growth medium), and / or (2) artificially produced, prepared, purified and / or manufactured. The isolated bacteria, protein, metabolite, or combination thereof may be separated from at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90% or more of the other components with which they were originally associated. In some embodiments, the purity of the isolated bacteria, protein, metabolite, or combination thereof may be greater than about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or greater than about 99%. As used herein, a substance is "pure" if it is substantially free of other components (e.g., other bacterial species). The terms "purified" and "purified" mean that, as will be apparent to those skilled in the art of bacterial culture or related technical fields (e.g., chemistry), the bacteria or other substance has been separated from at least some of the components with which it was associated when it was initially produced or generated (e.g., in nature or in an experimental setting) or during any time period after its initial production. If a bacterium or bacterial population is separated during or after production, such as from a material or environment containing the bacterium or bacterial population, the bacterium or bacterial population may be considered purified, and a purified bacterium or bacterial population may contain up to about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or more than about 90% of other materials and still be considered "isolated". In some embodiments, the purity of the purified bacteria and bacterial populations exceeds about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more than about 99%. In the case of the bacterial compositions provided herein, one or more bacteria present in the composition can be independently purified from one or more other bacteria produced in and / or present in the material or environment containing the bacteria. In some embodiments, if the bacteria or bacterial population comprises a single bacterial strain, it is "isolated". In some embodiments, such isolated bacteria can be mixed or combined with other isolated bacteria (e.g., in a specified combination of isolated bacteria). Bacterial compositions and their bacterial components are typically purified from the remaining habitat products.
[0117] As used herein, the term "genome" includes DNA comprising genes (coding nucleic acid sequences) and non-coding nucleic acid sequences of a microorganism, and thus includes nucleic acids introduced into, for example, the coding and non-coding DNA of a microorganism.
[0118] The term "Gram-variable" means giving a positive result and / or a negative result (i.e., retaining the color of the crystal violet staining reagent) in a Gram staining test. The retention of crystal violet staining by bacteria is related to the thickness of the peptidoglycan layer in the bacterial cell wall. Gram-positive bacteria have a thicker peptidoglycan layer. Gram staining is commonly used in the field of microbiology to help classify bacterial strains.
[0119] As used herein, the term "gut" is understood to refer to the human gastrointestinal tract, also known as the alimentary canal. The alimentary canal includes the mouth, pharynx, esophagus, stomach, small intestine (duodenum, jejunum, ileum), large intestine (cecum and colon), and rectum. Although the entire alimentary canal can be colonized by various microbial species, the majority of the alimentary canal microbiome, in terms of species number and biomass, resides in the intestinal tract (small intestine and large intestine).
[0120] The terms "marker", "biomarker", etc. refer to any compound that can be measured as an indicator of the physiological state of a biological system. A marker can be a biomarker comprising an amino acid sequence, a nucleic acid sequence, and fragments thereof. Exemplary biomarkers include, but are not limited to, cytokines, chemokines, growth factors and angiogenic factors, metastasis-related molecules, cancer antigens, apoptosis-related proteins, enzymes, proteases, adhesion molecules, cell signaling molecules, and hormones. A marker can also be a sugar, which in some embodiments may not be significantly metabolized in a biological system. The sugar can be, for example, mannitol, lactulose, sucrose, sucralose, and any combination of the foregoing.
[0121] "Measurement" refers to assessing the presence, absence, number or amount (which may be an effective amount) of a given substance in a sample, including deriving a qualitative or quantitative concentration level of the substance, or otherwise assessing the value or classification of a clinical parameter of a subject. Alternatively, the terms "determination" and "detection" may be used to refer to all measurements described in this specification.
[0122] The term "mucosal healing" as used herein refers to an improvement in one or more characteristics of an impaired mucosal layer. Such characteristics are typically determined by colonoscopy and include, but are not limited to, erythema, loss of vascular texture, fragility, bleeding, erosion, and ulceration. In some cases, mucosal healing refers to a complete improvement in the harmful effects characteristic of an impaired mucosal layer. Alternatively, mucosal healing may refer to a reduction or improvement in one or more negative effects characteristic of an impaired mucosal layer.
[0123] The term "pharmaceutical composition" as used herein refers to a combination of an active agent and a pharmaceutically acceptable carrier (e.g., a carrier commonly used in the pharmaceutical industry). The phrase "pharmaceutically acceptable" as used herein refers to compounds, substances, compositions and / or dosage forms that are suitable for contact with human and animal tissues, without excessive toxicity, irritation, allergic reactions or other problems or complications, and with a reasonable benefit / risk ratio, within the scope of reasonable medical judgment. In some embodiments of any of these aspects, a pharmaceutically acceptable carrier may be a carrier other than water. In some embodiments of any of these aspects, a pharmaceutically acceptable carrier may be a cream, an emulsion, a gel, a liposome, a nanoparticle and / or an ointment. In some embodiments of any of these aspects, a pharmaceutically acceptable carrier may be an artificial or engineered carrier (e.g., a carrier in which the active ingredient is found to be absent in nature or in vivo).
[0124] The term "phylogenetic tree" refers to a graph that represents the evolutionary relationship of one gene sequence to another gene sequence, generated using a set of phylogenetic reconstruction algorithms (e.g., parsimony, maximum likelihood, or Bayesian methods). The nodes in the tree represent different ancestral sequences, and the confidence of any node is provided by bootstrap or Bayesian posterior probability, which measures the uncertainty of the branch.
[0125] In some embodiments, the term "strain" refers to a terminal leaf in a phylogenetic tree, defined by a specific genetic sequence. The specific genetic sequence can be a concatenated alignment of 120 ubiquitous single copy proteins extracted from a genome assembly using GTDB-tk (Chaumeil et al., 2020) or other tools known in the art (Parks et al., 2018).
[0126] The term "clade" refers to the set of phylogenetic tree members downstream of a stable node (bootstrap value>90%) in a phylogenetic tree. A clade is a group of related organisms that represents all phylogenetic descendants from a common ancestor. A clade includes a group of terminal leaves in a phylogenetic tree that constitute a unique monophyletic evolutionary unit.
[0127] As used herein, "prebiotics" refers to ingredients that allow specific changes in the composition and / or activity of the gastrointestinal microbiota, which may (or may not) bring benefits to the host. Advantageous prebiotics are those that promote the growth of probiotic compositions or their beneficial functions, but do not promote the growth of pathogens and genes associated with pathogenicity (e.g., toxins).
[0128] As used herein, "probiotics" are understood to be "live microorganisms which when administered in adequate amounts confer a health benefit on the host" as currently defined by the World Health Organization.
[0129] The term "species" is defined as a group of closely related organisms that share greater than 97% 16S ribosomal RNA (rRNA) sequence homology and greater than 70% genomic hybridization and are sufficiently divergent from all other organisms to be recognized as a distinct unit. Species and other phylogenetic identifications are made according to classifications known to those skilled in the art of microbiology.
[0130] As used herein, "subject" refers to humans or animals. Typically, animals are vertebrates, such as primates, rodents, livestock, or game animals. Primates include chimpanzees, crab-eating monkeys, spider monkeys, and macaques (e.g., rhesus monkeys). Rodents include mice, rats, marmots, ferrets, rabbits, and hamsters. Domestic and game animals include cows, horses, pigs, deer, bison, buffaloes, felines (e.g., house cats), canines (e.g., dogs, foxes, wolves), avian animals (e.g., chickens, emus, ostriches), and fish (e.g., trout, catfish, and salmon). In some embodiments, subjects are mammals (e.g., primates (e.g., humans)). The terms "individual," "patient," and "subject" are used interchangeably herein.
[0131] Preferably, the subject is a mammal. The mammal may be a human, a non-human primate, a mouse, a rat, a dog, a cat, a horse or a cow, but is not limited to these examples. Mammals other than humans can be advantageously used as subjects representing animal models of inflammation and autoimmune disorders (e.g., digestive tract barrier function models). The subject may be male or female.
[0132] As used herein, the terms "treatment", "therapeutic", "therapeutic" and the like refer to therapeutic treatment, wherein the purpose is to reverse, alleviate, improve, inhibit, slow down or stop the progression or severity of the condition associated with a disease or disorder (e.g., inflammation or autoimmune disorder). The term "treatment" includes reducing or alleviating at least one adverse effect or symptom of a condition, disease or disorder associated with inflammation or autoimmune disorder. If one or more symptoms or clinical indicators are reduced, the treatment is usually "effective". Alternatively, if the progression of the disease is slowed down or stopped, the treatment is "effective". That is, compared to the expected situation when there is no treatment, "treatment" not only includes the improvement of symptoms or markers, but also includes the stopping or at least slowing down of symptom progression or deterioration. Beneficial or desired clinical results include, but are not limited to, alleviating one or more symptoms, alleviating the degree of disease, stabilizing the disease state (i.e., not worsening), delaying or slowing the progression of disease, improving or alleviating the disease state, alleviating (whether partially or completely) and / or reducing mortality, whether detectable or undetectable. The term "treatment" of a disease also includes alleviating the symptoms or side effects of the disease (including palliative care). Treatment does not need to cure the disease (i.e., completely reverse or eliminate the disease) to be considered effective.
[0133] In some embodiments, sequencing includes 16S rRNA gene sequencing, which may also be referred to as "16S ribosomal RNA sequencing", "16S rDNA sequencing" or "16S rRNA sequencing". Sequencing of the 16S rRNA gene can be used for genetic studies because it is highly conserved between different bacterial species, but is not present in eukaryotic species. In addition to the highly conserved regions, the 16S rRNA gene also includes 9 hypervariable regions (V1-V9) that vary between species. 16S rRNA gene sequencing generally includes using a plurality of universal primers that bind to conserved regions of the 16S rRNA gene, PCT amplifying a bacterial 16S rRNA gene region (including a hypervariable region), and sequencing the amplified 16S rRNA gene using the next generation sequencing technology described herein (see also, e.g., U.S. Pat. Nos. 5,654,418; 6,344,316; and 8,889,358; and U.S. Patent Publication Nos. 2013 / 157,265 and 2018 / 195,111, each of which is incorporated herein by reference in its entirety).
[0134] Unless explicitly stated otherwise, each embodiment described herein may be applicable to each and any embodiment after adaptation.
[0135] 2. Bacterial strains
[0136] The composition of the present invention comprises a bacterial strain of the genus Intestinicoccus. The examples show that the bacteria of this genus can be used to treat or prevent diseases associated with impaired digestive tract barrier function. The preferred bacterial strain is the species I. colisanans.
[0137] Intestinicoccus is a species of bacteria in the class Firmicutes. Its scientific classification is as follows: Bacteria (kingdom); Firmicutes (phylum); Clostridia (class); Oscillospirales (order); Acutalibacteraceae (family); Intestinicoccus (genus). Bacteria in the genus Intestinicoccus are Gram-indeterminate, have a coccoid shape, and are obligate anaerobes. These criteria are important because they can provide information about the phylogenetic classification of bacterial strains.
[0138] The species I. colisanans has not been described previously. This species has been isolated from a human fecal sample using the methods described in the examples below.
[0139] The breadth of the genus Intestinicoccus and the species I. colisanans can be defined by the Genome Taxonomy Database reference tree, a taxonomic classification system described by Parks et al., 2018.
[0140] In the examples, I. colisanans bacteria (i.e., I. colisanans MH27-1) deposited with accession number V21 / 015887 was tested, which is one of the preferred strains of the present invention. I. colisanans strain MH27-1 was deposited on August 6, 2021 by Microba IP Pty Ltd (388 Queen Street, Brisbane, Queensland 4000, Australia) under the name of "Intestinicoccus colisanans MH27-1" at the National Metrology Institute of International Depository Units (NMI, 1 / 153 Bertie Street, Port Melbourne, Victoria, 3207, Australia), with accession number V21 / 015887.
[0141] An exemplary 16S rRNA sequence of the tested I. colisanans MH27-1 strain is given in SEQ ID NO: 1. The bacterial strain of the I. colisanans species may contain a single 16S rRNA sequence within its genome, or may contain two or more 16S rRNA sequences (e.g., two copies, three copies, four copies, five copies, six copies, seven copies, eight copies, or more than eight copies) within its genome. In some embodiments, the bacterial strain may be identified as an I. colisanans MH27-1 strain by determining whether the strain contains a 16S rRNA sequence corresponding to SEQ ID NO: 1 by any method known in the art. The chromosomal sequence of strain I. colisanans MH27-1 is given in SEQ ID NO: 3 and 4. These sequences were generated using the Illumina NovSeq6000 platform.
[0142] The examples also show that bacterial strains closely related to strain MH27-1 can effectively treat or prevent inflammatory and autoimmune disorders through their beneficial effects on restoring the digestive tract barrier function.
[0143] For example, the I. colisanans bacteria deposited with accession number V21 / 015888 (i.e., I. colisanans MH27-2) was tested in the examples, which is another preferred strain of the present invention. An exemplary 16S rRNA sequence of the tested I. colisanans MH27-2 strain is listed in SEQ ID NO: 2. In some embodiments, the bacterial strain can be identified as an I. colisanans MH27-2 strain by determining whether the strain contains a 16S rRNA sequence corresponding to SEQ ID NO: 2 by any method known in the art. The strain I. colisanans MH27-2 was deposited on August 6, 2021 by Microba IP Pty Ltd (388 Queen Street, Brisbane, QLD 4000, Australia) under the name "Intestinicoccus colisanans MH27-2" at the National Metrology Institute (NMI, 1 / 153 Bertie Street, Port Melbourne, Victoria, 3207, Australia) with the deposit number V21 / 015888. The genome of the strain I. colisanans MH27-2 comprises a chromosome having a sequence as shown in one or both of SEQ ID NOs: 5 or 6.
[0144] In other embodiments, exemplary 16S rRNA sequences of I. colisanans strains MH27-3, MH27-4, MH27-5, and MH27-6 tested in the embodiments are listed in SEQ ID NOs: 7-10. In some embodiments, the bacterial strain can be identified as I. colisanans MH27-3 strain by determining whether the strain contains a 16S rRNA sequence corresponding to SEQ ID NO: 7 by any method known in the art. In some embodiments, the bacterial strain can be identified as I. colisanans MH27-4 strain by determining whether the strain contains a 16S rRNA sequence corresponding to SEQ ID NO: 8 by any method known in the art. In some embodiments, the bacterial strain can be identified as I. colisanans MH27-5 strain by determining whether the strain contains a 16S rRNA sequence corresponding to SEQ ID NO: 9 by any method known in the art. In some embodiments, the bacterial strain can be identified as I. colisanans MH27-6 strain by determining whether the strain comprises a 16S rRNA sequence corresponding to SEQ ID NO: 10 by any method known in the art.
[0145] The genome of strain I. colisanans MH27-3 comprises a chromosome having a sequence as shown in one or more of SEQ ID NOs: 11 to 14. The genome of strain I. colisanans MH27-4 comprises a chromosome having a sequence as shown in one or more of SEQ ID NOs: 15 to 18. The genome of strain I. colisanans MH27-5 comprises a chromosome having a sequence as shown in one or more of SEQ ID NOs: 19 to 22.
[0146] In certain embodiments, the bacterial strains of the present invention have a 16S rRNA sequence that is at least 97.5%, 98%, 98.5%, 99%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identical to the 16S rRNA sequence of the I. colisanans bacterial strain. Preferably, the bacterial strains of the present invention have a 16S rRNA sequence that is at least 97.5%, 98%, 98.5%, 99%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identical to any one of SEQ ID NOs: 1, 2 or 7-10. In some preferred embodiments, the bacterial strains of the present invention have a 16S rRNA sequence represented by any one of SEQ ID NOs: 1, 2 or 7-10.
[0147] The genome of the bacterial strain may comprise the 16S rRNA sequence shown in any one of SEQ ID NOs: 1, 2 or 7-10.
[0148] In certain embodiments, the bacterial strains of the present invention have a chromosome having sequence identity to one or both of the sequences shown in SEQ ID NO: 3 or 4. In preferred embodiments, the bacterial strains of the present invention have a chromosome having at least 90% sequence identity (e.g., at least 92%, 94%, 95%, 96%, 97%, 97.5%, 98%, 98.5%, 99%, 99.5% or 100% sequence identity) to one or both of the sequences shown in SEQ ID NO: 3 or 4 on at least 60% (e.g., at least 65%, 70%, 75%, 80%, 85%, 95%, 96%, 97%, 98%, 99% or 100%) of SEQ ID NO: 3 or 4. For example, the chromosome of the bacterial strain of the present invention may have at least 90% sequence identity with one or both of the sequences shown in SEQ ID NO: 3 or 4 at 70% of SEQ ID NO: 3 or 4; or, at least 90% sequence identity with one or both of SEQ ID NO: 3 or 4 at 80% of SEQ ID NO: 3 or 4; or, at least 90% sequence identity with one or both of SEQ ID NO: 3 or 4 at 90% of SEQ ID NO: 3 or 4; or, at least 90% sequence identity with one or both of SEQ ID NO: 3 or 4 at 100% of SEQ ID NO: 3 or 4; or, at least 95% sequence identity with one or both of SEQ ID NO: 3 or 4 at 70% of SEQ ID NO: 3 or 4; or, at least 95% sequence identity with one or both of SEQ ID NO: 3 or 4 at 80% of SEQ ID NO: 3 or 4; or, at least 95% sequence identity with one or both of SEQ ID NO: 3 or 4 at 80% of SEQ ID NO: 3 or 4; NO:3 or 4 has at least 95% sequence identity with one or both of SEQ ID NO:3 or 4 over 90% of SEQ ID NO:3 or 4; or, at least 95% sequence identity with one or both of SEQ ID NO:3 or 4 over 100% of SEQ ID NO:3 or 4; or, at least 98% sequence identity with one or both of SEQ ID NO:3 or 4 over 70% of SEQ ID NO:3 or 4; or, at least 98% sequence identity with one or both of SEQ ID NO:3 or 4 over 80% of SEQ ID NO:3 or 4; or, at least 98% sequence identity with one or both of SEQ ID NO:3 or 4 over 90% of SEQ ID NO:3 or 4; or, at least 98% sequence identity with one or both of SEQ ID NO:3 or 4 over 100% of SEQ ID NO:3 or 4. A particularly preferred strain of the present invention is the I. colisanans strain deposited under the accession number V21 / 015887.This is an exemplary MH27-1 strain tested in a DSS mouse model shown in the Examples and has been shown to be effective for treating disease. Therefore, the present invention provides cells (e.g., isolated cells) of the I. colisanans strain or its derivatives with a preservation number of V21 / 015887. The present invention also provides a composition comprising cells of the I. colisanans strain or its derivatives with a preservation number of V21 / 015887. The present invention also provides a biologically pure culture of the I. colisanans MH27-1 strain with a preservation number of V21 / 015887.
[0149] In certain embodiments, the bacterial strains of the present invention have a chromosome with sequence identity to SEQ ID NO: 5 or 6. In preferred embodiments, the bacterial strains of the present invention have a chromosome with at least 90% sequence identity (e.g., at least 92%, 94%, 95%, 96%, 97%, 97.5%, 98%, 98.5%, 99%, 99.5% or 100% sequence identity) to one or both of SEQ ID NO: 5 or 6 on at least 60% (e.g., at least 65%, 70%, 75%, 80%, 85%, 95%, 96%, 97%, 98%, 99% or 100%) of SEQ ID NO: 5 or 6. For example, the chromosome of the bacterial strain of the present invention can have at least 90% sequence identity with one or both of SEQ ID NO: 5 or 6 at 70% of SEQ ID NO: 5 or 6; or, at least 90% sequence identity with one or both of SEQ ID NO: 5 or 6 at 80% of SEQ ID NO: 5 or 6; or, at least 90% sequence identity with one or both of SEQ ID NO: 5 or 6 at 90% of SEQ ID NO: 5 or 6; or, at least 90% sequence identity with one or both of SEQ ID NO: 5 or 6 at 100% of SEQ ID NO: 5 or 6; or, at least 95% sequence identity with one or both of SEQ ID NO: 5 or 6 at 70% of SEQ ID NO: 5 or 6; or, at least 95% sequence identity with one or both of SEQ ID NO: 5 or 6 at 80% of SEQ ID NO: 5 or 6; or, at least 95% sequence identity with one or both of SEQ ID NO: 5 or 6 at 80% of SEQ ID NO: 5 or 6; NO:5 or 6 has at least 95% sequence identity with one or both of SEQ ID NO:5 or 6 over 90% of SEQ ID NO:5 or 6; or, at least 95% sequence identity with one or both of SEQ ID NO:5 or 6 over 100% of SEQ ID NO:5 or 6; or, at least 98% sequence identity with one or both of SEQ ID NO:5 or 6 over 70% of SEQ ID NO:5 or 6; or, at least 98% sequence identity with one or both of SEQ ID NO:5 or 6 over 80% of SEQ ID NO:5 or 6; or, at least 98% sequence identity with one or both of SEQ ID NO:5 or 6 over 90% of SEQ ID NO:5 or 6; or, at least 98% sequence identity with one or both of SEQ ID NO:5 or 6 over 100% of SEQ ID NO:5 or 6. A particularly preferred strain of the present invention is the I. colisanans strain deposited under the accession number V21 / 015888.This is an exemplary MH27-2 strain tested in the DSS mouse model in the Examples and shown to be effective for treating disease. Therefore, the present invention provides cells of the I. colisanans strain or its derivatives deposited under the deposit number V21 / 015888, such as isolated cells. The present invention also provides a composition comprising cells of the I. colisanans strain or its derivatives deposited under the deposit number V21 / 015888. The present invention also provides a biologically pure culture of the I. colisanans MH27-2 strain deposited under the deposit number V21 / 015888.
[0150] The derivative of the bacterial strain deposited under the preserving number V21 / 015887 or V21 / 015888 can be a progeny strain (offspring) or a bacterial strain cultivated (subclone) from the original strain. The derivative of the bacterial strain of the present invention can be modified, for example, at the gene level, without eliminating biological activity. Specifically, the derivative bacterial strain of the present invention has therapeutic activity. The derivative bacterial strain will have an activity suitable for the original bacterial strain (that is, the bacterial strain deposited under the preserving number V21 / 015887 or V21 / 015888) derived from it. In particular, the derivative bacterial strain will cause a suitable effect in at least one disease model (for example, colitis) as shown in the embodiments, which can be identified by using the culture and administration scheme described in the embodiments. Any derivative in V21 / 015887 or V21 / 015888 bacterial strain is typically the biotype (biotype) of the corresponding V21 / 015887 or V21 / 015888 bacterial strain.
[0151] Reference to cells of the I. colisanans strain deposited under accession number V21 / 015887 includes any cells having the same safety and therapeutic efficacy characteristics as the strain deposited under either of accession numbers V21 / 015887 or V21 / 015888, and such cells are encompassed by the present invention.
[0152] 2.1 Bacterial biotype
[0153] It is expected that bacterial strains that are biotypes of the bacteria deposited under accession number V21 / 015887 or V21 / 015888 may also be effectively used to treat or prevent inflammatory and autoimmune disorders. Biotypes are closely related strains that have the same or very similar physiological and biochemical characteristics.
[0154] As a biotype of bacteria with a deposit number of V21 / 015887 or V21 / 015888 and suitable for use in the present invention, it can be identified by sequencing other nucleotide sequences of bacteria deposited with deposit numbers V21 / 015887 or V21 / 015888. For example, substantially the entire genome can be sequenced, and the biotype strain of the present invention can have at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% sequence identity over at least 80% of its entire genome (e.g., at least 85%, 90%, 95% or 99%, or over its entire genome). Other suitable sequences for identifying biotype strains may include hsp60 or repeat sequences, such as BOX, ERIC, (GTG) 5 or REP (Masco et al., 2003; Kim et al., 2019). The biotype strain may have a sequence that has at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% sequence identity to the corresponding sequence of the bacterium deposited under accession number V21 / 015887 or V21 / 015888.
[0155] Alternatively, the strain is a biotype of the bacterium deposited under accession number V21 / 015887 or V21 / 015888, and restriction fragment analysis and / or PCR analysis can be used, for example using fluorescent amplified fragment length polymorphism (FAFLP) and repetitive DNA element (rep)-PCR fingerprint analysis, or protein profiling, or partial 16S or 23S rRNA sequencing. In some preferred embodiments, such techniques can be used to identify other suitable I. colisanans strains.
[0156] In certain embodiments, a strain that is a biotype of a bacterium deposited under accession number V21 / 015887 or V21 / 015888 and is suitable for use in the present invention is a strain that is suitable for use in the present invention when analyzed by amplified ribosomal DNA restriction analysis (ARDRA), for example, when using the Sau3AI restriction enzyme (for exemplary methods and guidance, see, for example, et al., 2011), providing a strain having the same pattern as the bacteria deposited under accession number V21 / 015887 or V21 / 015888. Alternatively, the biotype strain can be identified as a strain having the same carbohydrate fermentation pattern as the bacteria deposited under accession number V21 / 015887 or V21 / 015888.
[0157] In some embodiments, bacterial strains useful for the present invention can be identified by routine analysis of the metabolite production and consumption profiles of the bacterial strains. It is expected that the bacterial strains described above and elsewhere herein will produce acetic acid. Thus, in some embodiments, the bacterial strains of the present invention can induce the production of the metabolite acetic acid in vivo. In addition, in some embodiments, the bacterial strains of the present invention do not produce butyrate.
[0158] Any suitable method or strategy (including the assay described in the examples) can be used to identify other Intestinicoccus strains that can be used in the compositions and methods of the present invention, such as the biotype of the bacteria deposited under the deposit number V21 / 015887 or V21 / 015888. For example, the strains used in the present invention can be identified by culturing in anaerobic TY or PYG medium and / or applying the bacteria to a DSS-induced digestive barrier function model, and then evaluating cytokine / chemokine levels, as described in the examples. In particular, bacterial strains having growth patterns, metabolic types and / or surface antigens similar to those of the bacteria deposited under the deposit number V21 / 015887 or V21 / 015888 can be used in the present invention. Useful strains will have immunomodulatory activity comparable to that of the V21 / 015887 or V21 / 015888 strains. In particular, the biotype strains will have similar effects on host digestive tract function. In addition, it is expected that the biotypes will produce comparable effects in disease models (e.g., colitis, asthma, arthritis, multiple sclerosis, and uveitis disease models) as shown in the Examples, and will produce comparable effects on cytokine / chemokine levels as shown in the Examples, which can be identified using the culture and administration protocols described in the Examples.
[0159] 2.2 Bacterial strain vitality
[0160] In a preferred embodiment, the bacterial strain in the composition of the present invention is alive. In a preferred embodiment, the bacterial strain in the composition of the present invention is alive and is able to partially or completely colonize the intestinal tract. In some preferred embodiments, the bacterial strain in the composition of the present invention is alive. For example, the bacterial strain in the composition of the present invention is not heat-inactivated. The bacteria of the present invention may have immunomodulatory effects that non-live bacteria do not exhibit, for example because non-live bacteria cannot produce metabolites and interact with the immune system in a different way. The cell surface of live bacteria may also be significantly different from that of inactivated bacteria, particularly heat-inactivated bacteria.
[0161] In some alternative embodiments, the bacteria are not alive. For example, in some embodiments, the bacteria are heat-killed.
[0162] In some preferred embodiments, the bacterial strain used in the present invention is naturally occurring. For example, the bacterial strain has been isolated from the digestive tract of a mammal.
[0163] In some preferred embodiments, the bacterial strain used in the present invention has not been genetically engineered. For example, the bacterial strain has not been transformed with recombinant DNA.
[0164] 3. Composition
[0165] The compositions provided herein comprise, consist of or consist essentially of a therapeutically effective amount of one or more bacterial strains described above and / or elsewhere herein. In some embodiments, the bacteria in the compositions can be identified by strain, species, operational taxonomic unit (OTU), full genome sequence, 16S rRNA sequence, or other methods known in the art for defining different types of bacteria.
[0166] 3.1 Most recent common ancestor (MRCA)
[0167] In some embodiments, the composition comprises an effective amount of a bacterial strain that is a phylogenetic descendant of the MRCA of I. colisanans and I. sp002305575 (see Figure 1 B). Preferably, the phylogenetic classification is as defined in GTDB (Parks et al., 2018). In some embodiments, the phylogenetic classification is as defined in version 89 (r89) of GTDB.
[0168] In some embodiments, phylogenetic grouping programs known in the art can be used to determine whether the bacterial strain is a descendant of the MRCA of I.colisanans and I.sp002305575. In some embodiments, a rooted phylogenetic tree with I.colisanans and I.sp002305575 and a third taxon (e.g., a taxon to be classified) can be used, wherein the following analysis packages are applied: phylogenetic and evolutionary analysis ("ape"; https: / / cran.r-project.org / web / packages / ape / index) and phylogenetic tools for comparative biology ("phytools"; http: / / cran.r-project.org / web / packages / phytools / index.html) to determine whether the taxon of interest can be used for the composition of the present invention. Both ape and phytools are packages written in R for studying molecular evolution and phylogeny. The ape and phytools packages provide methods for phylogenetic and evolutionary analysis, and their use is known to those skilled in the art. In some embodiments, the following scripts can be used:
[0169] library("ape")
[0170] library("phytools")
[0171] input.tree=read.tree(file="tree_file")
[0172] intest=c("s__Intestinicoccus colisanans","s__Intestinicoccussp002305575")
[0173] intest.node=getMRCA(input.tree,intest)
[0174] intest.tree=extract.clade(input.tree,intest.node)
[0175] print(intest.tree$tip.label)
[0176] In some embodiments, after running the script, if the taxon of interest is in the printed list, it is a descendant of the MRCA of the two species.
[0177] In other embodiments, different phylogenetic grouping methods known in the art can be used to determine whether a bacterial strain is a descendant of the MRCA of I. colisanans and Figure 1 B), including the use of different analysis packages and methods based on different programming languages.
[0178] In some other embodiments, the bacterial strain is a phylogenetic descendant of the MRCA of I. colisanans and I. sp002305575, and is combined with a pharmaceutically acceptable carrier, diluent or excipient. Suitably, the MRCA is defined at node 23596 of the bac120 phylogenetic tree from GTDB. In some embodiments, the phylogenetic tree is created by version 89 of GTDB, however, any suitable subsequent version is considered to provide equally applicable results.
[0179] 3.2 16S rRNA sequence identity
[0180] In some embodiments, the 16S rRNA sequence of the bacterial species to be classified is obtained or determined. The query 16S rRNA sequence is compared with the 16S rRNA sequence from the bacterial species that has been classified as a member of the genus Intestinicoccus. In some embodiments, the query 16S rRNA sequence is compared with the 16S rRNA sequence shown in SEQ ID NO:1. In some embodiments, the query 16S rRNA sequence is compared with all known 16S rRNA sequences from the bacterial species that have been classified as members of the genus Intestinicoccus. In other embodiments, the query 16S rRNA sequence is compared with a subset of all known 16S rRNA sequences from the bacterial species that have been classified as members of the genus Intestinicoccus. Determine the percentage identity between the query sequence and the comparison sequence. If it is determined that the percentage identity of the query sequence is higher than a defined threshold, the bacterial species to be classified is classified as a member of the genus Intestinicoccus.
[0181] In some embodiments, the threshold sequence identity is 95%. In some other embodiments, the threshold sequence identity is 97.5%. In some other embodiments, the threshold sequence identity is 99.0%. In some embodiments, the threshold sequence identity is 94.5%, 94.6%, 94.7%, 94.8%, 94.9%, 95.0%, 95.1%, 95.2%, 95.3%, 95.4%, 95.5%, 95.6%, 95.7%, 95.8%, 95.9%, 96.0%, 96.1%, 96.2%, 96.3%, 96.4%, 96.5%, 96.6%, 96.7%, 96.8%, 96.9%, 97.0%, 97.1%, 97.2%, 97.3%, 97.4%, 97.5%, 97.6%, 97.7%, 97.8%, 97.9%, 98.0%, 98.1%, 98.2%, 98.3%, 98.4%, 98.5%, 98.6%, 98.7%, 98.8%, 98.9%, 99.0%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 9 ... .1%, 97.2%, 97.3%, 97.4%, 97.5%, 97.6%, 97.7%, 97.8%, 97.9%, 98.0%, 98.1%, 98.2%, 98.3%, 98.4%98.5%, 98.6%, 98.7%, 98.8%, 98.9%, 99.0%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100%.
[0182] In some embodiments, the 16S rRNA sequence of the bacterial species to be classified is obtained or determined. The query 16S rRNA sequence is compared with the 16S rRNA sequence (including the sequence listed in any one of SEQ ID NO: 1, 2 or 7-10) from the bacterial species that have been classified as members of the Acutalibacteraceae family. In some embodiments, the query 16S rRNA sequence is compared with all known 16S rRNA sequences from bacterial species that have been classified as members of the Acutalibacteraceae family. In other embodiments, the query 16S rRNA sequence is compared with a subset of all known 16S rRNA sequences from bacterial species that have been classified as members of the Acutalibacteraceae family. Determine the percentage identity between the query sequence and the comparison sequence. If it is determined that the percentage identity of the query sequence is higher than a defined threshold, the bacterial species to be classified is classified as a member of the family.
[0183] In some embodiments, the threshold sequence identity is 95%. In some embodiments, the threshold sequence identity is 98.7%. In some embodiments, the threshold sequence identity is 94.8%. In some embodiments, the threshold sequence identity is 94.5%, 94.6%, 94.7%, 94.8%, 94.9%, 95.0%, 95.1%, 95.2%, 95.3%, 95.4%, 95.5%, 95.6%, 95.7%, 95.8%, 95.9%, 96.0%, 96.1%, 96.2%, 96.3%, 96.4%, 96.5%, 96.6%, 96.7%, 96.8%, 96.9%, 97.0%, 97.1%, 97.2%, 97.3%, 97.4%, 97.5%, 97.6%, 97.7%, 97.8%, 97.9%, 98.0%, 98.1%, 98.2%, 98.3%, 98.4%, 98.5%, 98.6%, 98.7%, 98.8%, 98.9%, 99.0%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 9 ... .1%, 97.2%, 97.3%, 97.4%, 97.5%, 97.6%, 97.7%, 97.8%, 97.9%, 98.0%, 98.1%, 98.2%, 98.3%, 98.4%98.5%, 98.6%, 98.7%, 98.8%, 98.9%, 99.0%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100%.
[0184] In some embodiments, the composition comprises an at least partially isolated bacterial strain of I. colisanans as described above and / or elsewhere herein.
[0185] In certain embodiments, the bacterial strains of the present invention have a 16S rRNA sequence that is at least 97.5%, 98%, 98.5%, 99%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identical to the 16S rRNA sequence of the I. colisanans bacterial strain. Preferably, the bacterial strains of the present invention have a 16S rRNA sequence that is at least 97.5%, 98%, 98.5%, 99%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identical to any one of SEQ ID NO: 1 or 2. In some preferred embodiments, the bacterial strains of the present invention have a 16S rRNA sequence represented by any one of SEQ ID NO: 1 or 2. In some other preferred embodiments, the bacterial strains of the present invention have a 16S rRNA sequence represented by any one of SEQ ID NO: 7-10.
[0186] The genome of the bacterial strain may include the 16S rRNA sequence shown in any one of SEQ ID NOs: 1, 2, or 7-10.
[0187] 3.3 Genome sequence identity
[0188] In certain embodiments, the bacterial strains of the present invention have a chromosome having sequence identity to any one of SEQ ID NO: 3 or 4. In preferred embodiments, the bacterial strains of the present invention have a chromosome having at least 90% sequence identity (e.g., at least 92%, 94%, 95%, 96%, 97%, 97.5%, 98%, 98.5%, 99%, 99.5% or 100% sequence identity) to any one of SEQ ID NO: 3 or 4 over at least 60% (e.g., at least 65%, 70%, 75%, 80%, 85%, 95%, 96%, 97%, 98%, 99% or 100%) of SEQ ID NO: 3 or 4. For example, the chromosome of the bacterial strain of the present invention can have at least 90% sequence identity with one of SEQ ID NO: 3 or 4 over 70% of SEQ ID NO: 3 or 4; or, at least 90% sequence identity with one of SEQ ID NO: 3 or 4 over 80% of SEQ ID NO: 3 or 4; or, at least 90% sequence identity with one of SEQ ID NO: 3 or 4 over 90% of SEQ ID NO: 3 or 4; or, at least 90% sequence identity with one of SEQ ID NO: 3 or 4 over 100% of SEQ ID NO: 3 or 4; or, at least 95% sequence identity with one of SEQ ID NO: 3 or 4 over 70% of SEQ ID NO: 3 or 4; or, at least 95% sequence identity with one of SEQ ID NO: 3 or 4 over 80% of SEQ ID NO: 3 or 4; or, at least 90% sequence identity with one of SEQ ID NO: 3 or 4 over 90% of SEQ ID NO: 3 or 4; or SEQ ID NO: 3 or 4. A strain having at least 95% sequence identity to one of SEQ ID NO: 3 or 4; or, having at least 95% sequence identity to one of SEQ ID NO: 3 or 4 over 100%; or, having at least 98% sequence identity to one of SEQ ID NO: 3 or 4 over 70%; or, having at least 98% sequence identity to one of SEQ ID NO: 3 or 4 over 80%; or, having at least 98% sequence identity to one of SEQ ID NO: 3 or 4 over 90%; or, having at least 98% sequence identity to one of SEQ ID NO: 3 or 4 over 100%. A particularly preferred strain of the present invention is the I. colisanans strain deposited under accession number V21 / 015887. This is the exemplary MH27-1 strain tested in the DSS mouse model shown in the Examples and demonstrated to be effective in treating the disease.Therefore, the present invention provides a cell (e.g., an isolated cell) of the I. colisanans strain or a derivative thereof with a deposit number of V21 / 015887. The present invention also provides a composition comprising a cell of the I. colisanans strain or a derivative thereof with a deposit number of V21 / 015887. The present invention also provides a biologically pure culture of the I. colisanans MH27-1 strain with a deposit number of V21 / 015887.
[0189] In certain embodiments, the bacterial strains of the present invention have a chromosome having sequence identity to any one of SEQ ID NO: 5 or 6. In preferred embodiments, the bacterial strains of the present invention have a chromosome having at least 90% sequence identity (e.g., at least 92%, 94%, 95%, 96%, 97%, 97.5%, 98%, 98.5%, 99%, 99.5% or 100% sequence identity) to any one of SEQ ID NO: 5 or 6 over at least 60% (e.g., at least 65%, 70%, 75%, 80%, 85%, 95%, 96%, 97%, 98%, 99% or 100%) of SEQ ID NO: 5 or 6. For example, the chromosome of the bacterial strain of the present invention can have at least 90% sequence identity with one of SEQ ID NO: 5 or 6 over 70% of SEQ ID NO: 5 or 6; or, at least 90% sequence identity with one of SEQ ID NO: 5 or 6 over 80% of SEQ ID NO: 5 or 6; or, at least 90% sequence identity with one of SEQ ID NO: 5 or 6 over 90% of SEQ ID NO: 5 or 6; or, at least 90% sequence identity with one of SEQ ID NO: 5 or 6 over 100% of SEQ ID NO: 5 or 6; or, at least 95% sequence identity with one of SEQ ID NO: 5 or 6 over 70% of SEQ ID NO: 5 or 6; or, at least 95% sequence identity with one of SEQ ID NO: 5 or 6 over 80% of SEQ ID NO: 5 or 6; or, at least 90% sequence identity with one of SEQ ID NO: 5 or 6 over 90% of SEQ ID NO: 5 or 6; or SEQ ID NO: 5 or 6. A strain having at least 95% sequence identity to one of SEQ ID NO: 5 or 6; or, having at least 95% sequence identity to one of SEQ ID NO: 5 or 6 over 100%; or, having at least 98% sequence identity to one of SEQ ID NO: 5 or 6 over 70%; or, having at least 98% sequence identity to one of SEQ ID NO: 5 or 6 over 80%; or, having at least 98% sequence identity to one of SEQ ID NO: 5 or 6 over 90%; or, having at least 98% sequence identity to one of SEQ ID NO: 5 or 6 over 100%. A particularly preferred strain of the present invention is the I. colisanans strain deposited under accession number V21 / 015888. This is the exemplary MH27-2 strain tested in the DSS mouse model shown in the Examples and demonstrated to be effective in treating the disease.Therefore, the present invention provides a cell (e.g., an isolated cell) of an I. colisanans strain or a derivative thereof with a deposit number of V21 / 015888. The present invention also provides a composition comprising a cell of an I. colisanans strain or a derivative thereof with a deposit number of V21 / 015888. The present invention also provides a biologically pure culture of an I. colisanans MH27-2 strain with a deposit number of V21 / 015888.
[0190] 4. Functional characteristics of bacterial strains
[0191] Digestive tract barrier disorder is a key pathway leading to systemic inflammation. As demonstrated in the examples, the bacterial strains of the present invention and the composition comprising the strains can effectively enhance the digestive tract barrier function.
[0192] All inflammatory or autoimmune disorders mediated by digestive tract barrier disorders that result in systemic inflammation in a subject are suitable for treatment with the bacterial strains described above and / or elsewhere herein.
[0193] 4.1 Digestive tract barrier function
[0194] The digestive tract barrier (also called intestinal barrier) function regulates transport and host defense mechanisms at the interface between the mucosa and the outside world. Transcellular and paracellular traffic is strictly controlled by membrane pumps, ion channels, and tight junctions, so that permeability is adapted to physiological needs.
[0195] Foreign (i.e. non-host) substances (e.g., lipopolysaccharides (LPS) and other inflammatory compounds) are translocated from the intestinal lumen to the circulatory system and are inhibited by the epithelial barrier. One of the functions of this epithelial barrier is performed by tight junctions. Tight junctions, or zonula occludens, are tightly connected areas of two epithelial cells, whose membranes combine to form a barrier that is essentially impenetrable by liquid, thereby separating the vascular system from the digestive tract cavity. Any level of interference, especially bacterial translocation due to increased permeability and oral tolerance destruction due to impaired epithelial and T cell interactions, may lead to inflammation and tissue damage. Therefore, it has been shown that a reduction in tight junction barrier function can lead to increased transfer of undesirable substances (e.g., LPS) from the intestinal lumen to the circulatory system.
[0196] The present invention provides a method for restoring or improving the digestive tract barrier function of a subject, the method comprising applying a composition comprising I.colisanans bacterial strains to a subject, thereby restoring or improving the digestive tract barrier function of a subject. As used in this specification, digestive tract barrier integrity is a measure of digestive tract barrier function. High digestive tract barrier integrity can be associated with a lack of intestinal or digestive tract permeability, wherein a high level of digestive tract permeability indicates that digestive tract barrier integrity is low. In a related embodiment, the present invention also provides a method for maintaining healthy or normal digestive tract barrier function. Such methods can be used to prevent digestive tract barrier disorders in subjects (e.g., subjects in the remission phase of IBD) who are considered to have a high risk of digestive tract barrier disorders.
[0197] In some embodiments, a change, in particular an improvement, in the gut barrier integrity of a subject may be assessed by measuring at least one biomarker in a sample, in particular a biological sample.
[0198] In some embodiments of the methods and uses provided in this specification, the composition comprising the I.colisanans bacterial strain can increase or decrease the level of one or more digestive tract barrier integrity biomarkers in a sample from a subject. In some embodiments, depending on the specific biomarker, the increase or decrease in the marker level indicates that the digestive tract barrier integrity increases and / or the digestive tract permeability decreases. In some embodiments, the biomarker is selected from cytokines, chemokines, growth factors, angiogenic factors, enzymes, proteases, adhesion molecules, cell signaling molecules, hormones or sugars. In some embodiments, the biomarker includes a cytokine. In some embodiments, the marker includes a chemokine. In some embodiments, the marker includes a growth factor. In some embodiments, the marker includes angiogenic factors. In some embodiments, the marker includes an enzyme. In some embodiments, the marker includes a protease. In some embodiments, the marker includes an adhesion molecule. In some embodiments, the marker includes a cell signaling molecule. In some embodiments, the marker includes a hormone. In some embodiments, the marker includes a sugar.
[0199] This specification provides a method for determining intestinal permeability biomarkers. Biological samples from subjects, such as blood (plasma or serum) or tissues, can be used to measure the level of any suitable biomarker, including one or more of LPS, lipopolysaccharide binding protein (LPSBP), intestinal fatty acid binding protein (IFABP), Zonulin, bacteria and / or 16S rRNA, but are not limited to these markers. LPS, I-FABP and Zonulin can be measured by enzyme-linked immunosorbent assay ("ELISA"). The technology and kit of ELISA are well known to those skilled in the art. In some embodiments, LPS, I-FABP and / or Zonulin increased compared to controls in blood, serum, saliva, urine and / or plasma are used as indicators indicating increased intestinal permeability and thus reduced digestive tract barrier integrity.
[0200] LPSBP can also be measured by ELISA. In some embodiments, a significant change in LPSBP (higher or lower) compared to a control can be used as an indicator of increased intestinal permeability and can confirm reduced digestive tract barrier integrity.
[0201] In some embodiments, the increase of bacterial 16S rRNA is used as an indicator of increased intestinal permeability and thus reduced digestive tract barrier integrity. Standard nucleic acid isolation protocols can be used to purify bacterial 16S rRNA from blood, serum, organ tissues or urine. These are, for example, commercially available. The isolated nucleic acid can be detected by qPCR amplification using specific primers for bacterial 16S rRNA sequences, or by amplification using specific primers for bacterial 16S rRNA and sequencing the resulting amplicon.
[0202] Tight junction proteins expressed by intestinal epithelial cells and regulating intestinal permeability can also be used as biomarkers of intestinal permeability. In some embodiments, tight junction proteins are detected to determine changes in intestinal permeability and digestive tract barrier integrity. In some embodiments, the measured proteins may include but are not limited to claudins, occludin, ZO-1 and E-cadherin (adherin junction) proteins. Other tight junction proteins can also be detected. In some embodiments, tight junction proteins are measured using immunohistochemical staining. In some embodiments, tight junction proteins are measured using ELISA.
[0203] In some embodiments, plasma citrulline is measured to determine changes in intestinal permeability and gut barrier integrity. A decrease in plasma citrulline levels corresponds to a loss of epithelial cell mass, indicating increased gut barrier permeability.
[0204] In some embodiments, the method comprises orally administering an insoluble sugar (e.g., sucralose), collecting body fluids (e.g., urine or blood) after one or more prescribed time periods, and measuring the insoluble sugar contained in the body fluids by standard clinical analytical techniques. The insoluble sugar may include, but is not limited to, mannitol, lactulose, sucrose, sucralose, and any combination thereof.
[0205] In some embodiments, an in vitro assay is used to measure digestive tract barrier integrity. A particularly preferred in vitro assay suitable for measuring digestive tract barrier function is performed by transepithelial electrical resistance (TEER). Such assays are well known in the art (e.g., Srinivasan, 2015; and Lea, 2015).
[0206] 4.2 Mucosal healing
[0207] Mucosal healing has become an important endpoint for evaluating the efficacy of treatments for inflammatory and autoimmune disorders. The definition of complete mucosal healing currently used in clinical trials for IBD (e.g., CD and UC) is "the complete absence of any inflammatory and ulcerative lesions," but this definition lacks validation and does not include mucosal improvement and mucosal healing grading.
[0208] Mucosal healing is mainly defined by endoscopic assessment of intestinal inflammation. Various endoscopic scoring systems have been developed to assess the presence or absence of mucosal healing under endoscopic examination. These indices allow the determination of improvement of endoscopic lesions even when the rather stringent endpoint of mucosal healing and, therefore, complete disappearance of all mucosal ulcerations has not been reached. The endoscopic part of the clinical Mayo score, introduced in 1987, is the most commonly used score for the mucosal layer in clinical practice today (see Schroeder et al., 1987 ). It includes variables such as erythema, loss of vascular markings, friability, hemorrhage, erosions, and ulcers, ranging from 0 to 3. Mucosal healing is classically considered to be a score of 0 (normal mucosa) or 1 (mucosal erythema, reduced vascular markings, mild friability) ( D'Haens, 2007 ).
[0209] In some other embodiments, mucosal healing is determined to have occurred when the patient is determined to have an endoscopy sub-score of 0 or 1 as assessed by flexible sigmoidoscopy. In certain such embodiments, a patient experiencing mucosal healing is determined to have an endoscopy sub-score of 0.
[0210] Both corticosteroids and aminosalicylates have been used for decades and are the most commonly prescribed drugs for repairing the mucosal layer (e.g., in patients with UC) (Carvalho and Cotter, 2017). The mechanisms by which these drugs reduce mucosal inflammation include controlling nuclear factor (NF)-kB expression and inflammatory cytokines, which directly regulate cell migration and proliferation of epithelial cell lines. Anti-TNF drugs (e.g., infliximab, adalimumab, and golimumab) act at several steps of mucosal injury, limiting inflammatory infiltration and T-cell proliferation within the lamina propria (Baert, 1999) and downregulating the expression of metalloproteinases and proinflammatory molecules (Baert, 1999). They also act on regenerative processes, restoring the protective capacity of the mucosa by enhancing intestinal permeability and mucosal secretion, activating fibroblasts, and maintaining epithelial regeneration (Suenaert, 2002).
[0211] Other measures to assess mucosal healing are well known in the art and include measuring the biomarkers C-reactive protein and calprotectin. An advantage of using in vitro biomarker assays to assess mucosal healing is that such assays are generally much less invasive to the subject. Histopathology is another measure of inflammation that has been proposed to provide information particularly relevant to mucosal healing.
[0212] 4.3 STAT3 signaling pathway
[0213] Cytokine pathways mediate a wide range of biological functions, including many aspects of inflammation and immunity. Janus kinases (JAKs), including JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2), are cytoplasmic tyrosine kinases associated with type I and type II cytokine receptors and regulate cytokine signal transduction. The binding of cytokines to associated receptors triggers the activation of receptor-associated JAKs, which leads to tyrosine phosphorylation of JAK-mediated signal transduction and transcription activator (STAT) proteins, and ultimately leads to transcriptional activation of specific gene sets (Schindler et al., 2007, J.Biol.Chem.282:20059-63). Cytokine receptors typically function in the form of heterodimers, so there is usually more than one JAK kinase associated with the cytokine receptor complex. Specific JAKs associated with different cytokine receptor complexes have been identified through genetic studies and verified by other experimental evidence.
[0214] STAT3 plays an important role in the activation of a variety of autoimmune and inflammatory diseases (including IBD). The bacterial strain of the present invention significantly inhibits STAT3 activation mediated by IL-23. Therefore, the present invention provides a method for suppressing or otherwise inhibiting STAT3 signal transduction (i.e., STAT3 signal transduction mediated by IL-23) in a subject, the method comprising administering to the subject a composition comprising a bacterial strain as described above and / or elsewhere herein. Therefore, in some embodiments, the bacterial strain described herein directly or indirectly inhibits STAT3 activity. In some embodiments, the I.colisanans strain produces a bioactive molecule that is directly bound to a STAT3 polypeptide. In some alternative embodiments, the bacterial strain is an indirect inhibitor of STAT3 activation, for example, by binding to a STAT3 upstream molecule in a STAT3 signaling pathway mediated by IL-23, or by binding to a molecule that regulates STAT3 activity (e.g., ubiquitination). As an illustrative example, the bioactive agent can directly bind to or antagonize any one of IL-23, JAK2, or TYK2 to inhibit the STAT3 signaling pathway mediated by IL-23.
[0215] I. colisanans strains can reduce the activation of inflammatory cytokines (e.g., IL-6). Chronic inflammation induced by IL-6 can ultimately lead to cell death. Therefore, the bacterial strains of the present invention are particularly suitable for treating or preventing inflammation or autoimmune disorders. In some embodiments, the bacterial strains can be used to treat inflammation or autoimmune disorders characterized by enhanced IL-6 activation.
[0216] 4.4 Th17 inflammatory response
[0217] Some bacterial compositions of the present invention can effectively reduce Th17 inflammatory responses. Specifically, treatment with the compositions described above and elsewhere herein can modulate Th17 pathway cytokines (including TNF, IL-22, IL-21, and IL-17) and lead to clinical improvement in animal models of diseases mediated by the Th17 pathway. Therefore, the compositions of the present invention can be used to treat or prevent inflammation and autoimmune disorders, and in some embodiments, can be used to treat or prevent diseases or disorders mediated by Th17. In particular, the compositions of the present invention can be used to reduce or prevent increases in Th17 inflammatory responses.
[0218] Th17 cells are a subset of T helper cells that produce cytokines such as IL17A, IL17F, IL-21, and IL-22. Th17 cell differentiation can be driven by IL-23. These and other cytokines constitute an important component of the Th17 pathway, an established inflammatory signaling pathway that contributes to and participates in many inflammatory and autoimmune conditions (e.g., as described in Ye, 2015; Fabro, 2015; Yin, 2014; Cheluvappa, 2014; Schieck, 2014; Balato, 2014). Some Th17-mediated diseases can be improved or alleviated by inhibiting the Th17 pathway, which may be achieved by reducing the differentiation of Th17 cells or reducing their activity or reducing the levels of Th17 pathway cytokines. Diseases mediated by the Th17 pathway can be characterized by increased levels of cytokines produced by Th17 cells, such as IL-17A, IL-17F, IL-21, IL-22, IL-26, IL-9 (reviewed in Monteleone, 2011). Diseases mediated by the Th17 pathway can be characterized by increased expression of Th17-related genes, such as STAT3 or IL-23 receptor. Diseases mediated by the Th17 pathway can be associated with increased levels of Th17 cells.
[0219] IL-17 is a key cytokine that links T cell activation to neutrophil activation and mobilization, so IL-17 plays a key role in innate immunity. However, due to its role in neutrophil activation, it can promote inflammatory autoimmune diseases, such as inflammatory bowel disease, psoriasis and rheumatoid arthritis. IL-17 used herein may refer to any member of the IL-17 family, including IL-17A, IL-17B, IL-17C, IL-17D, IL-17E and IL-17F. The characteristics of IL-17-mediated diseases and conditions are the accumulation or presence of high expression of IL-17 and / or IL-17 positive cells in tissues affected by diseases or conditions. Similarly, IL-17-mediated diseases and conditions can be diseases and conditions that are aggravated by high IL-17 levels or increased IL-17 levels and alleviated by low IL-17 levels or reduced IL-17 levels. IL-17 inflammatory response can be local or systemic.
[0220] Examples of diseases and conditions that may be mediated by the Th17 pathway include, but are not limited to, inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis); multiple sclerosis; arthritis (e.g., rheumatoid arthritis, osteoarthritis, psoriatic arthritis, and juvenile idiopathic arthritis); neuromyelitis optica (Devic's disease); ankylosing spondylitis; spondyloarthritis; psoriasis; systemic lupus erythematosus; celiac disease; asthma (e.g., allergic asthma or neutrophilic asthma); chronic obstructive pulmonary disease (COPD); cancer (e.g., breast cancer, colon cancer, lung cancer, or ovarian cancer); uveitis; scleritis; vasculitis; Behcet's disease; atherosclerosis; atopic dermatitis; emphysema; periodontitis; allergic rhinitis; and allogeneic transplant rejection. Thus, in certain aspects, the present invention provides methods of treating or preventing one or more of these conditions or diseases by administering a composition as described above and / or elsewhere herein. In further preferred embodiments, these disorders or diseases are mediated by the STAT3 signaling pathway.In other preferred embodiments, these disorders or diseases are mediated by the Th17 pathway.
[0221] In certain embodiments, the present invention provides methods, and the compositions of the present invention are used in methods for reducing Th17 cell differentiation in the treatment or prevention of diseases or conditions mediated by Th17 pathways. In certain embodiments, the compositions of the present invention are used to treat or prevent inflammation or autoimmune disorders, wherein the treatment or prevention is achieved by reducing or preventing the increase of Th17 inflammatory responses. In certain embodiments, the compositions of the present invention are used to treat patients with inflammation or autoimmune disorders, wherein the patient's IL-17 levels are elevated or Th17 cells are elevated or Th17 inflammatory responses are exhibited. In certain embodiments, the patient may have been diagnosed with chronic inflammation or autoimmune disorders or diseases, or the compositions of the present invention may be used to prevent inflammation or autoimmune disorders or diseases from developing into chronic inflammation or autoimmune disorders or diseases. In certain embodiments, the disease or disorder may be unresponsive to TNF inhibitor treatment. These uses of the present invention may be applied to any specific disease or disorder listed in the previous paragraph.
[0222] The Th17 pathway is often associated with chronic inflammation and autoimmune disorders, so the compositions of the present invention are particularly suitable for treating or preventing the above chronic diseases or disorders. In certain embodiments, the compositions are used for patients with chronic diseases. In certain embodiments, the compositions are used to prevent the development of chronic diseases.
[0223] The compositions of the present invention can be used to treat diseases and conditions mediated by the Th17 pathway and to address Th17 inflammatory responses, and thus the compositions of the present invention are particularly useful for treating or preventing chronic diseases, treating or preventing diseases in patients who do not respond to other therapies (e.g., treatment with TNF inhibitors), and / or treating or preventing tissue damage and symptoms associated with Th17 cells. For example, it is known that IL-17 can activate matrix destruction in cartilage and bone tissue, and IL-17 has an inhibitory effect on matrix production in chondrocytes and osteoblasts, and thus the compositions of the present invention can be used to treat or prevent bone erosion or cartilage damage.
[0224] In certain embodiments, treatment with the compositions of the invention can reduce or prevent elevated levels of IL-17, particularly elevated levels of IL-17A. In certain embodiments, treatment with the compositions of the invention can reduce or prevent elevated levels of IFN-γ or IL-6. By reducing or preventing elevated levels of these cytokines, it can be used to treat or prevent inflammatory and autoimmune disorders and conditions, particularly those mediated by the Th17 pathway.
[0225] 4.5 Th1 inflammatory response
[0226] CD4+ T cells play an important role in the pathogenesis of inflammatory diseases / disorders, and many CD4+ T cell subsets have been identified as drivers that perpetuate chronic intestinal inflammation (see Imam et al., 2018). For example, T helper type 1 (Th1) cells accumulate in the intestine of IBD patients and are directly associated with the disease. Interferon-γ (IFN-γ) is a defining cytokine produced by Th1 cells. During intestinal inflammation, IFN-γ in combination with TNF is thought to drive β-catenin signaling in intestinal epithelial cells and restrict their differentiation and proliferation (Imam et al., 2018).
[0227] 5. Treatment Methods
[0228] In some embodiments, the invention provides a method of treating or preventing an inflammatory or autoimmune disorder in a subject, the method comprising administering to the subject a bacterial strain as described above and / or elsewhere herein.
[0229] Suitably, the inflammatory or autoimmune disorder is selected from the group consisting of inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis); asthma (e.g. allergic asthma or neutrophilic asthma); arthritis (e.g. rheumatoid arthritis, osteoarthritis, psoriatic arthritis or juvenile idiopathic arthritis); fatty liver disease (e.g. non-alcoholic fatty liver disease (NAFLD)); ankylosing spondylitis; psoriasis; systemic lupus erythematosus (SLE); scleroderma; Sjögren's syndrome; vasculitis; and type 1 diabetes.
[0230] 5.1 Inflammatory bowel disease (IBD)
[0231] The examples demonstrate that the compositions of the present invention have a beneficial restorative effect on the barrier function of the digestive tract, and they also have anti-inflammatory properties and are therefore useful for treating IBD. Therefore, in some embodiments, the present invention provides a method for treating or preventing inflammatory bowel disease using a composition comprising a bacterial strain of the genus Intestinicoccus. The inventors have determined that treatment with an Intestinicoccus strain reduces the severity of colitis in a mouse disease model. Therefore, the compositions of the present invention can be used to treat inflammatory diseases. In some embodiments, the compositions of the present invention are used to treat or prevent IBD. In some embodiments, the present invention provides a method for treating or preventing ulcerative colitis. In some embodiments, the present invention provides a method for treating or preventing Crohn's disease. In certain embodiments, the present invention provides a method for treating or preventing ulcers and / or bleeding when treating IBD, particularly when treating colitis and ulcerative colitis. In a preferred embodiment, the present invention provides a method for treating or preventing IBD in a subject, the method comprising administering to the subject a composition comprising a bacterial strain of the species I.colisanans. In a further preferred embodiment, the present invention provides a method for treating or preventing colitis (particularly ulcerative colitis) in a subject, the method comprising administering to the subject a composition comprising a bacterial strain of the species I. colisanans. In a further preferred embodiment, the present invention provides a method for reducing at least one side effect of colitis (particularly ulcerative colitis), including ulcers and / or bleeding.
[0232] IBD is a complex disease that can be caused by a variety of environmental and genetic factors. Factors that contribute to the onset of IBD include diet, microbiota, intestinal permeability, and genetic susceptibility to increased inflammatory responses to intestinal infections. Symptoms of inflammatory bowel disease include abdominal pain, vomiting, diarrhea, rectal bleeding, severe cramping / muscle cramps in the pelvic region, weight loss, and anemia. In certain embodiments, the composition is used to alleviate one or more symptoms associated with IBD. In certain embodiments, the composition of the present invention is used to prevent one or more symptoms of IBD.
[0233] IBD may be associated with other diseases or conditions, such as cardiovascular disease, neuropsychological disorders, and metabolic syndrome. In certain embodiments, the compositions of the invention are used to treat or prevent one or more diseases or conditions associated with IBD.
[0234] IBD is usually diagnosed by biopsy or colonoscopy. The measurement of fecal calprotectin can be used for preliminary diagnosis of IBD. Other laboratory tests for diagnosing IBD include complete blood count, erythrocyte sedimentation rate, comprehensive metabolic panel, fecal occult blood test or C-reactive protein test. Usually, the combination of laboratory tests and biopsy / colonoscopy is used to confirm the diagnosis of IBD. In certain embodiments, the compositions of the present invention are used to diagnose a subject as IBD.
[0235] In certain embodiments, IBD is Crohn's disease and / or ulcerative colitis. As described above, studies have shown that several inflammatory cytokines are upregulated in the inflammatory mucosa of patients with Crohn's disease and ulcerative colitis, including but not limited to cytokines mediated by STAT3 signaling and NFκB signaling pathways (e.g., IL-17, TNF, IL-21, IL-22). Therefore, inhibiting cytokine activity mediated by the STAT3 signaling pathway and / or cytokines mediated by the NFκB signaling pathway can help treat Crohn's disease and ulcerative colitis. In certain embodiments, the compositions of the present invention are used to treat or prevent Crohn's disease and / or ulcerative colitis.
[0236] Crohn's disease and ulcerative colitis are complex diseases with a range of possible causes, including genetic risk factors, diet, other lifestyle factors (such as smoking and alcohol consumption), and the composition of the microbiome. Crohn's disease can manifest anywhere in the GI tract, while ulcerative colitis is typically predominant in the large intestine and colon.
[0237] Gastrointestinal symptoms of IBD range from mild to severe and include abdominal pain, diarrhea, blood in the stool, ileitis, increased bowel movements, increased flatulence, intestinal strictures, vomiting, and perianal discomfort. The compositions of the present invention can be used to treat or prevent one or more gastrointestinal symptoms of Crohn's disease and / or ulcerative colitis.
[0238] Systemic symptoms of Crohn's disease and ulcerative colitis include growth defects, such as failure to maintain growth during adolescence, decreased appetite, fever and weight loss. Extraintestinal features of Crohn's disease include uveitis, photobia, episcleritis, gallstones, seronegative spondyloarthropathies, arthritis, enthesitis, erythema nodosum, pyoderma gangrenosum, deep venous thrombosis, pulmonary embolism, autoimmune hemolytic anemia, clubbing and osteoporosis. Extraintestinal features are other conditions associated with Crohn's disease and / or ulcerative colitis that manifest outside the gastrointestinal tract. Crohn's patients also show increased susceptibility to neurological complications, such as epilepsy, stroke, myopathy, peripheral neuropathy, headache and depression. In certain embodiments, the compositions of the invention are used to treat or prevent one or more systemic symptoms of Crohn's disease and / or ulcerative colitis. In certain embodiments, the compositions of the invention are used to treat or prevent one or more extraintestinal features of Crohn's disease and / or ulcerative colitis.
[0239] The diagnosis of Crohn's disease and ulcerative colitis usually involves performing multiple tests and surgical procedures, such as gastroscopy and / or colonoscopy and biopsy (usually of the ileum), radiological examinations, complete blood counts, C-reactive protein tests, and erythrocyte sedimentation rates. In certain embodiments, the compositions of the present invention are used in subjects diagnosed with Crohn's disease or ulcerative colitis. In some embodiments, the compositions of the present invention are used to treat subjects who have been diagnosed with Crohn's disease or ulcerative colitis.
[0240] Crohn's disease and ulcerative colitis are classified according to the extent of the affected area of the gastrointestinal tract (Gasche et al., 2000). Crohn's disease of the ileum and colon is classified as ileocolonic Crohn's disease. In some embodiments, the composition is used to treat or prevent ileocolonic Crohn's disease. In some embodiments, the composition is used in patients diagnosed with ileocolonic Crohn's disease. If only the ileum is affected, it is classified as Crohn's ileitis. If only the colon is affected, it is classified as Crohn's colitis. In certain embodiments, the composition is used to treat or prevent Crohn's ileitis. In certain embodiments, the composition is used to treat or prevent Crohn's ileitis in subjects diagnosed with Crohn's ileitis. In certain embodiments, the composition is used to treat or prevent Crohn's colitis. In certain embodiments, the composition is used to treat or prevent Crohn's colitis in subjects diagnosed with Crohn's colitis.
[0241] Crohn's disease and ulcerative colitis can be treated with a variety of therapeutic agents, such as corticosteroids (e.g., prednisone), immunosuppressants (e.g., azathioprine), or biologics (e.g., infliximab, adalimumab, golimumab, vedolizumab, and etozizumab). In certain embodiments, the compositions of the present invention are used to treat or prevent Crohn's disease or ulcerative colitis in combination with additional therapeutic agents (including, but not limited to, the above therapeutic agents). In certain embodiments, the additional therapeutic agent is used to treat or prevent Crohn's disease and / or ulcerative colitis.
[0242] 5.1 Autoimmune diseases
[0243] In humans, evidence of intestinal inflammation can be detected before the clinical onset of many autoimmune disorders, such as type 1 diabetes (T1D) (Bosi, 2006). Similarly, diabetes-susceptible rats show increased intestinal permeability before the onset of insulitis compared with diabetes-resistant rats (Meddings, 1999; Neu, 2005). These findings suggest that disruption of the integrity of the gastrointestinal barrier and subsequent increased antigen transport and low-grade intestinal inflammation precede the onset of T1D and are directly related to its pathogenesis rather than being secondary to metabolic changes (i.e., hyperglycemia) caused by diabetes. The gastrointestinal barrier is an essential "gatekeeper" that prevents the contents of the lumen from coming into contact with the body. This barrier is composed of the mucosal layer and the intestinal epithelial barrier (IEB), both of which are critical for preventing commensal bacteria, pathogens, and food antigens from entering the gastrointestinal tissues and systemic circulation from the lumen. IEBs are a single layer of epithelial cells that are held together by a complex junctional system consisting of tight junction adhesion molecules (JAMs), tricellulin, and angulin, whose interactions with each other and with intracellular scaffolding proteins, namely zonula occludens (ZOs), are essential for maintaining the integrity of tight junctions and controlling paracellular trafficking. Alterations in IEBs have been reported to be associated with gastrointestinal inflammation in T1D patients and rat models (Meddings, 1999; Sapone, 2006). In addition, the importance of the mucosal layer of the digestive tract, which is an important gastrointestinal barrier and contains immunomodulatory molecules such as antimicrobial peptides and mucins, has recently been reported (reviewed in Sorini et al., 2019).
[0244] In some embodiments, bacterial strains from I. colisanans species can provide therapeutic benefits in treating or preventing asthma (e.g., allergic asthma or neutrophilic asthma). In certain embodiments, the compositions of the invention are used to treat or prevent asthma in a subject. In certain embodiments, the invention provides a composition comprising a bacterial strain of I. colisanans species for treating or preventing asthma.
[0245] In some embodiments, bacterial strains from the species I. colisanans can provide therapeutic benefit in treating or preventing GVHD. In certain embodiments, the compositions of the invention are used to treat or prevent GVHD in a subject. In a preferred embodiment, the invention provides a composition comprising a bacterial strain of the species I. colisanans for treating or preventing GVHD.
[0246] In some embodiments, bacterial strains from the species I. colisanans can provide therapeutic benefit in treating or preventing arthritis (e.g., rheumatoid arthritis, osteoarthritis, psoriatic arthritis, or juvenile idiopathic arthritis). In certain embodiments, the compositions of the invention are used to treat or prevent arthritis in a subject. In certain embodiments, the invention provides a composition comprising a bacterial strain of the species I. colisanans for treating or preventing arthritis.
[0247] In some embodiments, bacterial strains from the species I. colisanans can provide therapeutic benefit in treating or preventing multiple sclerosis. In certain embodiments, the compositions of the invention are used to treat or prevent multiple sclerosis in a subject. In certain embodiments, the invention provides a composition comprising a bacterial strain of the species I. colisanans for treating or preventing multiple sclerosis.
[0248] In some embodiments, bacterial strains from the species I. colisanans can provide therapeutic benefit in treating or preventing psoriasis. In certain embodiments, the compositions of the present invention are used to treat or prevent psoriasis in a subject. In certain embodiments, the present invention provides compositions comprising bacterial strains of the species I. colisanans for treating or preventing psoriasis.
[0249] In some embodiments, bacterial strains from I. colisanans species can provide therapeutic benefit in treating or preventing systemic lupus erythematosus (SLE). In certain embodiments, the compositions of the present invention are used to treat or prevent SLE in a subject. In certain embodiments, the present invention provides compositions comprising bacterial strains of I. colisanans species for treating or preventing SLE.
[0250] In some embodiments, bacterial strains from the species I. colisanans can provide therapeutic benefit in treating or preventing allogeneic transplant rejection. In certain embodiments, the compositions of the invention are used to treat or prevent allogeneic transplant rejection in a subject. In certain embodiments, the invention provides a composition comprising a bacterial strain of the species I. colisanans for treating or preventing allogeneic transplant rejection.
[0251] 6. Preparation
[0252] In some embodiments, the composition of the present invention comprises less than 40 different bacterial strains. In some embodiments, the composition comprises less than 30 different bacterial strains. In some embodiments, the composition comprises less than 20 different bacterial strains. In some embodiments, the composition comprises less than 10 different bacterial strains. In some embodiments, the composition comprises less than 5 different bacterial strains. In some preferred embodiments, the composition comprises less than 3 different bacterial strains. In some preferred embodiments, the composition comprises a single bacterial strain. In some embodiments, the composition does not comprise Clostridium bacteria.
[0253] The composition of the present invention comprises bacteria (i.e. live bacteria and / or inactivated bacteria). In a preferred embodiment of the present invention, the composition is formulated in a dry form (e.g., lyophilized form). The composition of the present invention may include granules or gelatin capsules, such as hard gelatin capsules, which contain the bacterial strain of the present invention. Preferably, the composition of the present invention comprises lyophilized bacteria. Bacterial lyophilization is a mature procedure, and relevant guidance can be found in, for example, references (Miyamoto-Shinohara, 2008; and Day & Stacey, 2007).
[0254] The composition of the invention may comprise live active bacterial cultures. The examples show that the bacterial cultures of the invention have therapeutic effects.
[0255] In some embodiments, the bacterial strain in the composition of the present invention is not inactivated, for example, not heat inactivated. In some embodiments, the bacterial strain in the composition of the present invention is not inactivated, for example, not heat inactivated. In some embodiments, the bacterial strain in the composition of the present invention is not attenuated, for example, not heat attenuated. For example, in some embodiments, the bacterial strain in the composition of the present invention is not killed, inactivated and / or attenuated. For example, in some embodiments, the bacterial strain in the composition of the present invention is alive. For example, in some embodiments, the bacterial strain in the composition of the present invention is viable. For example, in some embodiments, the bacterial strain in the composition of the present invention can be partially or completely colonized in the intestinal tract. For example, in some embodiments, the bacterial strain in the composition of the present invention is viable and can be partially or completely colonized in the intestinal tract.
[0256] In some embodiments, the composition comprises a mixture of live bacterial strains and killed bacterial strains. In a preferred embodiment, the composition of the present invention is encapsulated so that the bacterial strain can be delivered to the intestinal tract. Encapsulation can protect the composition from degradation until it is delivered to the target location, and the encapsulation can be broken, for example, by chemical or physical stimulation (such as pressure, enzyme activity or physical disintegration) at the target location, which can be triggered by a change in pH value. Any appropriate encapsulation method can be used. Exemplary encapsulation techniques include encapsulation in a porous matrix, attachment or adsorption on a solid carrier surface, self-aggregation by flocculation or a cross-linking agent, and mechanical control behind a microporous membrane or microcapsule. Encapsulation guidance that can be used to prepare the composition of the present invention is widely available in the art (e.g., see Mitropoulou, 2013; and Kailasapathy, 2002).
[0257] The composition can be administered orally and can be in the form of tablets, capsules or powders. Encapsulated products are preferred because bacteria of the genus Intestinicoccus are obligate anaerobes.
[0258] The composition of the present invention comprises a therapeutically effective amount of the bacterial strain of the present invention. The therapeutically effective amount of the bacterial strain is sufficient to produce a beneficial effect on the patient. The therapeutically effective amount of the bacterial strain can be sufficient to cause delivery to the patient's intestinal tract and / or partial or complete colonization of the patient's intestinal tract.
[0259] For example, for an adult, a suitable daily dose of bacteria may be about 1 x 10 3 About 1x 10 11 Colony forming units (CFU); for example, about 1 x 10 7 About 1x 10 10 CFU; in another example, about 1x 10 6 About 1x 10 10 CFU; in another example, about 1x 10 7 About 1x 10 11 CFU; in another example, about 1x 10 8 About 1x 10 10 CFU; in another example, about 1x 10 8 About 1x 10 11 CFU.
[0260] In certain embodiments, the dosage of the bacteria is at least 10 9 cells per day, for example, at least 10 10 At least 10 11 or at least 10 12 cells.
[0261] In certain embodiments, a dose of the composition may comprise about 1 x 10 6 About 1x10 11 The amount of bacterial strains can be about 1 x 10 colony forming units (CFU) / g. This dosage can be suitable for adults. For example, the composition can contain about 1 x 10 3 About 1x 10 11 CFU / g of bacterial strain; for example, about 1 x 10 7 About 1x 10 10 CFU / g; in another example, about 1x 10 6 About 1x 10 10 CFU / g; in another example, about 1x 10 7 About 1x 10 11 CFU / g; in another example, about 1x 10 8 About 1x 10 10 CFU / g; in another example, about 1x 10 8 About 1x 10 11 CFU / g, about 1x10 8 About 1x 10 10 CFU / g. For example, about 1x 10 8 About 1x 10 10 CFU / g. The dosage may be, for example, up to or exceeding 1 g, 3 g, 5 g and 10 g.
[0262] In some embodiments, the compositions described above and / or elsewhere herein comprise, consist of, or consist essentially of about 1 x 10 3 About 1x 10 11 The amount of bacterial strains expressed in colony forming units / gram.
[0263] In some embodiments, the compositions described above and / or elsewhere herein comprise a bacterial strain at a dose of between 500 mg and 1000 mg, between 600 mg and 900 mg, between 700 mg and 800 mg, between 500 mg and 750 mg, or between 750 mg and 1000 mg. In certain embodiments, the invention provides the above pharmaceutical compositions, wherein the dry bacteria in the pharmaceutical composition are administered at a dose of between 500 mg and 1000 mg, between 600 mg and 900 mg, between 700 mg and 800 mg, between 500 mg and 750 mg, or between 750 mg and 1000 mg.
[0264] The composition may be formulated as a probiotic. Probiotics are defined by FAO / WHO as live microorganisms which when administered in adequate amounts confer a health benefit on the host.
[0265] Typically, probiotics, such as the compositions of the present invention, are optionally combined with at least one suitable prebiotic compound. Prebiotic compounds are typically indigestible carbohydrates, such as oligosaccharides or polysaccharides, or sugar alcohols, which are not degraded or absorbed in the upper digestive tract. Known prebiotics include commercial products such as inulin and trans-galacto-oligosaccharides.
[0266] Other prebiotic compounds (eg vitamin C) may be included as oxygen scavengers to improve in vivo delivery and / or partial or complete colonization and survival. Alternatively, the probiotic composition of the invention may be orally administered as a food or nutritional product (eg milk or whey-based fermented dairy product) or as a pharmaceutical product.
[0267] In certain embodiments, the probiotic composition of the present invention includes, relative to the total weight of the composition, about 1 to about 30% by weight (eg, 5 to 20% by weight) of a prebiotic compound. Known prebiotics include commercial products such as inulin and trans-galacto-oligosaccharides.
[0268] In some embodiments, the prebiotic is a carbohydrate selected from the group consisting of fructooligosaccharides (or FOS), short chain fructooligosaccharides, inulin, isomaltooligosaccharides, pectin, xylo-oligosaccharides (or XOS), chito-oligosaccharides (or COS), beta-glucan, gum arabic modified starch and resistant starch, polydextrose, tagatose, acacia fiber, carob, oat and citrus fiber. In one aspect, the prebiotic is a short chain fructooligosaccharide. Short chain FOS is a non-digestible carbohydrate, usually converted from beet sugar, comprising a sucrose molecule bonded to three glucose molecules.
[0269] The composition of the present invention may include a pharmaceutically acceptable excipient or carrier, such as an excipient or carrier described in the Handbook of Pharmaceutical Excipients. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical field, such as described in Remington Pharmaceutical Science. Examples of suitable carriers include lactose, starch, glucose, methylcellulose, magnesium stearate, mannitol, sorbitol, etc. Examples of suitable diluents include ethanol, glycerol, and water. Pharmaceutical carriers, excipients, or diluents may be selected according to the intended route of administration and standard pharmaceutical practice. The pharmaceutical composition may include one or more suitable adhesives, lubricants, suspending agents, coatings, and / or solubilizing agents as carriers, excipients, or diluents, or in addition to carriers, excipients, or diluents, may also include one or more suitable adhesives, lubricants, suspending agents, coatings, and / or solubilizing agents. Examples of suitable adhesives include starch, gelatin, natural sugars such as glucose, anhydrous lactose, free-flowing lactose, beta-lactose, corn sweeteners, natural and synthetic gums such as gum arabic, tragacanth or sodium alginate, carboxymethyl cellulose and polyethylene glycol. Examples of suitable lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, etc. Preservatives, stabilizers, colorants and even flavoring agents can be provided in the pharmaceutical composition. Examples of preservatives include sodium benzoate, sorbic acid, cysteine and 4-hydroxybenzoate, for example, in some embodiments, the preservative is selected from sodium benzoate, sorbic acid and 4-hydroxybenzoate. Antioxidants and suspending agents can also be used. Another example of a suitable carrier is sucrose. Another example of a suitable preservative is cysteine.
[0270] The composition of the present invention can be formulated into food. For example, in addition to providing the therapeutic effects of the present invention, food can also provide nutritional benefits, such as as a nutritional supplement. Similarly, food can be formulated to enhance the taste of the composition of the present invention, or make the composition more similar to ordinary food rather than a pharmaceutical composition, thereby being more attractive to consumers. In certain embodiments, the composition of the present invention is formulated into a dairy product. The term "dairy-based product" refers to any liquid or semi-solid dairy or whey-based product with different fat contents. Dairy-based products can be, for example, milk, goat milk, sheep milk, skim milk, whole milk, milk recombined from milk powder and whey without any processing, or processed products, such as yogurt, coagulated milk, curd, sour milk, full-fat yogurt, buttermilk and other yogurt products. Alternatively, milk can be plant milk, including, for example, soy milk, oat milk, almond milk, coconut milk or macadamia milk. Another important category includes milk beverages, such as whey beverages, fermented milk, condensed milk, baby milk; flavored milk, ice cream; milk-containing foods, such as candy.
[0271] In some embodiments, the compositions disclosed herein comprise one or more strains of bacteria of the genus Intestinicoccus and are free of bacteria from any other species, or contain only trace or biologically irrelevant amounts of bacteria from another species. Thus, in some embodiments, the present invention provides a composition for treatment, comprising one or more strains of bacteria of the genus Intestinicoccus (e.g., Intestinicoccus colisanans), free of bacteria from any other species, or contain only trace or biologically irrelevant amounts of bacteria from another species.
[0272] In some embodiments, the composition comprises one or more strains of bacteria of the genus Intestinicoccus and no bacteria from any other genus or only trace or biologically irrelevant amounts of bacteria from another genus. In some embodiments, the composition comprises one or more strains of bacteria of the genus Intestinicoccus (e.g., Intestinicoccus colisanans) and no bacteria from any other genus or only trace or biologically irrelevant amounts of bacteria from another genus.
[0273] In certain embodiments, compositions disclosed herein include single bacterial species and do not include any other bacterial species. In certain embodiments, compositions disclosed herein include single bacterial strains and do not include any other bacterial strains. For example, compositions of the present invention may include bacteria belonging only to Intestinicoccus colisanans strains. Such compositions may include only trace or biologically irrelevant amounts of other bacterial strains or species. Such compositions may be cultures substantially free of other biological species. In some embodiments, such compositions may be in dry form and substantially free of the organisms of other species.
[0274] In some embodiments, the present invention provides a composition for use in treatment, the composition comprising a single bacterial strain of the genus Intestinicoccus, which contains no bacteria from any other strain, or which contains only trace or biologically irrelevant amounts of bacteria from another strain.
[0275] In some embodiments, the present invention provides a composition for use in treatment, comprising a single bacterial strain of the genus Intestinicoccus (e.g., Intestinicoccus colisanans MH27-1, Intestinicoccus colisanans MH27-2, or Intestinicoccus colisanans MH27-3), which does not contain bacteria from any other strain, or which contains only trace or biologically irrelevant amounts of bacteria from another strain.
[0276] In certain embodiments, the compositions of the present invention comprise a single bacterial strain or species and do not comprise any other bacterial strain or species. Such compositions may comprise only trace or biologically irrelevant amounts of other bacterial strains or species. Such compositions may be cultures that are substantially free of other biological species.
[0277] In certain embodiments, the composition of the present invention is composed of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 kinds of bacterial strains or species. In certain embodiments, the composition is composed of 1 to 10 kinds, preferably 1 to 5 kinds of bacterial strains or species. In some embodiments, the composition disclosed herein includes more than one strain (for example, more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40 or 45 strains) from the same species, and optionally does not include the bacterium from any other species. In some embodiments, the composition disclosed herein includes less than 50 strains (for example, less than 45, 40, 35, 30, 25, 20, 15, 12, 10, 9, 8, 7, 6, 5, 4 or 3 strains) from the same species, and optionally does not include the bacterium from any other species. In some embodiments, compositions disclosed herein include 1-40, 1-30, 1-20, 1-19, 1-18, 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 2-50, 2-40, 2-30, 2-20, 2-15, 2-10, 2-5, 6-30, 6-15, 16-25 or 31-50 strains from the same species, and optionally do not include bacteria from any other species. In some embodiments, compositions disclosed herein include more than one species (e.g., more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 17, 20, 23, 25, 30, 35 or 40 species) from the same genus, and optionally do not include bacteria from any other genus. In some embodiments, compositions disclosed herein include less than 50 species (e.g., less than 50, 45, 40, 35, 30, 25, 20, 15, 12, 10, 8, 7, 6, 5, 4 or 3 species) from the same genus, and optionally do not include the bacterium from any other genus. In some embodiments, compositions disclosed herein include 1-50, 1-40, 1-30, 1-20, 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 2-50, 2-40, 2-30, 2-20, 2-15, 2-10, 2-5, 6-30, 6-15, 16-25 or 31-50 species from the same genus, and optionally do not include the bacterium from any other genus. The present invention includes any combination of the foregoing.
[0278] In some embodiments, the composition of the present invention comprises more than one bacterial strain or species.For example, in some embodiments, the composition of the present invention comprises more than one bacterial strain (for example, more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40 or 45 kinds of bacterial strains) from the same species, and optionally does not include the bacterium from any other species.In some embodiments, the composition of the present invention comprises less than 50 kinds of bacterial strains (for example, less than 45, 40, 35, 30, 25, 20, 15, 12, 10, 9, 8, 7, 6, 5, 4 or 3 kinds of bacterial strains) from the same species, and optionally does not include the bacterium from any other species. In some embodiments, the compositions of the present invention comprise 1-40, 1-30, 1-20, 1-19, 1-18, 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 2-50, 2-40, 2-30, 2-20, 2-15, 2-10, 2-5, 6-30, 6-15, 16-25 or 31-50 strains from the same species, and optionally do not comprise bacteria from any other species. In some embodiments, the compositions of the present invention comprise more than one species (e.g., more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 17, 20, 23, 25, 30, 35 or 40 species) from the same genus, and optionally do not comprise bacteria from any other genus. In some embodiments, the composition of the present invention comprises less than 50 species (e.g., less than 50, 45, 40, 35, 30, 25, 20, 15, 12, 10, 8, 7, 6, 5, 4 or 3 species) from the same genus, and optionally does not comprise the bacterium from any other genus. In some embodiments, the composition of the present invention comprises 1-50, 1-40, 1-30, 1-20, 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 2-50, 2-40, 2-30, 2-20, 2-15, 2-10, 2-5, 6-30, 6-15, 16-25 or 31-50 strains from the same genus, and optionally does not comprise the bacterium from any other genus. The present invention includes any combination of the foregoing.
[0279] In certain embodiments, the pharmaceutical compositions of the present invention comprise 1-50 different bacterial strains, such as 1-50, 1-40, 1-30, 1-20, 1-19, 1-18, 1-17, 1-16, 1-15, 1-14, 1-13, 1-12, 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, or 2 different bacterial strains. In certain embodiments, the pharmaceutical compositions of the present invention comprise 1-50 different bacterial strains, such as 1-50, 1-40, 1-30, 1-20, 1-19, 1-18, 1-17, 1-16, 1-15, 1-14, 1-13, 1-12, 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, or 2 different bacterial strains.
[0280] In some embodiments, the composition of the invention further comprises a bacterial strain having the same safety and therapeutic efficacy characteristics as the strain deposited at NMI (Australia) under deposit numbers V21 / 015887 and / or V21 / 015888.
[0281] In some embodiments where the composition of the present invention comprises more than one bacterial strain, species or genus, each bacterial strain, species or genus can be applied individually, simultaneously or sequentially. For example, the composition can comprise all of the more than one bacterial strain, species or genus, or the more than one bacterial strain, species or genus can be stored separately and applied separately, simultaneously or sequentially. In some embodiments, the more than one bacterial strain, species or genus are stored separately but mixed together before use.
[0282] Preferably, the compositions disclosed herein will be administered to the gastrointestinal tract (GI) tract so that the bacterial strains of the present invention can be delivered to the intestinal tract and / or partially or completely colonized in the intestinal tract. In other words, the bacteria can colonize part or all of the GI tract, and this colonization can be temporary or permanent. More specifically, the phrase "complete colonization of the intestinal tract" means that the bacteria have colonized all parts of the intestinal tract (i.e., the small intestine, large intestine, and rectum). Additionally or alternatively, the term "complete colonization" means that the bacteria are permanently implanted in some or all parts of the intestinal tract.
[0283] Similarly, the phrase "partial colonization of the intestine" means that the bacteria have colonized part but not all of the intestine. Additionally or alternatively, the term "partial colonization" means that the bacteria are temporarily implanted in part or all of the intestine.
[0284] The temporality of bacterial implantation can be determined by assessing the abundance of the bacterial strain of the invention (e.g., in a stool sample) periodically (e.g., daily or weekly) after the end of the administration interval to determine a washout period, i.e., the period between the end of the administration interval and the absence of detectable levels of the bacterial strain of the invention. In some embodiments, the washout period is 14 days or less, 12 days or less, 10 days or less, 7 days or less, 4 days or less, 3 days or less, 2 days or less, or 1 day or less.
[0285] In some embodiments, the bacteria described above or elsewhere herein are transiently implanted in the large intestine.
[0286] In some embodiments, the bacterial strains of the present invention are obtained from adult feces. In some embodiments where the composition of the present invention comprises more than one bacterial strain, all bacterial strains are obtained from adult feces, or if other bacterial strains are present, they are only present in very small amounts. The bacteria can be cultured after being obtained from adult feces and used in the composition of the present invention.
[0287] In some embodiments, the one or more Intestinicoccus bacterial strains are the only therapeutically active agent in the composition of the invention. In some embodiments, the bacterial strains in the composition are the only therapeutically active agent in the composition of the invention.
[0288] The compositions for use according to the invention may or may not require marketing approval.
[0289] In certain embodiments, the present invention provides the above-mentioned pharmaceutical composition, wherein the bacterial strain is in a dry form. In some cases, the bacterial strain is reconstructed before administration. In some cases, reconstruction is carried out by using a diluent as described herein. In certain embodiments, the present invention provides the above-mentioned pharmaceutical composition, wherein the bacterial strain is spray-dried. In certain embodiments, the present invention provides the above-mentioned pharmaceutical composition, wherein the bacterial strain is freeze-dried or spray-dried and wherein the bacterial strain is alive. In certain embodiments, the present invention provides the above-mentioned pharmaceutical composition, wherein the bacterial strain is freeze-dried or spray-dried and wherein the bacterial strain is viable. In certain embodiments, the present invention provides the above-mentioned pharmaceutical composition, wherein the bacterial strain is freeze-dried or spray-dried and wherein the bacterial strain can be partially or completely colonized in the intestinal tract. In certain embodiments, the present invention provides the above-mentioned pharmaceutical composition, wherein the bacterial strain is dry (for example, freeze-dried or spray-dried) and wherein the bacterial strain is viable and can be partially or completely colonized in the intestinal tract. In some identical embodiments and some alternative embodiments, the bacterial strain can be temporarily colonized in the intestinal tract.
[0290] In some cases, the lyophilized or spray-dried bacterial strain is reconstituted prior to administration. In some cases, reconstitution is performed using a diluent described herein.
[0291] The composition of the present invention may comprise a pharmaceutically acceptable excipient, diluent or carrier.
[0292] In certain embodiments, the present invention provides a pharmaceutical composition comprising: a bacterial strain of the present invention; and a pharmaceutically acceptable excipient, carrier or diluent; wherein when administered to a subject in need, the amount of the bacterial strain is sufficient to treat or prevent inflammation or autoimmune disorders. In some preferred embodiments, inflammation or autoimmune disorders are selected from the following groups: inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis); asthma (e.g., allergic asthma or neutrophilic asthma); arthritis (e.g., rheumatoid arthritis, osteoarthritis, psoriatic arthritis or juvenile idiopathic arthritis); fatty liver disease (e.g., non-alcoholic fatty liver disease (NAFLD)); ankylosing spondylitis; psoriasis; systemic lupus erythematosus (SLE); scleroderma; Sjögren's syndrome; vasculitis; and type 1 diabetes.
[0293] In certain embodiments, the present invention provides a pharmaceutical composition comprising: a bacterial strain of the present invention; and a pharmaceutically acceptable excipient, carrier or diluent; wherein the amount of the bacterial strain is sufficient to treat or prevent inflammation or autoimmune disorders mediated by the STAT3 signaling pathway. In a preferred embodiment, the disorder is selected from inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis); asthma (e.g., allergic asthma or neutrophilic asthma); arthritis (e.g., rheumatoid arthritis, osteoarthritis, psoriatic arthritis or juvenile idiopathic arthritis); fatty liver disease (e.g., non-alcoholic fatty liver disease (NAFLD)); ankylosing spondylitis; psoriasis; systemic lupus erythematosus (SLE); scleroderma; Sjögren's syndrome; vasculitis; and type 1 diabetes.
[0294] In certain embodiments, the present invention provides the above pharmaceutical composition, wherein the amount of the bacterial strain relative to the weight of the composition is about 1×10 3 About 1×10 11 Colony forming units (CFU).
[0295] In certain embodiments, the present invention provides the above pharmaceutical composition, wherein the composition is administered in a dose of up to or exceeding 1 g, 3 g, 5 g or 10 g.
[0296] In certain embodiments, the present invention provides the above-mentioned pharmaceutical composition, wherein the composition is administered by a method selected from the group consisting of oral, rectal, subcutaneous, nasal, buccal and sublingual.
[0297] In certain embodiments, the present invention provides the above pharmaceutical composition, which comprises a carrier selected from lactose, starch, glucose, methylcellulose, magnesium stearate, mannitol and sorbitol.
[0298] In certain embodiments, the present invention provides the above pharmaceutical composition, which comprises a diluent selected from ethanol, glycerol and water.
[0299] In certain embodiments, the present invention provides the above-mentioned pharmaceutical composition, which comprises an excipient selected from starch, gelatin, glucose, anhydrous lactose, free-flow lactose, β-lactose, corn sweetener, gum arabic, tragacanth, sodium alginate, carboxymethyl cellulose, polyethylene glycol, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate and sodium chloride.
[0300] In certain embodiments, the present invention provides the above pharmaceutical composition, which further comprises at least one of a preservative, an antioxidant, and a stabilizer.
[0301] In certain embodiments, the present invention provides the above pharmaceutical composition, comprising a preservative selected from the group consisting of sodium benzoate, sorbic acid and 4-hydroxybenzoic acid esters.
[0302] In certain embodiments, the present invention provides the above-mentioned pharmaceutical composition, wherein the bacterial strain is in a dried form (eg, freeze-dried, spray-dried, fluidized bed dried, etc.).
[0303] In certain embodiments, the present invention provides the above-mentioned pharmaceutical composition, wherein when the composition is stored in a sealed container at about 4°C or about 25°C and the container is placed in an atmosphere with 50% relative humidity, at least 80% of the bacterial strain measured in colony forming units is maintained after at least about 1 month, 3 months, 6 months, 1 year, 1.5 years, 2 years, 2.5 years or 3 years.
[0304] In some embodiments, the compositions of the present invention are provided in a sealed container comprising a composition described herein. In some embodiments, the sealed container is a pouch or bottle. In some embodiments, the compositions of the present invention are provided in a syringe comprising a composition described herein.
[0305] In some embodiments, the composition of the present invention can be provided as a pharmaceutical preparation. For example, the composition can be provided as a tablet or a capsule. In some embodiments, the capsule is a gelatin capsule ("gel-cap"). The capsule can be a hard capsule or a soft capsule. In some embodiments, the preparation is a soft capsule. Soft capsules are such capsules, and since softeners such as glycerol, sorbitol, maltitol and polyethylene glycol are added to the capsule shell, the capsule can therefore have a certain elasticity and softness. Soft capsules can be produced, for example, based on gelatin or starch. Gelatin-based soft capsules are commercially available from various suppliers. Depending on the method of administration, such as oral or rectal administration, soft capsules can have various shapes, such as round, oval, rectangular or torpedo-shaped. Soft capsules can be produced by conventional processes, such as by Scherer process, Accogel process or instillation or blowing process.
[0306] In some embodiments, the compositions disclosed herein are administered orally. Oral administration may involve swallowing so that the compound enters the gastrointestinal tract.
[0307] Pharmaceutical formulations suitable for oral administration include solid plugs, solid particulates, semisolids and liquids (including multiphase or dispersed systems), such as tablets; soft or hard capsules containing multi- or nanoparticles, liquids (e.g., aqueous solutions), emulsions or powders; lozenges (including liquid-filled); chewables; gels; rapidly dispersible dosage forms; films; ovules; sprays; and buccal / mucosal adhesive patches.
[0308] In some embodiments, the pharmaceutical formulation is an enteric formulation, i.e., a gastric fluid-resistant formulation (e.g., gastric fluid pH-resistant), which is suitable for oral delivery of the composition of the invention to the intestinal tract. Enteric formulations may be particularly useful when the bacteria or other components in the composition are acid-sensitive (e.g., susceptible to degradation under gastric conditions).
[0309] In some embodiments, the enteric formulation includes an enteric coating. In some embodiments, the formulation is an enteric coating dosage form. For example, the formulation can be an enteric coated tablet or an enteric coated capsule, etc. The enteric coating can be a conventional enteric coating, such as a conventional coating for oral tablets, capsules, etc. The formulation can include a film coating, such as a film layer of an enteric polymer (e.g., an acid-insoluble polymer).
[0310] In some embodiments, the enteric formulation is enteric in nature, for example, resistant to gastric juice and does not require an enteric coating. Thus, in some embodiments, the formulation is an enteric formulation that does not include an enteric coating. In some embodiments, the formulation is a capsule made of a thermogel material. In some embodiments, the thermogel material is a cellulosic material, such as methylcellulose, hydroxymethylcellulose, or hydroxypropylmethylcellulose (HPMC). In some embodiments, the capsule comprises a shell that does not contain any film-forming polymer. In some embodiments, the capsule comprises a shell, and the shell comprises hydroxypropylmethylcellulose and does not comprise any film-forming polymer (as described in U.S. Patent Publication No. US2016 / 0067188). In some embodiments, the formulation is an enteric capsule that is enteric in nature (e.g., from Capsugel ).
[0311] In some embodiments, the composition is a probiotic or medical food comprising a I. colisanans bacterial strain. The bacteria can be administered as a probiotic, capsule, tablet, caplet, pill, lozenge, powder and / or granule. The strain can also be formulated into a nutrient, a conventional food, a medical food or a medicine. The bacteria can also be administered as part of a fecal transplant or by a suppository. In some embodiments, the composition is formulated for delivery to the digestive tract, as further described herein, and in some embodiments, the composition also comprises a prebiotic.
[0312] 6.1 Co-administration with other active agents
[0313] In some embodiments, the methods described herein may also include co-administering a second active agent and / or treatment to the subject (e.g., as part of a therapy). Combination therapy (if employed) may be adjusted according to the specific indication. For example, when administering an I. colisanans species strain to treat an inflammatory disease (e.g., inflammatory bowel disease), it may be co-administered with an anti-inflammatory agent or therapy known in the art or approved for clinical treatment of an inflammatory disease. Other indications may similarly be co-administered with, for example, an I. colisanans species strain as described herein and an active agent known in the art or approved for clinical treatment of these indications.
[0314] Suitable anti-inflammatory agents that may be used to treat inflammatory bowel disease include, but are not limited to, 5-aminosalicylic acid, corticosteroids, azathioprine, infliximab, and adalimumab.
[0315] The present invention also includes a composition as described above, further comprising an anti-inflammatory agent.Such a composition may optionally be in the form of a single composition, or alternatively in the form of two or more separate compositions.
[0316] 7. Screening Methods
[0317] The present invention also includes methods for identifying bacterial strains suitable for the methods of the present invention. Such methods typically include screening for bacterial strains with specific functional activity. Suitable assays include the assays described in the following examples, but any assay for measuring digestive barrier function, mucosal healing, regulation of NF-κB activation, or regulation of STAT3 signaling is equally applicable.
[0318] In some embodiments, the screening method identifies the ability of an Intestinicoccus bacterial strain to modulate the STAT3 signaling pathway. By way of illustrative example, the invention provides a method of blocking or otherwise inhibiting activation of STAT3 signaling in a target cell, the method comprising contacting the target cell with at least a soluble component of a bacterial cell preparation of the species Intestinicoccus colisanans to block or otherwise inhibit activation of STAT3 signaling in the target cell.
[0319] In some embodiments of this type, the target cells are selected from functional reporter cells (eg, HEK cells) for screening bacterial strains, immune cells (eg, Th17 immune cells), epithelial cells, and endothelial cells.
[0320] In some embodiments, the bacterial cell preparation comprises a bacterial cell culture. Suitably, the soluble fraction may comprise the supernatant of a bacterial cell culture. In some embodiments of this type, the soluble fraction is substantially free of bacterial cells.
[0321] In some alternative embodiments, the bacterial cell preparation comprises a bacterial cell pellet. Preferably, the bacterial cells in the cell pellet are cracked by any method known in the art. After cell lysis, the soluble fraction of the cell lysate is typically separated from the insoluble fraction. Before the screening assay, the cell lysate can be further processed (e.g., diluted in a buffer), or exposed to a treatment reagent.
[0322] 8. Mode of administration
[0323] Preferably, the composition of the present invention is administered to the GI tract so as to enable the bacterial strain of the present invention to be delivered to the intestinal tract. Preferably, the composition of the present invention is formulated for administration to the GI tract so as to enable the bacterial strain of the present invention to be delivered to the intestinal tract. In some embodiments, the composition of the present invention is formulated for administration to the GI tract so as to enable the bacterial strain of the present invention to be delivered to the intestinal tract and to partially or completely colonize the intestinal tract.
[0324] In certain embodiments, the compositions of the present invention may be applied as a foam, spray, or gel.
[0325] In certain embodiments, the compositions of the invention may be administered as suppositories, such as rectal suppositories, for example in the form of cocoa butter (cocoa butter), synthetic hard fats (e.g., WITEPSOL), glycerin gelatin, polyethylene glycol or soap glycerin combination.
[0326] In certain embodiments, the compositions of the invention are administered to the gastrointestinal tract via a tube, e.g., a nasogastric tube, an orogastric tube, a gastric tube, a jejunostomy tube (J tube), a percutaneous endoscopic gastrostomy (PEG), or via a port, e.g., a chest wall port providing access to the stomach, jejunum, and other suitable access ports.
[0327] The compositions of the present invention can be applied once, or can be applied sequentially as part of a treatment regimen. In certain embodiments, the compositions of the present invention are applied daily (once or multiple times). In certain embodiments, the compositions disclosed herein are applied regularly, such as every day, every two days or every week, and continue for a long time, such as at least one week, two weeks, one month, two months, six months or one year.
[0328] In some embodiments, the compositions disclosed herein are administered for 7 days, 14 days, 16 days, 21 days, or 28 days, or no more than 7 days, 14 days, 16 days, 21 days, or 28 days. For example, in some embodiments, the compositions disclosed herein are administered for 16 days.
[0329] In certain embodiments of the invention, treatment according to the invention is accompanied by an assessment of the patient's intestinal microbiota. If delivery and / or partial or complete colonization of the strain of the invention is not achieved so that no therapeutic effect is observed, the treatment can be repeated, or if delivery and / or partial or complete colonization is successful and a therapeutic effect is observed, the treatment can be stopped.
[0330] In certain embodiments, the compositions of the invention can be administered to a pregnant animal, such as a mammal, such as a human, to prevent the development of an inflammatory or autoimmune disorder (such as those disclosed herein) in its fetus in utero and / or after birth.
[0331] The composition of the present invention can be applied to patients who have been diagnosed with the following diseases: diseases or conditions mediated by digestive tract barrier dysfunction, or have been determined to be at risk of diseases or conditions mediated by digestive tract barrier dysfunction; diseases or conditions mediated by the STAT3 signaling pathway, or have been determined to be at risk of diseases or conditions mediated by the STAT3 signaling pathway; or inflammatory or autoimmune disorders (such as those disclosed herein). The composition can also be applied to healthy patients as a preventive measure to prevent the occurrence of diseases or conditions mediated by the STAT3 signaling pathway.
[0332] The compositions disclosed herein can be administered to patients who have been diagnosed with an inflammatory or autoimmune disorder, particularly an inflammatory or autoimmune disorder mediated by the microbiota-gut axis, or who have been identified as being at risk for an inflammatory or autoimmune disorder, particularly an inflammatory or autoimmune disorder mediated by the microbiota-gut axis. The compositions can also be administered to healthy patients as a preventive measure to prevent the occurrence of an inflammatory or autoimmune disorder, particularly an inflammatory or autoimmune disorder mediated by the microbiota-gut axis.
[0333] The compositions of the invention may be administered to patients who have been determined to have an abnormal intestinal microbiota. For example, the patient may have reduced or absent colonization with bacteria of the genus Intestinicoccus, particularly I. colisanans.
[0334] The composition of the present invention may be administered as a food (eg, a nutritional supplement).
[0335] Typically, the compositions of the invention are used to prevent or treat human disease, although they can also be used to treat animals, including monogastric mammals such as poultry, pigs, cats, dogs, horses or rabbits. The compositions of the invention can be used to enhance the growth and performance of animals. If administered to animals, oral gavage can be used.
[0336] In some embodiments, the subject to which the composition is administered is an adult human. In some embodiments, the subject to which the composition is administered is a human infant.
[0337] 9. Cultivation Methods
[0338] The bacterial strains used in the present invention can be cultured using standard microbiological techniques, see for example the references in McSweeney, 2005.
[0339] The solid or liquid medium used for culturing can be selected from TY or PYG medium, for example.
[0340] Exemplary media formulations suitable for use with the present invention include those provided in Table 1.
[0341] Table 1 Culture medium formula
[0342]
[0343] In order that the invention may be readily understood and put into practice, particularly preferred embodiments will now be described by way of the following non-limiting experimental examples. Example
[0344] Intestinicoccus colisanans in health and disease
[0345] Inflammatory bowel disease is characterized by changes in the structure and function of the microbiome, with the prevalence and abundance of specific gut bacteria significantly reduced in the IBD gut compared to the healthy gut. Multiple studies have suggested that these bacteria may modulate IBD pathogenesis (Mallone et al., 2011; Sokol et al., 2008), however, a key obstacle to the development of new therapeutics using these bacteria is that low-resolution 16S rRNA-based analyses do not provide sufficient resolution to accurately distinguish healthy and IBD-associated strains at low taxonomic levels (i.e., genus, species, strain).
[0346] The inventors investigated the prevalence of I. colisanans in inflammatory and autoimmune conditions using the Microba Disease Database (MDD), which contains high-resolution fecal gut metagenomic data and associated host metadata for 6,020 adults. Metagenomic sequence reads were analyzed using the Microba Community Profiler (MCP) (Parks et al., 2021).
[0347] I. colisanans are thought to be ubiquitous in healthy individuals but less frequently detected in inflammatory and autoimmune conditions ( Figure 1 A). The strongest effects were observed in the two major subtypes of IBD, including ulcerative colitis and Crohn's disease ( Figure 2 A and Table 2). This observation was replicated in an independent IBD cohort previously published at Harvard University ((Franzosa et al., 2018) Figure 1 B and Table 3).
[0348] Table 2. Correlation statistics between I. colisanans and inflammatory diseases
[0349]
[0350] Table 3. Correlation statistics between I.COLISANAS and IBD
[0351]
[0352] Isolation and genome-scale analysis of I. colisanans
[0353] To better understand the role of I. colisanans in health and IBD pathogenesis, we isolated two new isolates, termed I. colisanans MH27-1 and MH27-2, from healthy human donors by generating dilution-to-extinction enrichments followed by plating to obtain single colonies. I. colisanans MH27-1 and MH27-2 grew on TY- and PYG-based media and were typically observed as Gram-stained, chromosomal cells ( Figure 2 A).
[0354] Phylogenetic reconstruction of the genus Intestinicoccus using I. colisanans MH27-1 and MH27-2 and high-quality GenBank and RefSeq genomes from NCBI revealed that the isolate was placed with high confidence in the I. colisanans clade, close to several uncultured species ( Figure 2 B) and are sister to the genus Acutalibacter. I. colisanans MH27-1 and I. colisanans MH27-2 are sugar fermenters predicted to utilize a variety of carbohydrate sources, particularly starch, galactose, and mannose. Complete or nearly complete biosynthetic pathways have been identified for most amino acids, except tryptophan, glycine, histidine, phenylalanine, and tyrosine. Uptake and fermentation pathways have also been identified for several amino acids (Arg, Asp, Cys, Met, Glu, Gln, Met, Ser, and Thr), but these pathways are likely not the primary energy source. Metabolic modeling of I. colisanans MH27-1 and I. colisanans MH-27-2 isolates suggests that the major byproduct of fermentation is acetic acid when fed glucose and other hexoses. AntiSmash identified two RiPPsactipeptides BGCs in both strains that have no close homology to BGCs in public databases. DeepBGC identified the same sactipeptides RiPP and seven additional putative BGCs (with coding regions >1 and deepBGC scores >0.75).
[0355] I. Colisanans enhance digestive tract barrier function
[0356] To evaluate the role of I. colisanans in the healthy intestine, naive C57Bl / 6SPF mice were treated with I. colisanans MH27-1 for 8 days ( Figure 3A). We did not observe any morbidity or changes in overall appearance, behavior, posture, mobility, and neurobehavior during this treatment period. Similarly, animals treated with I. colisanans MH27-1 showed no significant changes in body weight, nor were colon length and weight / length ratio affected compared to vehicle controls ( Figure 3 I. colisanans MH27-1 did not induce any significant histological changes in the colon compared with vehicle, as determined by evaluating epithelial damage, inflammation, and hypervascularization individually or as a combined histopathological score ( Figure 3 EH).
[0357] The inventors hypothesized that big data approaches could be used to identify novel candidate live biotherapeutics for inflammatory bowel disease. Therefore, we tested the therapeutic efficacy of I. colisanans MH27-1 in an acute model of DSS-induced colitis in mice ( Figure 4 A), as this is a well-established model of epithelial injury and repair. DSS treatment resulted in significant disease activity compared to vehicle controls. Figure 4 B), which has been shown to be an accurate and reliable indicator of colitis (Britto, 2019). As expected, prednisone exacerbated DSS-induced weight loss (Yamamoto, 2013); however, treatment with I. colisanans MH27-1 or F. prausnitzii A2-165 improved DSS-induced weight loss ( Figure 4 B). Endoscopic analysis showed that disease activity gradually increased in all treatment groups; however, F. prausnitzii A2-165 and I. colisanans MH27-1 resulted in lower disease activity at day 6, whereas prednisone did not, relative to the vehicle-treated group ( Figure 4 C).
[0358] Histological analysis of DSS-treated mice revealed significant intestinal damage characterized by loss of intestinal crypts, epithelial erosions, and ulcers. Notably, treatment with I. colisanans MH27-1 resulted in a marked remodeling of intestinal crypts and re-epithelialization ( Figure 4 D) showed significant pathological improvement, as evidenced by histopathological healing ( Figure 4 E) and epithelial damage ( Figure 4 As expected, prednisone and F. prausnitzii A2-165 also resulted in significant improvements in disease pathology.
[0359] The therapeutic efficacy of I. colisanans MH27-2 in an acute mouse DSS colitis model was examined, with prednisone as a positive control drug.DSS treatment resulted in significant colitis as evidenced by histopathological scoring of colonic tissue damage and inflammation.
[0360] Daily treatment with I.colisanans MH27-2 or the positive control drug prednisone improved histological signs of colitis. Specifically, DSS-treated mice treated daily with I.colisanans MH27-2 had significantly lower total histological scores than DSS-control mice ( Figure 4 G). This effect was also observed in each histological subscore, indicating that treatment with I. colisanans MH27-2 alleviated epithelial damage in DSS-treated mice ( Figure 4 H) and inflammation ( Figure 4 I).
[0361] The therapeutic efficacy of I. colisanans MH27-2 drug substance (DS) was examined in an acute mouse DSS colitis model, with minocycline and prednisone as positive controls. DSS treatment resulted in significant colitis, as evidenced by in vivo colitis measures (disease activity index, body weight, fecal occult blood) and histopathological damage of colonic tissue (histological score and subscore).
[0362] Daily treatment with I.colisanans MH27-2 DS (2x10 6 cells / day)( Figure 4 J) or treatment with the positive control minocycline significantly improved the disease activity index (p<0.05). Specifically, daily treatment with I.colisanans DS or minocycline improved body weight change ( Figure 4 K) and fecal occult blood ( Figure 4 L) of the disease activity index subscore. Daily treatment with minocycline or I.colisanans MH27-2 DS (dose 2x10 8 cells / day), the total histopathological score of DSS-treated mice was significantly improved ( Figure 4 M). This treatment effect was characterized by mucosal structural scores ( Figure 4 N), erosion / ulcer score ( Figure 4 O) and percent involvement score ( Figure 4 P) have improved.
[0363] The IL-23-Th17 cell immune axis is central to the pathogenesis of inflammatory bowel disease and a validated therapeutic target (Friedrich, 2019). Since the DSS model of murine colitis is primarily supported by Th1-polarized immunity (Yang, 2017), we also tested the therapeutic efficacy of I. colisanans MH27-1 in the murine SKG model. SKG mice carry a ZAP-70 gene mutation and develop IL-23-driven Crohn's disease-like ileitis and autoimmune inflammatory arthritis after disease induction with Curdlan ( Figure 5 A) (see, Benham, 2014). Histological analysis of vehicle-treated mice showed significant intestinal damage 7 days after curdlan treatment, characterized by inflammatory cell infiltration and granuloma formation. As expected, treatment with anti-IL-23 monoclonal antibody significantly reduced histological damage. Treatment with I. colisanans MH27-1 also resulted in significant improvement in pathology, as evidenced by improved histopathological scores ( Figure 5 B). Similarly, treatment with I. colisanans MH27-1 also resulted in a significant reduction in the production of cytokines central to disease pathogenesis, including IL-6 and IL-12 (IL12p70) ( Figure 5 C, D).
[0364] The therapeutic effect of I. colisanans MH27-2 was also examined in an acute mouse TNBS-induced colitis model, using cyclosporin A as a positive control ( Figure 5 E). The TNBS model is widely used because it shares the same immunopathology as Crohn's disease. TNBS treatment results in significant macroscopic damage, which is ameliorated by treatment with cyclosporine A or I.colisanans MH27-2 ( Figure 5 F). Notably, I. colisanans MH27-2 showed significant (p<0.05) improvement in ulceration / inflammation scores ( Figure 5 G). TNBS treatment resulted in significant histological damage, which was ameliorated by treatment with cyclosporine A or I. colisanans MH27-2 ( Figure 5 H). Compared with the vehicle group, colitis lesions (including diffuse mucosal architectural abnormalities, ulcers, intestinal crypt dilatation, abnormal crypts, crypt disappearance, mucosal gland distortion, goblet cell disappearance, and focal to multifocal inflammatory cell infiltration) were less prominent in the I. colisanans MH27-2 treated group, and the lesion scores were significantly (p<0.05) reduced in the treated group, as reflected by improvements in the degree of inflammation, erosion or ulceration, epithelial regeneration, and percentage involvement scores ( Figure 5Treatment with I. colisanans MH27-2 significantly reduced IL-6 concentrations compared to vehicle-treated TNBS controls ( Figure 5 M).
[0365] Taken together, these data suggest that I. colisanans MH27-1 does not cause any adverse effects in DSS-treated or naive mice and that I. colisanans MH27-1 and 2 promote mucosal healing in C57Bl / 6 and SKG mice treated with DSS or TNBS.
[0366] I. Colisanans inhibit IL-6-mediated STAT3 activation
[0367] Elevated levels of the proinflammatory cytokine IL-6 and signaling through its receptor IL-6R have been implicated in the pathogenesis of IBD. Notably, IL-6 promotes chronic intestinal inflammation due to its proinflammatory and anti-apoptotic effects on immune cells. These effects are mediated by IL-6 receptor binding, leading to JAK kinase activation and STAT3 dimerization as well as activation of MAPK / ERK and other downstream kinases. Here, we used HEK-Blue TM IL-6 reporter cell line We examined whether I. colisanans MH27-1 and MH27-2 were able to inhibit STAT3 activation mediated by canonical and trans signaling of IL-6. HEK-Blue TM The IL-6 reporter cell line constitutively expresses the human IL-6 receptor, and binding of IL-6 to this receptor triggers the expression of the STAT3-responsive SEAP reporter gene. Tofacitinib was used as a control and, as expected, completely blocked IL-6 and IL-6 / IL-6R-mediated STAT3 activation ( Figure 6 The results showed that the original culture supernatants of I. colisanans MH27-1, MH27-2 and MH27-3 and their <3 kDa filtered fractions significantly inhibited the SEAP reporter gene activity compared with the culture medium ( Figure 6 AC), while the original culture supernatant of I. colisanans MH27-4 and MH27-5 also inhibited the SEAP reporter gene activity (Figure DE). In contrast, the original culture supernatant of R. bromii MCB950 and its <3 kDa filtered fraction did not significantly inhibit the SEAP reporter gene activity (Figure Figure 6 F). In addition, I. colisanans MH27-2 inhibited IL-6 trans-signaling-mediated STAT3 activation ( Figure 6 G).
[0368] I. Colisanans promote migration of human intestinal epithelial cells
[0369] Digestive barrier damage often occurs in IBD. Rapid migration of intestinal epithelial cells is a key component of the wound healing process to reestablish homeostasis. To determine whether I. colisanans MH27-1 or MH27-2 affect the motility of intestinal epithelial cells, we used Migration assay. HCT116 cells were seeded The apical side of the chamber was placed on the surface of the membrane and the ability of I. colisanans extracts to promote cell migration towards the basolateral side of the chamber was assessed. Untreated cells had a basal level of migration towards the basolateral side of the membrane and this was not affected by TY medium or treatment with the enteric bacterium Clostridium bolteae BAA-613 ( Figure 7 A). I. colisanans MH27-1 and MH27-2 significantly promoted the basolateral migration of HCT116 cells ( Figure 7 A).
[0370] The pro-migratory effect of I. colisanans was further confirmed using the IncuCyte scratch wound assay. After scratch wound induction, HCT116 cells in the presence of I. colisanans MH27-2 extract showed accelerated wound closure compared to control cells treated with medium ( Figure 7 B).
[0371] I. colisanans MH27 inhibits IL-23-mediated STAT3 activation
[0372] The inventors next sought to investigate whether bacterial products naturally produced by the intestinal bacterium I. colisanans MH27 could modulate IL-23-mediated STAT3 activation. The JAK-STAT immune axis is a well-established and validated drug target for IBD (Salas et al., 2020) and other diseases (McLornan et al., 2021), and JAK-STAT pathway signaling is the target of several approved IBD therapies, including anti-IL-23 antibodies (e.g., Ustekinumab) and small molecule inhibitors (e.g., Tofacitinib) (Hu et al., 2021). Since STAT3 inhibition can reduce destructive inflammation, I. colisanans MH27 and / or its bioactive substances may be used as novel immunomodulatory therapies for IBD and other diseases. Therefore, the inventors used HEK-Blue TM IL-23 reporter cell line We examined whether I. colisanans MH27 could inhibit IL-23-mediated STAT3 activation.TM The IL-23 reporter cell line constitutively expresses the human IL-23 receptor, and binding of IL-23 to the receptor triggers the expression of the STAT3-responsive SEAP reporter gene. The pharmacological JAK-STAT inhibitor tofacitinib was used as a control.
[0373] As expected, tofacitinib completely blocked IL-23-mediated STAT3 activation ( Figure 8 ). Both the cell-free culture supernatant and the <3 kDa filtered culture supernatant of I. colisanans MH27 significantly inhibited SEAP reporter gene activity compared to the TY medium control. In contrast, neither the original supernatant nor the <3 kDa filtered supernatant prepared from Ruminococcus bromii MCB950 inhibited SEAP reporter gene activity relative to the MCM medium control ( Figure 8 , right figure).
[0374] These data suggest that the secretome of I. colisanans MH27, but not R. bromii MCB950, can inhibit the IL-23 / STAT3 signaling axis in vitro. Based on the fractionation of culture supernatants, the inhibitory effect on STAT3 activation may be mediated by one or more secreted low molecular weight bioactive substances.
[0375] I. Colisanans improve IFNγ-driven reduction in digestive tract barrier integrity
[0376] The ability of I. colisanans MH27 culture supernatants to modulate barrier function was examined using T84 cells. Basolateral treatment with IFNγ was performed to disrupt barrier function. After 48 hours of addition of IFNγ to T84 cells, resistance dropped substantially, indicating an increase in barrier permeability. Treatment with <3 kDa fractionated culture supernatants from I. colisanans MH27 improved the reduction in TEER relative to the YG / V medium control, most notably after 168 hours ( Fig. 9 , assessed by two-way ANOVA test, at 168, 192, 216, 240, 288, 312, and 336 h, p < 0.05).
[0377] I. Colisanans improve IL-6-driven reduction in digestive tract barrier integrity
[0378] The ability of I. colisanans MH27-2 to modulate barrier function was examined by monitoring the TEER of T84 cells during and after IL-6, a known barrier disruptor, induced loss of barrier integrity. Treatment of T84 cells with IL-6 for 96 hours resulted in a significant decrease in TEER, as expected, indicating increased barrier permeability. Simultaneous treatment with I. colisanans MH27-2 culture supernatant extract ameliorated the IL-6-mediated decrease in TEER in a dose-dependent manner ( Fig.10 ).
[0379] I. Colisanans improve IFNγ-mediated reduction of ZO1 expression
[0380] Tight junctions (TJs) form a continuous barrier between epithelial cells and function to control paracellular permeability. ZO1 plays a key role in tight junction assembly, so we evaluated the ability of I. colisanans MH27 supernatant extract to alleviate IFNγ-mediated loss of ZO1 expression in T84 cells. Stimulation with IFNγ significantly reduced ZO1 expression ( Fig.11 Pretreatment with YG / V extract did not significantly affect the reduction of ZO1 expression ( Fig.11 In contrast, pretreatment with supernatant extracts of I. colisanans MH27-1, MH27-2, and MH27-3 ameliorated the IFNγ-induced decrease in ZO1 expression ( Fig.11 ).
[0381] I.colisanans produce metabolites that modulate digestive tract barrier integrity
[0382] Based on the ability of I. colisanans supernatant extracts to modulate ZO1 expression, we next examined the ability of I. colisanans MH27-2 culture supernatant fractions obtained using Strata X-100 to modulate ZO1 expression. By this approach, we determined that the ability to modulate ZO1 expression could be fractionated and localized to the 15% and 30% fractions ( Fig.12 AC).
[0383] Metabolites produced by I. colisanans MH27 can ameliorate IFNγ-mediated reduction in ZO1 expression
[0384] Based on these data, the inventors speculate that I. colisanans produces metabolites that can regulate the inflammatory response and barrier integrity of intestinal epithelial cells. Thirty metabolites (classified as level 1 or 2a) that increased ≥1.5 times compared to the YG / V medium control were identified in the cell-free culture supernatant (Table 4). These metabolites include previously reported metabolites that regulate inflammation, immune cell infiltration, oxidative stress and barrier function (e.g., ornithine, indole-3-lactic acid, allopurinol, propionylcarnitine, pyrogallic acid, 3-(2-hydroxyethyl) indole and N-acetylcysteine, etc.). Compared to the YG / V medium control, another 29 and 48 metabolites increased ≥1.5 times in the 15% and 30% fractions, respectively (Table 4). These metabolites include previously reported metabolites that regulate inflammation and barrier integrity (e.g., tryptol, indole-3-lactic acid, indole-3 propionic acid, cyclo(-Phe-Pro)). The immunomodulatory metabolite indole-3-acrylic acid was also identified in the 60% fraction. Note that some of the identified metabolites were not present in the control sample, so fold changes could not be calculated.
[0385] Having identified candidate gastrointestinal barrier modulating metabolites, the inventors next evaluated the ability of the selected metabolites to modulate IFNγ-mediated loss of ZO1 expression in T84 cells. To this end, T84 cells were pretreated with ornithine, indole-3-acrylic acid (IAyA), or indole-3-propionic acid (IPA) for 18 h prior to stimulation with IFNγ for 48 h. As previously observed, stimulation with IFNγ resulted in a significant reduction in ZO1 expression ( Fig.13 A, B). Pretreatment with ornithine, IAyA, and IPA significantly ameliorated the IFNγ-induced reduction in ZO1 expression ( Fig.13 A, B). Separately, we also determined that cyclic (-Phe-Pro) inhibited IL-23-mediated STAT3 activation ( Fig.13 C).
[0386] Table 4. Metabolites identified in the supernatant (SN), 15% and 30% fractions
[0387]
[0388]
[0389]
[0390] I. colisanans exhibit anti-inflammatory IL-10 / IL-12 cytokine ratio
[0391] Previous studies have shown that the ability of bacteria to induce IL-10 and IL-12 secretion from PBMCs in vitro correlates with their immunomodulatory capacity in vivo (Foligne et al., 2007; Sokol et al., 2008). Specifically, the IL-10:IL-12 ratio is widely used to distinguish strains that exhibit anti-inflammatory (high IL-10:IL-12 ratio) or pro-inflammatory (low IL-10:IL-12 ratio), with an average IL-10:IL-12 ratio >5 being associated with protection against TNBS-induced experimental colitis. Therefore, the ability of I. colisanans to induce cytokine production from PBMCs was assessed.
[0392] Treatment with I. colisanans resulted in an IL-10:IL-12 ratio of 30 ( Fig.14 ), which further supports the strong anti-inflammatory activity observed in the above data.
[0393] I. colisanans exhibit NF-κB inhibitory activity
[0394] The NF-κB signaling axis plays a key role in the pathogenesis of inflammatory bowel disease (IBD) and is a recognized and validated therapeutic target. We demonstrated that cell-free culture supernatants and <3 kDa filtered culture supernatants from I. colisanans MH27-2, MH27-3, and MH27-5 significantly inhibited luciferase reporter activity compared to medium control. In contrast, crude supernatant prepared from R. bromii MCB950 did not inhibit reporter activity compared to medium control ( Fig.15 A, D).
[0395] Materials and Methods
[0396] Bacterial strains, culture conditions, and analysis
[0397] Fecal samples were collected from healthy adults with no history of gastrointestinal disease and mixed with an equal weight / volume of sterile oxygen-free glycerol solution (McSweeny, 2005). Donors had not taken antibiotics within 3 months prior to the collection of fecal samples. All samples were collected under informed consent and ethical guidelines approved by Bellberry Limited (HREC2018-05-400-A-6). I. colisanans and Faecalibacterium prausnitzii were routinely handled in a Coy vinyl anaerobic chamber with an anaerobic atmosphere (85% N2: 10% CO2: 5% H2). I. colisanans was routinely cultured in TY or YG / V medium (Table 1), while F. prausnitzii was cultured in TY medium (Table 1). All isolates were stored by mixing 3 mL of actively growing culture with an equal volume of glycerol solution and storing at -80°C.
[0398] Isolation of I. colisanans
[0399] A donor stool sample, in which I. colisanans was present at a relative abundance of 0.37%, was inoculated into a custom medium (trehalose 1 g / L, alanine 400 mg / L, tryptophan 80 mg / L, methionine 200 mg / L, phenylalanine 200 mg / L, tyrosine 200 mg / L, butyrate 400 μL / L, salt 2 75 ml / L, salt 3 75 ml / L, sodium bicarbonate 8 g / L, resazurin 1 mL / L, cysteine hydrochloride 1 mL / L, vitamin solution 1 ml / L) and then serially diluted to extinction to generate I. colisanans isolates. The extinction dilution series was sequenced and a low-diversity enrichment culture with a relative abundance of 77% for I. colisanans was identified. This enrichment culture was then used to establish a further extinction dilution series and a low-diversity enrichment with more than 79% I. colisanans was identified. Colonies were recovered on PYG agar and then picked into PYG broth. Thus, a dual culture consisting of I. colisanans and Ruthenibacterium lactatiformans was identified. To generate a contamination-free culture of I. colisanans, the dual culture was inoculated into YCFAmod broth and the enriched culture was then streaked onto YCFAmod agar. Two distinct colony types were observed after a few days and purified. Through this approach, a Gram-stained, chromococcal-like isolate was identified and named I. colisanans MH27-1 after whole genome sequencing.
[0400] The I. colisanans MH27-2 isolate was generated by inoculating a donor stool sample with a relative abundance of 0.38% I. colisanans into a custom culture medium (maltose 1 g / L, alanine 400 mg / L, tryptophan 80 mg / L, methionine 200 mg / L, phenylalanine 200 mg / L, tyrosine 200 mg / L, histidine 125 mg / L, salt 2 75 ml / L, salt 3 75 ml / L, sodium bicarbonate 8 g / L, resazurin 1 mL / L, cysteine hydrochloride 1 mL / L, vitamin solution 1 ml / L) and then serially diluted to extinction. The extinction dilution culture series was sequenced and an enrichment with a relative abundance of 72.6% of I. colisanans was identified. The enrichment was streaked onto PYG plates and an isolate with cocci-like cell morphology was identified. After purification, a Gram-stained, erratic, cocci-like isolate was identified and named I. colisanans MH27-2 after whole genome sequencing.
[0401] The I. colisanans MH27-3 isolate was generated by inoculating a donor stool sample with a relative abundance of 0.38% I. colisanans into a custom culture medium (maltose 1 g / L, alanine 400 mg / L, tryptophan 80 mg / L, methionine 200 mg / L, phenylalanine 200 mg / L, tyrosine 200 mg / L, histidine 125 mg / L, salt 2 75 ml / L, salt 3 75 ml / L, sodium bicarbonate 8 g / L, resazurin 1 mL / L, cysteine hydrochloride 1 mL / L, vitamin solution 1 ml / L) and then serially diluted to extinction. The extinction dilution culture series was sequenced and an enrichment with a relative abundance of 14.5% I. colisanans was identified. This enrichment was used to inoculate a second extinction dilution experiment in the same GDI medium, resulting in a 28% new enrichment of I. colisanans and <27% relative abundance of other bacterial species. The enrichment was plated on YG / V, and a single colony consisting of variably Gram-stained cocci-like cells was identified. The colony was picked and streaked twice more on YG / V agar. After whole genome sequencing, the axenic isolate was called I. colisanans MH27-3.
[0402] I. colisanans MH27-4, MH27-5, and MH27-6 were generated from donor stool samples using a microbial-based single-cell sorting method. For I. colisanans MH27-4, approximately 1 g of stool sample with a relative abundance of 0.3% I. colisanans was mixed with 1 mL of anaerobic buffer dilution solution and vortexed for 10 seconds to separate the bacteria from the stool residue. For I. colisanans MH27-5, approximately 1 g of stool sample with a relative abundance of 0.67% I. colisanans was mixed with 1 mL of anaerobic buffer dilution solution and vortexed for 10 seconds to separate the bacteria from the stool residue. For I. colisanans MH27-6, approximately 1 g of stool sample containing a relative abundance of 2.5% I. colisanans was mixed with 1 mL of anaerobic buffer diluent and vortexed for 10 seconds to separate the bacteria from the stool residue. Similarly, Ruminococcus bromii MCB950 was generated from donor fecal samples using a microbial-based single-cell sorting approach and used for comparative analysis. For R. bromii MCB950, approximately 1 g of fecal sample containing 5.5% relative abundance of R. bromii was mixed with 1 mL of anaerobic buffer diluent and vortexed for 10 seconds to separate the bacteria from fecal debris. The samples were analyzed using a BD FACSAria equipped with a 100 μm nozzle and a small particle detector according to the manufacturer's instructions. TM Bacterial cells were sorted on a Fusion flow cytometer. The system pressure was 20 psi, events were triggered on scatter, and the threshold was set using 0.2 μm filtered PBS, which allowed very few events from the noise floor. Bacterial cells were also sorted using a CytoFLEX SRT benchtop cell sorter inside a COY anaerobic chamber. The setup and quality control of the instrument were performed according to the manufacturer's instructions. The anaerobic chamber was filled with dry ice to keep the instrument within the set temperature range. Prior to sorting, the jackets of the Fusion and SRT were purged with nitrogen for one hour. To sort bacterial cells, an aliquot was filtered through a 40 μm filter and 10 μl of anaerobic buffer was prepared using 0.2 μm filtered diluent (i.e., 38 ml / L each of salt solutions 2 and 3 (McSweeney et al., 2005)). -3 Diluted filtrate. Run the diluted filtrate to determine the dilution, get 500-1200 events per second. Gate the target on scatter and exclude doublets ( Fig.16). Single cells were maintained on TY agar plates and incubated at 37°C for up to 3 weeks. Isolates were identified by whole genome sequencing after growth in TY broth. By this approach, isolates related to I. colisanans and R. bromii were initially identified. I. colisanans isolates were purified by repeated streaking of single colonies on YG / V agar; R. bromii were purified by repeated streaking of single colonies on TY agar. The final purified isolates were stored in glycerol and submitted for whole genome sequencing, and by this approach isolates designated I. colisanans MH27-4 and MH27-5 were generated.
[0403] For I. colisanans MH27-6, an enrichment containing I. colisanans MH27-6 was identified after culturing the cell sorted isolate in TY broth at a relative abundance of 10.6%. From a glycerol stock of this enrichment, 200 μl was used to inoculate YG / V medium, enriching I. colisanans to a relative abundance of 71.5%. I. colisanans colonies were generated and subsequently purified by streaking on YG / V agar. The final purified isolate was stored in glycerol and submitted for whole genome sequencing, and by this method the isolate designated I. colisanans MH27-6 was generated.
[0404] Metabolic reconstruction
[0405] Protein coding sequences were predicted and annotated using the annotation function in enrichM (0.6.2). Briefly, enrichM identified protein coding sequences using prodigal (version) in -p meta mode. Amino acid sequence queries were then performed using DIAMOND (version) against the UniRef100 database (version), and the EC, TCDB, and eggnog classifications were inherited from the id mapping files distributed with UniRef. Functional domains, key metabolic markers, and carbohydrate-activated (CAZy) enzymes were annotated using Hmmer hmmsearches (version 3.1b2) against Pfam (version 33.0), TIGRFAM (version 15.0), and dbCAN2 (downloaded in September 2019), respectively. Metabolic pathways were identified using the classification function in enrichM, which evaluates annotations and their genomic locations based on manually defined metabolic pathway definitions. A pathway was considered to be present in a genome if the following conditions were met: the genome encoded >80% of the desired proteins and passed all required synteny checks. These automatically predicted pathways were then manually evaluated. In addition, gutSMASH (version 1.0.0) was applied to identify common functions mediated by the gut microbiome.
[0406] Phylogenetic tree
[0407] Clades 23560 in the GTDB r89 species representative tree were visualized using the R libraries phytools (v0.7.70), ape (v5.4), and ggtree (v2.2.4). A separate genome tree was constructed from high-quality genomes (≥90%, contamination and ≤5% contamination from checkM analysis) from the genus Intestinicoccus (NCBI r89) and the MH27 isolate. For each genome, a set of 122 bacteria-specific conserved marker genes was extracted from each genome using gtdbtk identify. These genes were aligned to draw HMMs and concatenated into a single alignment using gtdbtk align, and maximum likelihood phylogenetic trees were then constructed from these alignments using FastTree (v2.1.10) and gtdbtk infer. Nonparametric bootstrap values were inferred from 1000 replicates using GenomeTreetk (v0.1.6).
[0408] Preparation of bacterial strains for animal experiments
[0409] I. colisanans strains were grown to early stationary phase in PYG or YG / V. F. prausnitzii was grown in TY medium. The cell density of each individual culture was calculated using a Helber counting chamber. To prepare the bacterial gavage solution, each individual culture was centrifuged at 5,000g for 10 minutes under a layer of sterile heavy mineral oil, and the cell-free supernatant was discarded. The cell pellet was washed in 1.5 ml of sterile anaerobic buffer diluent (38 ml / L each of salt solutions 2 and 3 (McSweeney, 2005), 1 ml / L 0.1% (w / v) resazurin solution, 1 g / L L-cysteine) and then centrifuged again. Finally, the washed cell pellet was suspended in a 1 / 2 concentration glycerol solution (15% v / v glycerol solution in anoxic buffer diluent) to a final concentration of 1x10 9 cells / ml, aliquoted and frozen at -80°C until needed. Viability of cell preparations was confirmed by thawing individual aliquots and streaking on agar plates. Identity and purity of each single strain preparation was confirmed by whole genome sequencing.
[0410] DSS-induced acute colitis model
[0411] For the prevention model, six-week-old C57BL / 6 female mice purchased from the Animal Resource Center (Western Australia, Australia) were randomly divided into groups and then co-caged for 7 days before the experiment. In order to induce the disease, mice were treated with 3.5% DSS in drinking water obtained at will for 6 days. Naive age-matched control mice were treated and received drinking water without DSS. All treatments started 1 day before DSS was provided, and all mice were killed 2 days after the last DSS treatment. For treatment, mice were anesthetized with isoflurane and orally gavaged with 200 μL bacterial preparations or vehicle controls. Prednisone (2 mg / kg) was given by intraperitoneal injection after anesthesia. Body weight and fecal consistency were recorded every day. Fecal samples were collected every day. After killing, colon, liver and spleen were collected for analysis. Blood was collected by cardiac puncture.
[0412] For the treatment model, groups of 10 or 20 female C57BL / 6 mice were used. All animals, except the healthy group, received 2.5% dextran sulfate sodium (DSS) in their drinking water for 6 days (day 0 to day 5). DSS was then withdrawn and replaced with normal drinking water for another 5 days (day 6 to day 10). For treatment, mice were orally gavaged once daily with 200 μL of I.colisanans MH27-2 at a dose of 2x10 8living cells, or a vehicle consisting of sterile glycerol and phosphate-buffered saline. The positive control drug prednisone was also administered by oral gavage at a dose of 2 mg / kg per day. Treatment began on day 4 and was administered for 7 consecutive days until day 10. Animals were sacrificed on day 10, approximately 4 hours after the last treatment. The colon was removed, flushed, weighed, photographed, and cut longitudinally. Colon tissue was fixed with 4% formalin and preserved in 70% ethanol for histopathological examination using the Swiss-roll method.
[0413] Endoscopic and histological scoring
[0414] Animals were examined with a small animal gastrointestinal endoscope (Karl Storz Endoskope, Tuttlingen, Germany) on days -1, 2, and 6 to assess the extent of colonic mucosal inflammation (Marks, 2015; and Liu, 2019). Briefly, mice were anesthetized with isoflurane and a colonoscope was inserted through the rectum. Images captured by high-definition video were examined in a blinded manner to assess the presence and extent of disease pathology (Table 5). Histological scoring was performed essentially as described by Marks et al. (Marks, 2015). Briefly, samples were fixed in 4% formalin, paraffin-embedded, and sectioned. Tissue sections were stained with hematoxylin and eosin to assess disease pathology and with alcian blue to assess mucin production. Slides were imaged using an Aperio digital imaging system (Leica Biosystems, Nuβloch, Germany). To grade the severity of colitis, the degree of inflammation and epithelial damage in tissue sections was semi-quantitatively graded using an established scoring system (Table 6). The samples were then randomized and subsequently scored by a trained gastrointestinal pathologist in a blinded manner.
[0415] SKG model of mouse ileitis
[0416] Five-week-old SKG female mice (n=3 males; n=3 females) were randomized and then co-housed for 3 weeks before the experiment. To induce disease, mice were administered curdlan (1,3-β-glucan, 3 mg per mouse) intraperitoneally (ip). Age-matched naive control mice were treated similarly, except that they were administered saline intraperitoneally. All treatments were initiated before curdlan administration, and all mice were sacrificed 7 days after curdlan treatment. For bacterial treatment, mice were orally gavaged with 200 μl of bacterial preparation or vehicle control starting 2 days before curdlan administration. Anti-mouse IL-23p19 monoclonal antibody (Thermo Fisher, 30 μg per mouse) was administered by intraperitoneal injection one day before curdlan administration. Fecal samples were collected daily. Body weight was measured on days -2, 0, and 7. After sacrifice, colon, distal small intestine, mesenteric lymph nodes, and spleen were collected for analysis. Blood was collected by cardiac puncture.
[0417] Clinical and histological scoring
[0418] Histological scoring was performed essentially as described by Benham et al., 2014. Briefly, samples were fixed in 4% formalin, embedded in paraffin, and sectioned. Tissue sections were stained with hematoxylin and eosin to assess disease pathology and with alcian blue to assess goblet cells. Slides were imaged using an Olympus VS120 slide scanner (Olympus Corporation, Tokyo, Japan). To grade the severity of ileitis, the degree of inflammation and epithelial damage in tissue sections was semiquantitatively graded using an established scoring system (Table 7) (Benham et al., 2014). The samples were then randomized and subsequently scored in a blinded manner by an independent trained pathologist.
[0419] To characterize the cytokines present in the serum, mice were euthanized by CO2 asphyxiation, blood was collected by cardiac exsanguination, and serum was separated by centrifugation. Serum samples were stored at -80°C. These serum samples were subsequently thawed and used in the LEGENDplex Mouse Inflammation Plate (13-plex) (BioLegend, catalog number 740446) to determine the effects on cytokine production (IL-23, IL-1α, IFN-γ, TNF, MCP-1, IL-12p70, IL-1β, IL-10, IL-6, IL-27, IL-17A, IFN-β, GM-CSF). Serum samples were diluted 2-fold and then incubated with capture beads conjugated with antibodies against specific analytes. After washing, a biotinylated detection antibody mixture was added to form a "capture bead-analyte-detection antibody" sandwich. Streptavidin-phycoerythrin (SA-PE) was added to bind the biotinylated detection antibody. After the final wash, the mixture was analyzed by flow cytometry, where beads were differentiated based on size and internal fluorescence intensity. Cytokine concentrations were determined by PE fluorescence and compared to a standard curve of known cytokine concentrations using BioLegend's LEGENDplex data analysis software. The unique size and fluorescence properties of the beads allowed for the simultaneous measurement of 13 cytokines.
[0420] TNBS mouse colitis model
[0421] Groups of 5 or 10 male BALB / c mice were used. Mice were fasted overnight (day 1) and then challenged with 2,4,6-trinitrobenzenesulfonic acid solution (TNBS) on day 2. Distal colitis was induced by intracolonic instillation of TNBS (1 mg dissolved in 0.1 mL 50% ethanol), after which the animals were kept in a vertical position for 30 seconds to ensure that the solution remained in the colon. For treatment, 200 μl of I. colisanans MH27-2 at 1x10 9 Cells / day or vehicle (sterile glycerol and phosphate solution) were orally gavaged into mice. The positive control cyclosporin A was administered once daily by oral gavage at a dose of 75 mg / kg, from day 1 (i.e., 1 day before TNBS) to day 4, for a total of 4 consecutive days (days 1-4). On the day of TNBS challenge, vehicle, I.colisanans MH27-2, and cyclosporin A were given 2 hours before TNBS. Animals were sacrificed on day 5; blood was collected from all animals by cardiac puncture. Colon tissue was also harvested and quickly frozen with liquid nitrogen for cytokine measurements. On day 5, mice were euthanized by CO2 asphyxiation. Each colon was removed, flushed, and then cut 4 cm from the anus. Tissue sections were fixed in 10% formalin and stored in 70% ethanol for histopathological examination.
[0422] Macroscopic scoring of TNBS colitis
[0423] On day 5, mice were euthanized by CO2 asphyxiation, and the colon was weighed and measured in length. In addition, adhesions between the colon and other organs were observed when the abdominal cavity was opened before resection of the colon, and the presence of colonic ulcers was observed after resection and weighing of each colon. Macroscopic scoring (Table 8) was performed, and photos of the complete colon were taken.
[0424] Histopathological scoring of TNBS colitis
[0425] Each colon was removed, flushed, macroscopically scored, photographed, weighed and measured in length, and then cut into two parts 4 cm from the anus; one part was fixed with 10% formalin and stored in 70% ethanol for histopathology, and the other part was snap-frozen with liquid nitrogen for cytokine measurement (IL-6). For histological analysis (colitis score; basically as described by Dieleman LA et al., 1998), four micron tissue sections were prepared and stained with hematoxylin and eosin (H&E) under an optical microscope (LEICA DM2700 M, USA). Histological criteria include: abnormal mucosal structure, degree of inflammation, erosion or ulceration, epithelial regeneration, and percentage involved in the disease process. The score was generated based on the observations of the observer by examining two sections of the colon of each animal. The total colitis score (total colitis index) was added to obtain a comprehensive histological score of 0 to 40 (Table 9). Cytokines were measured using a Millipore ELISA kit and a protocol adapted from product information and manuals. The 2x sections were scored between 0-20 and the total score ranged from 0-40 when added together.
[0426] Cell migration assay
[0427] The TRANSWELL migration assay was used to assess the migration of HCT116 cells during exposure to I. colisanans culture supernatant extracts. These bacterial extracts were prepared using Amberlite XAD-7 resin essentially as described previously by Colosimo et al. (Colosimo, 2019). Briefly, a single colony was inoculated and grown until early stationary phase. This "seed culture" broth was used to inoculate 600 mL of TY broth, and the cultures were incubated until early stationary phase. The culture supernatant was prepared as follows: the culture was centrifuged at 4000g for 30 minutes and the cell-free supernatant was passed through a 3 kDa filter (Sartorius Biosystems, Inc., MD) according to the manufacturer's instructions. 50 ultrafiltration unit 3kDa MWCO PES). Activated Amberlite XAD-7 resin was added to 400mL 3kDa filtered cell-free supernatant (10% w / v) and the slurry was gently shaken overnight at 4°C. The resin was collected, washed with 400mL deionized water, and then mixed with 120mL 100% methanol. After incubation for 2 hours with gentle shaking, the methanol eluate was collected. A second elution was performed in 120mL 100% methanol as described above, and the two eluates were finally combined and dried under vacuum using a rotary evaporator. The extract was completely suspended in 100% DMSO (hereinafter referred to as 1000X) and stored at -20°C.
[0428] Human HCT116 intestinal epithelial cells were maintained in McCoys 5a medium supplemented with 10% FBS and 1% Pen / Strep. To evaluate cell migration, 3.5 x 10 4 HCT116 cells were seeded in 100 μL of 10% FBS medium in the upper compartment of a 6.5 mm insert in a 24-well plate (8 μm pore size, Corning Costar) with a TC-treated polycarbonate membrane. 600 μl of 10% FBS medium was added to the lower compartment. The cells were left for 24 hours. After washing with DPBS, 100 μL and 600 μL of 0.5% FBS medium were added to the upper and lower compartments, respectively. Then, a 0.5-fold concentrated I. colisanans extract was added to the lower compartment. After 16 hours, the cells were washed with DPBS, and the cells attached to the top of the membrane were carefully removed with a cotton swab. The migrated cells at the bottom of the membrane were then fixed in 70% ethanol for 10 minutes and then stained in 0.25% crystal violet for 5 minutes. Wash with water Inserts were dried, and membranes were mounted on glass slides with 50% aqueous glycerol and imaged immediately. The experiment was performed in biological and technical triplicates, and for each replicate, two representative images of the membrane were taken at 10× magnification. The number of migrated cells was automatically counted using ImageJ and the average cell number is displayed. The extent of cell migration is expressed as the average number of migrated cells in two microscopic fields per well from 3 biological replicates and 3 technical replicates.
[0429] use A live cell imaging system (Essen BioScience) and a transwell migration assay were used to evaluate the migration of HCT116 cells during exposure to sterile culture supernatant of I. colisanans. Human HCT116 intestinal epithelial cells were maintained in McCoys 5a medium supplemented with 10% FBS and 1% Pen / Strep. For the scratch wound test, 3.5 x 10 4 HCT116 cells were seeded on poly-L-ornithine-coated ImageLock 96-well plates (Essen BioScience). The WoundMaker tool induced uniform scratch wounds in nearly confluent cell monolayers. The cells were washed twice with DPBS and treated with I. colisanas supernatant extract (prepared using Amberlite XAD-7 resin as described below in the "Preparation of bacterial supernatant and culture medium extracts") at 0.3x in 200 μL 0.5% FBS McCoys 5a medium. A similarly prepared bacterial culture medium extract served as a negative control. Immediately after adding the stimulus, the culture plate was transferred to Each well was imaged every 2 hours to monitor cell migration for 72 hours. Data were analyzed using integrated analysis software.
[0430] Table 5
[0431] Digestive tract barrier dysfunction score by colonoscopy
[0432]
[0433]
[0434] Table 6 Histological colitis scores
[0435]
[0436] Table 7 Histological scoring system for ileum of SKG mice
[0437]
[0438] For the total histological score, the scores of sections 1, 2, and 3 were added and then multiplied by the cross-sectional area involved.
[0439] Table 8 Macroscopic colitis scores
[0440]
[0441]
[0442] Table 9
[0443] Histological colitis score
[0444]
[0445] Characterization of IL-6 and IL-6 / IL-6R-mediated STAT3 inhibitory activity
[0446] To evaluate IL-6 and IL-6 / IL-6R-mediated STAT3 inhibitory activity, three independent colonies were inoculated and grown to early stationary phase. Then, two technical replicates were inoculated with each seed culture, thereby generating six technical replicates from three biological replicates. These technical replicates were grown to early stationary phase, and the cell-free culture supernatant was harvested as described previously (Giri et al., 2019). The 3 kDa The culture supernatant was size fractionated using the column.
[0447] IL-6 and IL-6 / IL-6R-mediated STAT3 activity was assessed using the HEK Blue IL-6 cell line (Invivogen). Briefly, 50,000 cells per well were seeded in triplicate in a 96-well plate 24 hours before the start of the assay. Bacterial supernatant or sterile bacterial culture medium was added to the cells at a final concentration of 10% v / v for 60 minutes of pretreatment. Then, recombinant human IL-6 (2 ng / mL) or IL-6 / IL-6R complex (400 ng / mL) (R&D Systems) was added, and the cells were incubated at 37°C for 24 hours. The ability of the supernatant to inhibit IL-6 or IL-6 / IL-6R-mediated STAT3 activation was compared with the Janus kinase inhibitor tofacitinib (10 μM). After 24 hours, STAT3-regulated SEAP reporter activity was assessed using the Quanti Blue solution recommended by the manufacturer (Invivogen). The results are the average of three (IL-6) or one (IL-6 / IL-6R) independent experiments. Use the manufacturer's recommended Cytotoxicity was assessed using the 2.0 cell viability assay (Promega, Australia).
[0448] Characterization of IL-23-mediated STAT3 inhibitory activity
[0449] I. colisanans MH27-3 supernatant samples were prepared using standard protocols. In short, three independent colonies of the target bacteria were inoculated and grown to the early stationary phase. Then, two technical replicates were inoculated using each seed culture from three biological replicates, resulting in six technical replicates. These technical replicates were grown to the early stationary phase and the original cell-free culture supernatant was harvested. The supernatant was also purified by 3 kDa according to the manufacturer's instructions (Merck Millipore). The culture supernatant was size fractionated using a 400 μM column. R. bromii MCB950 supernatant samples were prepared similarly except that two biological replicates were used to generate four technical replicates.
[0450] HEK Blue IL-23 cell line (Invivogen) was used to evaluate IL-23-mediated STAT3 activity. In brief, the HEK-Blue IL-23 reporter cell line was stably transfected with IL23R, STAT3, and secretory embryonic alkaline phosphatase (SEAP) reporter genes. IL-6 stimulation resulted in STAT3-dependent SEAP expression. SEAP was secreted into the culture medium, and the extent of SEAP expression could be quantified using QUANTI-Blue solution. HEK-Blue IL-23 cells were cultured in DMEM supplemented with 10% FBS according to the manufacturer's instructions.
[0451] For the IL23-STAT3 assay, 50,000 HEK-Blue TM IL-23 cell lines were cultured overnight in 96-well plates. Supernatants were initially tested at a final concentration of 10%, 25%, or 50% v / v, with a final concentration of IL-23 of 5 ng / mL. For all experiments and treatments shown herein, supernatants were tested at a final concentration of 25% (v / v). IL-23 was tested at a final concentration of 5 ng / mL, while tofacitinib was tested at a final concentration of 5 μM. IL-23 alone and a combination of IL-23 and tofacitinib were included in this assay as positive and negative controls for IL-23 signaling. Treated cells were incubated at 37°C for 6 hours.
[0452] Using QUANTI-Blue TM The SEAP production was quantified by the solution and recorded as optical density (OD) at 630 nm using a PHERAstar FS plate reader (BMG Labtech). The inhibition of STAT3 signaling by the bacterial supernatant was compared with the activation of STAT3 signaling by its associated culture medium control. It is noteworthy that in some cases, the culture medium control itself showed a certain degree of STAT3 signal inhibition, however, in many cases the effect of the associated leads was stronger than that of the culture medium.
[0453] All experiments were repeated at least three times. All data were generated by at least three technical replicates and at least three biological replicates. T-test and ANOVA test were performed accordingly using GraphPad Prism 9 software.
[0454] Preparation of bacterial supernatants and culture medium extracts
[0455] The bacterial culture supernatant was prepared by inoculating three independent I. colisanans MH27-2 colonies and culturing to early stationary phase. The three "seed cultures" were each inoculated with 160 mL of YG / V broth in duplicate, and the cultures were then cultured again until early stationary phase. The culture supernatant was collected and prepared by centrifuging the culture at 4000 g for 30 minutes and then passing the cell-free supernatant through an Amicon Ultra-15 3kDa centrifugal filter.
[0456] The preparation of bacterial culture supernatant extracts was performed using Amberlite XAD-7 resin as described by Colosimo et al. (cited above). In brief, activated Amberlite XAD-7 resin was added to 150 mL of 3 kDa filtered cell-free supernatant (10% w / v) and gently shaken overnight at 4°C. The resin was collected, washed with 150 mL of deionized water, and mixed with 50 mL of 100% methanol. After incubation for 2 hours under gentle shaking, the methanol eluate was collected. A second elution was performed in 25 mL of 100% methanol as described previously, the two eluates were combined, and dried with a rotary evaporator under vacuum. The dried extract was resuspended in 100% DMSO at 100X concentration and stored at -80°C.
[0457] Bacterial culture supernatant solid phase extraction fractions were prepared using a Strata-X 33 μM polymer reverse phase column. Briefly, after conditioning and equilibration, the 3 kDa filtered cell-free supernatant was loaded into the column, washed 4 times with an equal volume of deionized water, and then eluted with 15%, 30%, 60%, and 100% acetonitrile. Each eluate was dried with a rotary evaporator under vacuum and resuspended in 100% DMSO at 100X concentration and stored at -80°C.
[0458] Metabolomics analysis based on LC-MS / MS
[0459] Targeted metabolomics analysis was performed by MS-Omics (Denmark). Briefly, to evaluate the metabolites produced by I. colisanans MH27, six independent colonies were inoculated and grown to early stationary phase. Then, two technical replicates of YG / V were inoculated using each seed culture, generating 12 technical replicates from six biological replicates. These technical replicates were grown to early stationary phase, and the cell-free culture supernatant was harvested after centrifugation at 12,550 g for 3 min in an anaerobic chamber. The culture supernatant was quickly frozen on dry ice and then stored at -80 °C until testing.
[0460] Analyses were performed using a Thermo Scientific Vanquish LC coupled to a Thermo Q Exactive HF MS. An electrospray ionization interface was used as the ionization source. Analyses were performed in negative and positive ionization modes. UPLC was performed using a slightly modified version of the protocol described by Catalin et al. (UPLC / MS Monitoring of Water-Soluble B Vitamins in Cell Culture Media in Minutes, Water Application Note 2011, 720004042en). Peak areas were extracted using Compound Discoverer 3.1 (ThermoScientific). Compounds were identified at four levels; Level 1: identification by retention time (compared to an internal authentic standard), accurate mass (acceptable deviation of 3 ppm), and MS / MS spectra; Level 2a: identification by retention time (compared to an internal authentic standard), accurate mass (acceptable deviation of 3 ppm); Level 2b: identification by accurate mass (acceptable deviation of 3 ppm) and MS / MS spectra; Level 3: identification by accurate mass only (acceptable deviation of 3 ppm).
[0461] Non-targeted metabolomics analysis was performed using a Thermo Scientific UltiMate 3000 UHPLC coupled to a Thermo Q Exactive Plus MS. Elution was performed with 0.1% formic acid and a gradient of acetonitrile from 3% to 95% at a flow rate of 0.25 μL / min for a total of 85 min. An electrospray ionization interface was used as the ionization source. MS data were acquired from MS1 Survey at 35,000 resolution from m / z 100 to 1,500 in data-dependent acquisition mode, with up to ten MS2 scans in CID / HCD mode and one microscan in positive or negative mode acquired per cycle at 35,000 resolution. The maximum injection time was set to 100 ms and the MS2 precursor window was set to 1.2 m / z. The normalized collision energy was set to step energy mode, where the normalized collision energies (NCEs) from 20%, 30%, and 40% were combined, and the default charge state was set to z=1. The MS2 experiment was set to automatically trigger within 5 to 10 seconds of the first appearance of the peak. The dynamic exclusion time was set to 10 seconds. Ion species with unassigned charge states and isotopic peaks were excluded. Further metabolite profiling and key metabolite identification were performed using the GNPS platform described by Aron et al. (9).
[0462] Barrier function assessment
[0463] The ability of I. colisanans MH27 to prevent loss of barrier integrity was assessed by measuring transepithelial electrical resistance (TEER) on confluent monolayers of T84 intestinal epithelial cells. T84 cells were purchased from CellBank Australia and cultured in Dulbecco's modified Eagle's medium nutrient mixture 12 (DMEM / F12; ThermoFisher Scientific, Waltham, MA, USA) supplemented with 5% fetal bovine serum and 1% penicillin-streptomycin. T84 cells were seeded into 24-well Millicell polycarbonate cell culture inserts (pore size 0.4 μm) (PSHT010R5) at a seeding density of 60.000 cells per well in 400 μL of culture medium; and 24 ml of culture medium was added to a single-well feed tray. The culture medium of the two compartments was changed every other day. After 7 days of culture, the upper part of the plate assembly containing the cell culture insert was transferred from the feed tray to a 24-well receiving tray (PSMW010R5) containing 800 μL of culture medium per well. The TEER value of each well was measured daily using a Millicell ERS-2 volt-ohm meter. Once cells in all wells reached a stable TEER reading above 1500Ω, the experiment was started.
[0464] In the first experiment, 3kDa filtered bacterial culture medium (YG / V) or 3kDa filtered I.colisanansMH27 bacterial culture supernatant was diluted to 10% v / v in T84 medium, added to the apical compartment and pretreated for one hour. Then, IFNγ (50ng / ml) was added to the basal compartment to destroy barrier integrity. After 48 hours of IFNγ treatment, the culture medium containing IFNγ in the basolateral compartment was removed, the wells were washed twice with warm PBS, and fresh T84 culture medium was added. From then on, the culture medium in the lower compartment was replaced every 24 hours. Similarly, the treatment based on YG / V and I.colisanans MH27-2 in the apical compartment was updated every 24 hours, and the TEER value was measured just before and directly after the treatment. The data from two biological replicates (each replicate was measured in duplicate) are expressed as the percentage difference of the TEER value compared with the control (untreated T84 cells). Statistical significance was determined by unpaired t-test.
[0465] In the second experiment, 2X, 1X and 0.5X concentrations of bacterial culture extract (YG / V) or I.colisanans MH27-2 bacterial extract were added to the apical compartment. IL-6 (10 ng / mL) was then added to destroy barrier integrity and removed after 96 hours of treatment. Treatment and culture medium were updated every 24 hours, and TEER values were measured in duplicate. Data from two biological replicates (two replicates for each replicate) were expressed as percentage differences in TEER values compared to controls (untreated T84 cells). Statistical significance was determined by unpaired t-test.
[0466] Assessment of tight junction-associated protein expression
[0467] The ability of I. colisanans MH27-1, MH27-2 and MH27-3 to prevent IFNγ-mediated loss of expression of Zonula Occludens 1 (ZO1) was evaluated by immunofluorescence staining and confocal microscopy. T84 cells were cultured as described above and seeded onto microscope slides in 24-well plates at a seeding density of 150.000 cells per well in 800 μL of culture medium. Cells were grown for three weeks with culture medium replaced every other day. For I. colisanans, cells were pretreated with a 3 kDa filtered extract control (YG / V) or a 3 kDa filtered complete or fractionated I. colisanans MH27 bacterial extract (diluted to 1X in culture medium), incubated overnight at 37°C and 5% CO2, after which 100 ng / mL IFNγ was added to selected wells. For metabolites produced by I. colisanans, T84 cells were pretreated with 1 mM ornithine, indole-3-acrylic acid or indole-3-propionic acid for 18 h and then stimulated with IFNγ for 48 h. The cells were incubated for an additional 48 h and then fixed with 4% paraformaldehyde for 15 min, washed three times with PBS and stained in the dark. To do this, the coverslips were first incubated with 0.1% Triton X-100 in 5% BSA / PBS for 10 min. The cells were washed three times with PBS and incubated in 5% BSA / PBS for 2 h. Next, the cells were washed three times with PBS and incubated with rabbit anti-human ZO1 primary antibody (5 μg / mL, Invitrogen) in 5% BSA / PBS for 2 h and then washed three more times with PBS. The cells were incubated with Alexa Fluor in 5% BSA / PBS 488-conjugated goat anti-rabbit IgG H&L secondary antibody (1:2000, ThermoFisher Scientific) and DAPI (1:1000, ThermoFisher Scientific) were incubated together for 1 hour. The coverslips were washed three times with PBS, once with ultrapure water, and then mounted using ProLong Gold AntifadeMountant (Invitrogen). Images were acquired using an inverted all-electric Nikon / Spectral Spinning Disc confocal microscope (X-1 Yokogawa Spinning disc, Borealis improved) and a 60x NA 1.49 Plan Apochromat oil immersion objective (Nikon). Images of cells were acquired using a coupled device (CCD) camera (Andow Clara) and Nikon elements imaging software (Nikon, version 4.40). Four separate images were captured for each condition. Maximum projection images were assembled, and the relative brightness of stained cells on each image was quantified and calculated using Fiji ImageJ (version 1.53t) and normalized to unstimulated control cells. Raw data from the experiments can be found in Appendix 3-5. Statistical significance was determined by one-way ANOVA with Dunnett's multiple comparison correction.
[0468] PBMC isolation and stimulation
[0469] PBMCs were isolated from the peripheral blood of healthy donors. The cells were adjusted to a density of 2 x 10 in RPMI 1640 supplemented with gentamicin (150 μg / mL), 2 mM L-glutamine, and 10% heat-inactivated FBS. 6 Cells / mL were plated in 24-well tissue culture plates. After overnight incubation at 37°C in a 5% CO2 incubator, 50 μL of live I. colisanans strain MH27-2 was added to a multiplicity of infection of 1:1. After 24 hours of stimulation at 37°C in a 5% CO2 incubator, the supernatant was collected and clarified by centrifugation. The supernatant was stored at -80°C until needed. IL-10 and IL 12 were quantitatively analyzed using the Ella automated immunoassay system according to the manufacturer's instructions (Protein Simple).
[0470] Assessment of NF-κB regulatory activity
[0471] NF-κB activity was assessed using a custom LS174T goblet cell-like cell line stably transfected with a NF-κB reporter lentivirus carrying firefly luciferase under the control of a minimal (m)CMV promoter and a tandem repeat of the NF-kB transcriptional response element. Stimulation with TNF results in NF-κB-p65-dependent luciferase expression, which can be quantified using the Pierce Firefly Luc One-Step Glow Assay Kit (Thermo Scientific). LS174T-NF-κB cells were cultured in DMEM supplemented with 10% FBS. For the NF-κB assay, 50,000 LS174T-NF-κB cell lines were grown overnight in 96-well plates. Cells were pretreated with bacterial supernatant at a starting concentration of 25% v / v for 30 minutes at 37°C. Then, TNF was added to a final concentration of 50 ng / ml. TNF alone and TNF plus the NF-κB inhibitor indole-3-carbinol (I3C), included in the assay at a final concentration of 5 mM, served as positive and negative controls for NF-κB signaling. Treated cells were incubated at 37 °C for 7 h. Luciferase activity was quantified using the Pierce Firefly Luc One-Step Glow assay kit and recorded using a PHERAstar FS plate reader (BMG Labtech). Modulation of NF-κB signaling by bacterial supernatants was compared to activation of NF-κB signaling by their associated media controls.
[0472] The disclosures of each and every patent, patent application, and publication cited herein are hereby incorporated by reference in their entirety.
[0473] Citation of any reference herein shall not be construed as an admission that such reference is available as "prior art" to the present application.
[0474] Throughout the specification, the purpose is to describe the preferred embodiments of the present invention, but it is not intended to limit the present invention to any one embodiment or specific feature set. Therefore, it will be understood by those skilled in the art that various modifications and changes may be made to the illustrated specific embodiments in view of the present disclosure without departing from the scope of the present invention. All such modifications and changes are intended to be included within the scope of the appended claims.
[0475] References
[0476] Arumugam,M.et al.,Enterotypes of the human gut microbiome. Nature 473(7346):174-180(2011).
[0477] Azad et al.,Probiotic supplementation during pregnancy or infancy forthe prevention of asthma and wheeze:systematic review and meta-analysis.BMJ.(2013)347:f6471.
[0478] Benham H,Rehaume LM,Hasnain SZ,Velasco J,Baillet AC,Ruutu M,etal.Interleukin-23Mediates the Intestinal Response to Microbialβ-1,3-Glucanand the Development of Spondyloarthritis Pathology in SKG Mice.Arthritis&Rheumatology.2014;66(7):1755-67.
[0479] Brestoff J.R.and Atris D.,Commensal bacteria at the interface of hostmetabolism and the immune system.Nat.Immunol.,14:676-684(2013).
[0480] Britto SL,Krishna M,Kellermayer R.Weight loss is a sufficient andeconomical single outcome measure of murine dextran sulfate sodiumcolitis.FASEB bioAdvances.2019;1(8):493-7.
[0481] Chan,W.,Chen,A.,Tiao,D.,Selinger,C.&Leong,R.Medication adherence ininflammatory bowel disease.Intest.Res.15,434(2017).
[0482] Chaumeil,P.A.,Mussig,A.J.,Hugenholtz,P.,and Parks,D.H.,GTDB-Tk:AToolkit to Classify Genomes with the Genome Taxonomy Database.(2020)Bioinformatics 36(6):1925–27.
[0483] Cheluvappa et al.,(2014)Clin.Exp.Immunol.175(2):316-22.
[0484] Colosimo DA,Kohn JA,Luo PM,Piscotta FJ,Han SM,Pickard AJ,etal.Mapping interactions of microbial metabolites with human G-protein-coupledreceptors.Cell Host&Microbe.2019;26(2):273-82.e7.
[0485] D’Haens,G,Sandborn,WJ,Feagan,BG,et al.A review of activity indicesand efficacy end points for clinical trials of medical therapy in adults withulcerative colitis.Gastroenterology.2007;132:763–86.
[0486] Fabro et al.,(2015)Immunobiology,220(1):124-35.
[0487] Friedrich M,Pohin M,Powrie F.Cytokine Networks in the Pathophysiologyof Inflammatory Bowel Disease.Immunity.2019;50(4):992-1006.
[0488] Foligne B,Nutten S,Grangette C,Dennin V,Goudercourt D,Poiret S,etal.Correlation between in vitro and in vivo immunomodulatory properties oflactic acid bacteria.World Jour Gastroenterol.2007;13(2):236-43.
[0489] GBD 2017 Inflammatory Bowel Disease Collaborators,The global,regional,and national burden of inflammatory bowel disease in 195 countriesand territories,1990-2017:a systematic analysis for the Global Burden ofDisease Study 2017;Lancet,5(1):17-30.
[0490] Geva-Zatorsky,N.et al.Mining the human gut microbiota forimmunomodulatory organisms.Cell 168,928–943(2017).
[0491] Giri R,Hoedt EC,Shamsunnahar K,McGuckin MA,Morrison M,Capon RJ,etal.Secreted microbial metabolites modulate gut immunity and inflammatorytone.bioRxiv.2019:2019.12.16.861872.
[0492] Goldin B.R.,Gorbach S.L.Clinical indications for probiotics:anoverview.Clin Infect Dis.(2008)46 Suppl2:S96-100.
[0493] Handbook of Pharmaceutical Excipients,2nd Edition,(1994),Edited by AWade and PJ Weller.
[0494] Hu X,li J,Fu M,Zhao X,Wang W.The JAK / STAT signaling pathway:frombench to clinic.Signal Transduction and Targeted Therapy.2021;6(1):402.
[0495] Kabat,A.M.,Srinivasan,N.&Maloy,K.J.Modulation of immune developmentand function by intestinal microbiota.Trends Immunol.35,507–517(2014).
[0496] Kailasapathy et al.(2002)Curr.Issues Intest.Microbiol.3(2):39-48.
[0497] Karagozian,R.&Burakoff,R.The role of mesalamine in the treatment ofulcerative colitis.Ther.Clin.Risk Manag.3,893(2007).
[0498] Kim et al.,Intestinicoccus butyricigenes sp.nov.,a butyrate-producingbacterium isolated from human faeces,J.Microbio.57(1):38-44;(2019).
[0499] Liu G,Mateer SW,Hsu A,Goggins BJ,Tay H,Mathe A,et al.Plateletactivating factor receptor regulates colitis-induced pulmonary inflammationthrough the NLRP3 inflammasome.Mucosal Immunol.2019;12(4):862-73.
[0500] Mallone R.,Mannering S.I.,Brooks-Worrell B.M.,Durinovic-BellóI.,CilioC.M.,Wong F.S.,et al.Isolation and preservation of peripheral bloodmononuclear cells for analysis of islet antigen-reactive T cell responses:position statement of the T-Cell Workshop Committee of the Immunology ofDiabetes Society.Clin Exp Immunol.2011;163(1):33-49.
[0501] Marks E,Goggins BJ,Cardona J,Cole S,Minahan K,Mateer S,et al.Oraldelivery of prolyl hydroxylase inhibitor:AKB-4924 promotes localized mucosalhealing in a mouse model of colitis.Inflamm Bowel Dis.2015;21(2):267-75.
[0502] Masco,L.et al.,Identification of Bifidobacterium species using rep-PCR fingerprinting,Systematic and Applied Microbiology,26(4):557-563(2003).
[0503] McLornan DP,Pope JE,Gotlib J,Harrison CN.Current and future status ofJAK inhibitors.Lancet.2021;398(10302):803-16.
[0504] McSweeney C.S.,Denman S.E.,Mackie R.I.,Rumen bacteria.In:Makkar HPS;Methods in gut microbial ecology for ruminants.23-37(2005).
[0505] Meddings,J.B.,Jarand,J.,Urbanski,S.J.,Hardin,J.,Gall,D.G.Increasedgastrointestinal permeability is an early lesion in the spontaneouslydiabetic BB rat.Am.J.Physiol.276,G951–G957(1999).
[0506] Mitropoulou et al.(2013)J.Nutr.Metab.(2013)716861.
[0507] Remington’s Pharmaceutical Sciences,Mack Publishing Co.(A.R.Gennaroedit.1985).
[0508] Monteleone et al.,(2011)BMC Medicine.2011,9:122.
[0509] Parks,D.H.,Chuvochina,M.,Waite,D.W.,Rinke,C.,Skarshewski,A.,Chaumeil,P.A.,and Hugenholtz,P.A Standardized Bacterial Taxonomy Based on GenomePhylogeny Substantially Revises the Tree of Life.(2018)Nature Biotechnology.
[0510] Salas A,Hernandez-Rocha C,Duijvestein M,Faubion W,McGovern D,VermeireS,et al.JAK-STAT pathway targeting for the treatment of inflammatory boweldisease.Nature Reviews Gastroenterology&Hepatology.2020;17(6):323-37.
[0511] Sapone,A.et al.,Zonulin upregulation is associated with increased gutpermeability in subjects with type 1diabetes and their relatives.Diabetes 55,1443–1449(2006).
[0512] Schieck et al.,(2014)J.Allergy Clin.Immunol.133(3):888-91.
[0513] Schindler et al.,JAK-STAT signaling:from interfeons to cytokines,J.Biol.Chem.(2007)282(28):20059-63.
[0514] Schroeder,KW,Tremaine,WJ,Ilstrup,DM.Coated oral 5-aminosalicylic acidtherapy for mildly to moderately active ulcerative colitis.A randomizedstudy.N.Engl.J.Med.1987;317:1625–9.
[0515] Sokol H,Pigneur B,Watterlot L,Lakhdari O,Bermudez-Humaran LG,Gratadoux JJ,et al.Faecalibacterium prausnitzii is an anti-inflammatorycommensal bacterium identified by gut microbiota analysis of Crohn diseasepatients.Proc.Natl.Acad.Sci.U S A.2008;105(43):16731-6.
[0516] D.et al.,Efficiency of PCR-based methods in discriminatingBifidobacterium longum ssp.Longum and Bifidobacterium longum ssp.infantisstrains of human origin.J.Microbiol.Methods,(2011)87(1):10-6.
[0517] United States Patent Publication No.2016 / 0067188.
[0518] Yamamoto A,Itoh T,Nasu R,Nishida R.Effect of sodium alginate ondextran sulfate sodium-and 2,4,6-trinitrobenzene sulfonic acid-inducedexperimental colitis in mice.Pharmacology.2013;92(1-2):108-16.
[0519] Yang F,Wang D,Li Y,Sang L,Zhu J,Wang J,et al.Th1 / Th2 Balance andTh17 / Treg-Mediated Immunity in relation to Murine Resistance to DextranSulfate-Induced Colitis.Journal of immunology research.2017;2017:7047201.
[0520] Ye et al.,(2015)PLoS One,10(1):e0117704.
[0521] Yin et al.,(2014)Immunogenetics,66(3):215-8.
Claims
1. A cell of the Intestinicoccus colisanans strain with a deposit number of V21 / 015887 or V21 / 015888 or a derivative thereof.
2. The cell of claim 1, wherein the cell is at least partially isolated.
3. A biologically pure culture of the Intestinicoccus colisanans strain with the deposit number V21 / 015887 or V21 / 015888 or a derivative thereof.
4. A composition comprising the cell of claim 1 or 2 or the culture of claim 3.
5. A composition comprising a bacterial strain, wherein the bacterial strain has a 16S rRNA sequence that is at least about 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identical to any one of SEQ ID NOs: 1, 2 or 7-10, or has a 16S rRNA gene sequence represented by any one of SEQ ID NOs: 1, 2 or 7-10.
6. The composition of claim 4 or claim 5, further comprising a pharmaceutically acceptable excipient, diluent or carrier.
7. A pharmaceutical composition comprising a bacterial strain having a 16S rRNA sequence and a pharmaceutically acceptable carrier, diluent or excipient, wherein the 16S rRNA sequence is at least about 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identical to the 16S rRNA sequence of a bacterial strain of the species Intestinicoccus colisanans.
8. A pharmaceutical composition comprising a bacterial strain and a pharmaceutically acceptable carrier, diluent or excipient, wherein the bacterial strain is a phylogenetic descendant of the MRCA of I. colisanans and I. sp002305575.
9. The pharmaceutical composition of claim 8, wherein the MRCA is defined at node 23596 of the bac120 phylogenetic tree from the Genome Taxonomy Database (GTDB) version 89.
10. The composition according to any one of claims 5 to 9, wherein the bacterial strain is at least partially isolated.
11. A composition according to any one of claims 4 to 10, wherein the bacterial strain is viable or non-viable.
12. A composition according to any one of claims 4 to 11, wherein the composition is in dry form.
13. The composition according to claim 12, wherein the composition is formulated as a capsule, tablet, pill, lozenge, troche, powder or granules.
14. A composition according to claim 12 or claim 13, wherein the composition is dried by freeze drying, spray drying, fluid bed drying, vacuum drying or a combination thereof.
15. A composition according to any one of claims 4 to 14, wherein the composition is formulated for delivery to the digestive tract.
16. A composition according to any one of claims 4 to 15, further comprising a prebiotic.
17. A composition according to any one of claims 4 to 16, further comprising one or more additional bacterial strains.
18. A composition according to claim 17, wherein the one or more additional bacterial strains are at least partially isolated.
19. A composition according to any one of claims 4 to 18, wherein the composition does not comprise bacteria of the genus Clostridium.
20. A cell, culture or composition according to any one of claims 1 to 19, wherein the bacterial strain produces an agent that attenuates or weakens Signal Transducer and Activator of Transcription 3 (STAT3) signalling in a cell.
21. The cell, culture or composition according to claim 20, wherein the active agent is a small molecule, a peptide or a nucleotide.
22. A cell, culture or composition according to claim 20 or claim 21 wherein the active agent is released by the bacteria.
23. A cell, culture or composition according to any one of claims 20 to 22, wherein the active agent specifically binds to any one of STAT3, JAK2, TYK or IL-23.
24. A cell, culture or composition according to any one of claims 1 to 23, wherein the bacterial strain produces one or more metabolites selected from the group consisting of cyclo(-Phe-Pro), indole-3-lactic acid, allopurinol, propionylcarnitine, pyrogallic acid, 3-(2-hydroxyethyl)indole, N-acetylcysteine, tryptol, indole-3 propionic acid, ornithine, acetate, and / or combinations thereof.
25. A cell, culture or composition according to any one of claims 1 to 24, wherein the bacterial strain is of the species I. colisanans.
26. A food or beverage product comprising the composition of any one of claims 4 to 25.
27. A method for restoring or improving a digestive tract barrier function of a subject, the method comprising administering a bacterial strain of the genus Intestinicoccus to the subject, thereby restoring or improving the digestive tract barrier function.
28. The method according to claim 27, wherein the bacterial strain is a phylogenetic descendant of the MRCA of I. colisanans and I. sp002305575.
29. The product according to claim 28, wherein the MRCA is defined at node 23596 of the bac120 phylogenetic tree from the Genome Taxonomy Database (GTDB) version 89.
30. The method according to any one of claims 27 to 29, wherein the bacterial strain belongs to the species I. colisanans.
31. The method according to any one of claims 27 to 30, wherein the restoration or improvement of the digestive tract barrier function is characterized by at least one of the following: (i) increasing the quality and / or quantity of mucin; (ii) improving the integrity of tight junction proteins; (iii) reducing the translocation of intestinal luminal contents into the systemic circulation; or (iv) reducing intestinal ulcers and / or intestinal wounds.
32. The method according to claim 31, wherein the intestinal luminal contents include lipopolysaccharide (LPS).
33. The method according to any one of claims 27 to 32, wherein the restoration or improvement of the digestive tract barrier dysfunction results in a reduction in systemic inflammation in the subject.
34. The method according to claim 33, wherein systemic inflammation is determined in the subject when the level of inflammatory cytokines (e.g., IL-1β, IL-8, IL-6 and TNF) in a sample from the subject is above a predetermined threshold.
35. A method of inducing or enhancing mucosal healing in a subject, the method comprising administering to the subject an amount of a bacterial strain of the genus Intestinicoccus sufficient to induce epithelial cell migration and / or proliferation; thereby inducing mucosal healing in the subject.
36. A method according to claim 35, wherein the bacterial strain is a phylogenetic descendant of the MRCA of I. colisanans and I. sp002305575.
37. The product according to claim 36, wherein the MRCA is defined as at node 23596 of the bac120 phylogenetic tree from the Genome Taxonomy Database (GTDB) version 89.
38. The method according to any one of claims 35 to 37, wherein the bacterial strain belongs to the species I. colisanans.
39. A method according to any one of claims 35 to 38, wherein mucosal healing is measured using one or more fecal or serum markers.
40. The method according to claim 39, wherein the one or more stool markers are selected from the group consisting of calprotectin, lactoferrin, metalloproteinase (MMP)-9 and lipocalin-2.
41. The method according to any one of claims 35 to 40, wherein mucosal healing is measured using endoscopic scoring.
42. A method of reducing inflammation in a subject, the method comprising administering to the subject a therapeutically effective amount of a bacterial strain of the genus Intestinicoccus, thereby reducing inflammation in the subject.
43. A method according to claim 42, wherein the bacterial species is a phylogenetic descendant of the MRCA of I colisanans and I.sp002305575.
44. The product of claim 43, wherein the MRCA is defined as at node 23596 of the bac120 phylogenetic tree from the Genome Taxonomy Database (GTDB) version 89.
45. The method of any one of claims 42 to 44, wherein the bacterial strain belongs to the species I. colisanans.
46. The method of any one of claims 42 to 45, wherein the inflammation is local inflammation of the digestive tract environment or systemic inflammation.
47. The method of any one of claims 42 to 46, wherein the bacterial strain attenuates the NFκB pathway (eg, by reducing or inhibiting NFκB).
48. A method of blocking or inhibiting activation of STAT3 signaling in a target cell, the method comprising contacting the target cell with at least a soluble component of a cell preparation of a bacterium of the genus Intestinicoccus to block or otherwise inhibit activation of STAT3 signaling in the target cell.
49. The method according to claim 48, wherein the bacterial strain is a phylogenetic descendant of the MRCA of I. colisanans and I. sp002305575.
50. The product of claim 49, wherein the MRCA is defined at node 23596 of the bac120 phylogenetic tree from the Genome Taxonomy Database (GTDB) version 89.
51. The method according to any one of claims 48 to 50, wherein the bacterial strain belongs to the species I. colisanans.
52. The method according to any one of claims 48 to 51, wherein the target cell is selected from the group consisting of a reporter cell (eg, a HEK cell), an immune cell (eg, a Th17 immune cell), an epithelial cell, and an endothelial cell.
53. A method according to any one of claims 48 to 52, wherein the bacterial cell preparation comprises a bacterial cell culture.
54. The method according to claim 53, wherein the soluble fraction comprises the supernatant of the bacterial cell culture.
55. A method according to any one of claims 48 to 54, wherein the soluble fraction is substantially free of bacterial cells.
56. A method according to any one of claims 48 to 55, wherein the bacterial cell preparation comprises a bacterial cell pellet.
57. The method according to claim 56, wherein the soluble component comprises a soluble fraction of lysed cells.
58. The method of claim 57, wherein the soluble fraction is substantially separated from the insoluble cellular fraction by centrifugation.
59. A method according to any one of claims 48 to 58, wherein the method is performed in vitro.
60. A method for blocking or otherwise inhibiting STAT3 signaling in the digestive tract environment of a subject, the method comprising administering to the subject a strain of bacteria of the genus Intestinicoccus to block or otherwise inhibit STAT3 signaling in the digestive tract environment of the subject.
61. The method according to claim 60, wherein the bacterial strain is a phylogenetic descendant of the MRCA of I. colisanans and I. sp002305575.
62. The product according to claim 61, wherein the MRCA is defined at node 23596 of the bac120 phylogenetic tree from the Genome Taxonomy Database (GTDB) version 89.
63. The method according to any one of claims 60 to 62, wherein the bacterial strain belongs to the species I. colisanans.
64. The method according to any one of claims 60 to 63, wherein the cell is an immune cell (eg, a Th17 immune cell), an epithelial cell or an endothelial cell.
65. The method according to any one of claims 60 to 64, wherein the cell is an epithelial cell, wherein the bacterial strain or molecule increases the production of IL-22 in the subject.
66. A method according to any one of claims 60 to 65, wherein the bacterial strain produces a molecule, wherein the molecule is a direct inhibitor or an indirect inhibitor of STAT3.
67. The method according to any one of claims 60 to 66, wherein the bacterial strain produces a molecule, wherein the molecule directly inhibits at least one of an IL-23 polypeptide, a JAK2 polypeptide, a TYK2 polypeptide or a STAT3 polypeptide.
68. The method according to any one of claims 27 to 67, wherein the bacterial strain produces a metabolite selected from the group consisting of cyclo(-Phe-Pro), indole-3-lactic acid, allopurinol, propionylcarnitine, pyrogallic acid, 3-(2-hydroxyethyl)indole, N-acetylcysteine, tryptol, indole-3 propionic acid, ornithine, acetate and / or combinations thereof.
69. The method of any one of claims 27 to 68, wherein the bacterial strain has a 16S rRNA sequence that is at least about 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identical to a 16S rRNA sequence of a bacterial strain of the species I. colisanans; or wherein the bacterial strain has a 16S rRNA gene sequence of an I. colisanans bacterial strain.
70. The method of any one of claims 27 to 69, wherein the bacterial strain has a 16S rRNA sequence that is at least about 97.5%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% identical to SEQ ID NO: 1, 2, or 7-10, or wherein the bacterial strain has a 16S rRNA gene sequence represented by any one of SEQ ID NO: 1, 2, or 7-10.
71. A method according to any one of claims 27 to 70, wherein the bacterial strain is the I. colisanans strain with deposit number V21 / 015887 or V21 / 015888, or a derivative thereof.
72. A method according to any one of claims 27 to 71, wherein the bacterial strain is at least partially isolated.
73. A method according to any one of claims 27 to 72, wherein the bacterial strain is formulated as a pharmaceutical composition further comprising a pharmaceutically acceptable carrier, diluent or excipient.
74. A method according to claim 73, wherein the composition is in dry form.
75. The method according to claim 74, wherein the dry form is selected from the group consisting of granules, granules and powders.
76. A method according to claim 74 or claim 75, wherein the composition is dried by freeze drying, spray drying, fluid bed drying, vacuum drying or a combination thereof.
77. The method according to any one of claims 73 to 76, wherein the pharmaceutical composition is formulated for oral administration.
78. A method of treating or preventing an inflammatory or autoimmune disorder in a subject, the method comprising administering to the subject an effective amount of an Intestinicoccus bacterial strain, thereby treating or preventing the inflammatory or autoimmune disorder.
79. A method according to claim 78, wherein the bacterial strain is a phylogenetic descendant of the MRCA of I. colisanans and I. sp002305575.
80. The product according to claim 79, wherein the MRCA is defined as at node 23596 of the bac120 phylogenetic tree from the Genome Taxonomy Database (GTDB) version 89.
81. The method according to any one of claims 78 to 80, wherein the bacterial strain belongs to the species I. colisanans.
82. The method according to any one of claims 78 to 81, wherein the inflammatory or autoimmune disorder is selected from: inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis); asthma (e.g., allergic asthma or neutrophilic asthma); fatty liver disease (e.g., non-alcoholic fatty liver disease (NAFLD)); ankylosing spondylitis; systemic lupus erythematosus (SLE); scleroderma; Sjögren's syndrome; and vasculitis.
83. The method according to any one of claims 78 to 82, wherein the inflammatory or autoimmune disorder is inflammatory bowel disease (IBD).
84. The method according to any one of claims 78 to 83, wherein when administered to a subject, the bacterial strain blocks or otherwise inhibits STAT3 signaling in at least one cell of the subject.
85. The method according to claim 84, wherein the cell is an epithelial cell, an immune cell (eg, a Th17 immune cell) or an endothelial cell.
86. The method of any one of claims 78 to 84, wherein the bacterial strain produces one or more metabolites selected from the group consisting of cyclo(-Phe-Pro), indole-3-lactic acid, allopurinol, propionylcarnitine, pyrogallic acid, 3-(2-hydroxyethyl)indole, N-acetylcysteine, tryptol, indole-3 propionic acid, ornithine, acetate, and / or combinations thereof.
87. The method of any one of claims 78 to 86, wherein the bacterial strain has a 16S rRNA sequence that is at least about 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% identical to a 16S rRNA sequence of an Intestinicoccus bacterial strain.
88. The method of any one of claims 78 to 87, wherein the bacterial strain has a 16S rRNA sequence that is at least about 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% identical to any one of SEQ ID NOs: 1, 2, or 7-10, or wherein the bacterial strain has a 16S rRNA gene sequence represented by any one of SEQ ID NOs: 1, 2, or 7-10.
89. A method according to any one of claims 78 to 88, wherein the bacterial strain is at least partially isolated.
90. A method according to any one of claims 78 to 89, wherein the bacterial strain is formulated into a pharmaceutical composition together with a pharmaceutically acceptable carrier, diluent and / or excipient.
91. The method according to claim 90, wherein the composition is in dry form.
92. The method according to claim 91, wherein the dry form is selected from the group consisting of granules, granules and powders.
93. The method according to claim 91 or 92, wherein the composition is dried by freeze drying, spray drying, fluid bed drying, vacuum drying or a combination thereof.
94. The method according to any one of claims 78 to 93, wherein an anti-inflammatory agent is co-administered to the subject.
95. The method according to claim 94, wherein the anti-inflammatory agent is selected from the group consisting of 5-aminosalicylic acid, corticosteroids, azathioprine, infliximab, and adalimumab.
96. The method according to any one of claims 27 to 95, wherein treating comprises identifying the subject as deficient in I. colisanans enteric bacteria prior to administering the composition to the subject.
97. The method of claim 96, wherein determining the deficiency in the subject comprises measuring I. colisanans bacteria in the subject's feces by 16S rRNA sequencing and / or whole genome sequencing.
98. A composition according to any one of claims 27 to 97, wherein the bacterial strain is alive or dead.
99. A composition according to any one of claims 27 to 98, further comprising a prebiotic.
100. A composition according to any one of claims 27 to 99, further comprising one or more additional bacterial strains.
101. The method according to any one of claims 27 to 100, wherein the subject is a mammalian subject.
102. The method according to any one of claims 27 to 101, wherein the subject is a human subject.
103. A composition comprising a bacterial strain of the genus Intestinicoccus for use in therapy.
104. A composition comprising the bacterial strain Intestinicoccus colisanans for use in therapy.
105. A composition comprising a bacterial strain of the genus Intestinicoccus for use in treating or preventing an inflammatory or autoimmune disorder.
106. A composition comprising the Intestinicoccus colisanans bacterial strain for use in treating or preventing an inflammatory or autoimmune disorder.
107. A composition according to any one of claims 103 to 106, wherein the bacterial strains are I. colisanans and I. Phylogenetic descendants of the MRCA of sp002305575.
108. The product according to claim 106, wherein the MRCA is defined as at node 23596 of the bac120 phylogenetic tree from the Genome Taxonomy Database (GTDB) version 89.
109. Use of a bacterial strain of the genus Intestinicoccus in the manufacture of a medicament for treating inflammatory or autoimmune disorders.
110. Use according to claim 109, wherein the bacterial strain is a phylogenetic descendant of the MRCA of I. colisanans and I. sp002305575.
111. The product according to claim 110, wherein the MRCA is defined at node 23596 of the bac120 phylogenetic tree of the Genome Taxonomy Database (GTDB) version 89.
112. Use of an I. colisanans bacterial strain in the preparation of a medicament for treating inflammatory or autoimmune disorders.
113. A composition or use according to any one of claims 103 to 112, wherein the inflammatory or autoimmune disorder is selected from: inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis); asthma (e.g. allergic asthma or neutrophilic asthma); fatty liver disease (e.g. non-alcoholic fatty liver disease (NAFLD)); ankylosing spondylitis; systemic lupus erythematosus (SLE); scleroderma; Sjögren's syndrome; and vasculitis.
114. A composition or use according to any one of claims 103 to 113, wherein the inflammatory or autoimmune disorder is inflammatory bowel disease (eg Crohn's disease or ulcerative colitis).
115. A composition or use according to any one of claims 103 to 114, wherein the bacterial strain is an I. colisanans strain with deposit number V21 / 015887 or V21 / 015888 or a derivative thereof.
116. A composition for treating an inflammatory or autoimmune disorder, the composition comprising a bacterial strain of the genus Intestinicoccus and an anti-inflammatory agent.
117. A composition according to claim 116, wherein the bacterial strain is a phylogenetic descendant of the MRCA of I. colisanans and I. sp002305575.
118. A composition according to claim 117, wherein the MRCA is defined at node 23596 of the bac120 phylogenetic tree from the Genome Taxonomy Database (GTDB) version 89.
119. A composition according to any one of claims 116 to 118, wherein the bacterial strain belongs to the species I. colisanans.
120. A composition according to any one of claims 116 to 119, wherein the anti-inflammatory agent is selected from the group consisting of: 5-aminosalicylic acid, corticosteroids, azathioprine, infliximab and adalimumab.
121. A composition for treating an inflammatory or autoimmune disorder, the composition comprising a bacterial strain of the genus Intestinicoccus; and a nutritional supplement.
122. A composition according to claim 121, wherein the bacterial strain is a phylogenetic descendant of the MRCA of I. colisanans and I. sp002305575.
123. The product of claim 122, wherein the MRCA is defined at node 23596 of the bac120 phylogenetic tree from the Genome Taxonomy Database (GTDB) version 89.
124. A composition according to any one of claims 121 to 123, wherein the bacterial strain belongs to the species I. colisanans.
125. A method of improving or maintaining the health of a subject, the method comprising administering to the subject a composition comprising an I. colisanans bacterial strain, thereby maintaining or improving the health of the subject.
126. The method of claim 125, further comprising administering a nutritional supplement to the subject.
127. An edible or drinkable product comprising a bacterial strain of the genus Intestinicoccus; and a nutritional supplement.
128. The product according to claim 127, wherein the bacterial strain is a phylogenetic descendant of the MRCA of I. colisanans and I. sp002305575.
129. The product according to claim 128, wherein the MRCA is defined as at node 23596 of the bac120 phylogenetic tree from the Genome Taxonomy Database (GTDB) version 89.
130. The product according to any one of claims 127 to 129, wherein the bacterial strain belongs to the species I. colisanans.
131. The product according to any one of claims 127 to 130, wherein the nutritional supplement is a prebiotic.
Citation Information
Patent Citations
Composition, method and kit for detecting bacteria by means of sequencing
US20130157265A1
Hydroxypropyl methyl cellulose hard capsules and process of manufacture
US20160067188A1
16s ribosomal RNA universal primers and use thereof in microbiological analysis and diagnostics
US20180195111A1
Nucleic acid probes useful for detecting microorganisms associated with vaginal infections
US5654418A
Nucleic acid analysis techniques
US6344316B1
